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CHAPTER I 
 
INTRODUCTION 
 
1.1 Significance 
Force – excitation coupling in single cardiac myocytes 
Since 1900, cardiovascular disease (CVD) has been the No.1 killer in the United 
States. Nearly 2500 Americans die of CVD each day, an average death in every 35 
seconds. CVD claims more lives each year than the next 4 leading causes of death 
combined, which are cancer, chronic lower respiratory disease, accidents, and diabetes 
mellitus. 
Heart failure is a chronic and progressive disorder of the heart characterized by 
progressive deterioration of cardiac pump function. It poses a 1 in 5 lifetime risk on both 
men and women  [2, 3]. Heart failure is typically a secondary entity that occurs when the 
myocardial function is diminished by an underlying pathological condition such as 
cardiomyopathy (acquired from chronic ischemia, hypertension or diabetes), valve 
disease, congenital malformation, or arrhythmia. The long-term response of the heart to 
these initiating insults is electrical and mechanical remodeling leading to a progressive 
deterioration of contractile function [4-6]. While the causes of heart failure are 
distinctively different, the functional characteristics of the failing myocardium are 
surprisingly consistent. In the early stage of heart failure the first changes observed are 
slowing of the rates of contraction and relaxation and prolongation of the action potential. 
Later, in a more advanced stage of heart failure, reduced force production and shortening 
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are consistently observed  [4-8]. The pathophysiological mechanism behind myocardial 
failure is not known but there is reason to believe that it originates from alterations in 
force – excitation coupling of the component cardiac myocytes [6]. It is well understood 
that in muscle cells calcium plays an important role in the process that couples an 
electrical depolarization to force generation. In the heart, depolarizing pace maker cells 
generate a depolarizing wave that spreads rapidly from one myocyte to another across 
gap junctions [9], causing an almost synchronous depolarization of the entire heart. 
Intracellular calcium concentration rises as a consequence of the electrical depolarization 
and directly activates the contractile machinery of the cell to produce force and 
contraction. In contrast to skeletal muscle in which force is graded by the recruitment of 
muscle fibers, in heart muscle, all cells participate in each beat [10]. As a result, cardiac 
contractile force can only be regulated by changing the force developed by the individual 
cardiomyocyte. Therefore, force-excitation coupling in the heart is generally studied in 
isolated cardiac myocytes.  
Furthermore, the isolated cardiac myocyte is a more suitable model to study the dynamics 
of active and passive force generation than any multicellular preparation (e.g. trabeculae 
and papillary muscles). Mechanical studies in excised cardiac muscle have led to 
ambiguous results because of the poorly defined viscoelasticity of the extracellular matrix 
[11, 12], and because no clear representation of the relation between passive and active 
forces is evident  [13]. Additional series elasticity in large muscle preparations may arise 
from the end compliance related to the attachment of recording devices. Finally, 
inhomogenities of strain and stress even in one-dimensional isolated muscle preparations 
have shown to produce a significant structural and functional nonuniformity in both 
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passive and active responses [14]. It is customarily assumed that the load (force) and 
strain are uniformly distributed throughout the cross section and along the length of the 
specimen. The implicit assumption of a uniform contractile state is evident in almost all 
the papillary muscle literature that presents data on muscle contraction dynamics.  
The same argument is true when intracellular electrical activity is monitored in tissue 
preparations using fluorescent dyes. Because of the large volume of excised muscle 
preparations, the dye distribution may be highly nonuniform and may even change during 
the measurement.  
In summary, the isolated intact isolated cardiac myocyte is the ideal model for studying 
force – excitation contraction coupling because it provides almost direct access to a 
relatively small number of contractile units (sarcomeres) in a single cohesive structure 
well defined by the sarcolemma membrane. 
 
Phospholamban – a target protein for therapy of myocardial dysfunction  
Disordered cellular calcium homeostasis is a hallmark of heart failure. This observation 
was first documented by Gwathmey and co-workers [15] and has been described multiple 
times in various models of heart failure. In fact, dysregulation of calcium handling is 
universal in structural heart disease, although, the details of this ‘remodeling’ process 
differ amongst different models, between animal species and between different time 
points during disease progression [7, 8, 16]. The reduction in contractile force 
development in failing human cardiac myocytes is accompanied by a markedly prolonged 
declining phase of the Ca2+ transients [15, 17-20]. Intracellular calcium release during the 
cardiac cycle is graded and depends largely on the amount of Ca2+ entering the cell 
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through sarcolemmal ion channels (in a process called calcium induced calcium release, 
CICR) and on the filling state of the sarcoplasmic reticulum (SR), the intracellular 
calcium store. The prolongation of the Ca2+ transient is the direct result of a decrease in 
the activity of the intracellular Ca2+ pump (SERCA2a), which is responsible for the 
transport of cytosolic Ca2+ back into the SR. The reduced rate of SR Ca2+ uptake 
decreases the amount of calcium available for release during the cardiac cycle. As a 
result, force generation, contraction amplitude and rate of relaxation are diminished in 
heart failure. Phospholamban (PLN) is an intracellular SR protein and a negative 
regulator of SERCA2a activity [21, 22]. The PLN – SERCA2a interaction controls the 
calcium content of the SR and ultimately cardiac contractility  [23, 24]. It is well 
established that a decrease in PLN phosphorylation and in the SERCA2a/PLN expression 
ratio contributes to the contractile dysfunction in myocardial failure [25, 26]. In fact, 
overexpression of SERCA2a via gene transfer restored calcium handling, contractility 
and the frequency response in isolated failing human cardiomyocytes [19, 27]. The 
results of targeting PLN in failing human cardiac myocytes are promising: (1) Decreasing 
phospholamban expression restores contractility in failing ventricular myocytes; (2) 
ablation of phospholamban results in improvement in contractility similar to that of 
SERCA2a overexpression. Studies by Kranias et al.  [23, 24, 28] have clearly shown that 
murine models of phospholamban knockout have enhanced contractility. 
 
Frequency adaptation in phospholamban and CaMKII deficient cardiac myocytes 
An important observation made in many in vitro studies is that non-failing and failing 
human myocytes have similar contractile characteristics at low workloads, i.e. slow 
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pacing rates, low extracellular [Ca2+] or in the absence of catecholamine stimulation [15, 
29, 30]. Specifically, peak force (or shortening) is not significantly different in non-
failing vs. failing human LV muscles or myocytes at slow (< 30 bpm), and the rates of 
force development or shortening are only modestly lower than normal in failing cardiac 
muscle. Increasing the pacing rate within the physiological range causes the contractility 
to increase in non-failing myocytes (positive force – frequency relationship) but causes it 
to decrease in cardiac myocytes isolated from failing human hearts (negative force – 
frequency relationship) [15, 30]. These results support the hypothesis that changes in 
cellular Ca2+ handling are a final common pathway for progressive deterioration of 
cardiac pump function in myocardial failure at increasing pacing rates. In fact, abnormal 
SR Ca2+ loading has been suggested to produce significant changes in force – excitation 
coupling in failing human myocytes at physiological stimulation frequencies  [31, 32]. 
The interpretation of these results is severely complicated by the fact that the mechanism 
of frequency adaptation in the heart is not well understood in both nonfailing and failing 
cardiac myocytes.  
When the stimulation frequency is increased, the mammalian heart responds with an 
acceleration of relaxation (FDAR) allowing it to refill more rapidly between beats  [33]. 
Schouten et al.  [34] speculated that a faster relaxation at steady state (SS) vs. post-rest 
beats was due to the activity of the endogenous enzyme Ca2+/Calmodulin dependent 
protein kinase II (CaMKII). Several reports showed that the higher average cytosolic 
[Ca2+] occurring at a higher heart rate, could activate CaMKII in a frequency-dependent 
manner to phosphorylate PLN leading to an increase in SERCA2a activity, a decline in 
[Ca2+]i and an acceleration of relaxation  [35-37]. However, recent results from Valverde 
 6
et al. indicate that PLN phosphorylation by CaMKII may not be the mechanism of FDAR 
in the heart [33]. These results lead to a key hypothesis of this dissertation and are 
discussed in more detail in Chapter V. 
 
1.2 Specific aims 
The following specific aims describe the objectives of the dissertation: 
Aim 1. Develop experimental techniques to measure absolute intracellular calcium 
concentration in isolated cardiac myocytes with high temporal resolution. A single 
cardiac myocyte high bandwidth fluorescence detection system was designed and 
constructed based on an inverted microscope and combined with an optical fiber array 
which was coupled to photomultipliers. The fluorescent Ca2+ indicators Fluo-3, X-rhod-1 
and Indo-1 were used to quantify changes in intracellular Ca2+ concentrations occurring 
during the cardiac cycle. A high temporal resolution (< 0.5 ms) permitted the recording of 
the fast (~ 10 ms) upstroke of the Ca2+ release.  
Aim 2. Develop and apply the Nanophysiometer, a microfluidic network combined with 
a thin film microelectrode array for long-term physiological multi parameter recordings 
from single cardiac myocytes. The Nanophysiometer has extensively been used to 
measure extracellular potentials, intracellular Ca2+ concentrations and sarcomere length 
from isolated cardiac myocytes. Most importantly, the Nanophysiometer automatically 
aligned and stabilized single cells during long-term contraction measurements. On-chip 
thin-film microelectrodes were used for electric field stimulation but were also applied 
for recording extracellular potentials and ion- and metabolite concentrations in the 
extracellular space (e.g. pH, K+, O2, glucose, lactate, etc.). 
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Aim 3. Develop methods to quantify sarcomere force generation in single cardiac 
myocytes with high spatial resolution. A single cardiac myocyte contractility system was 
set up using a high speed CCD camera in combination with an inverted microscope. 
Sarcomere acceleration was measured in single cardiac myocytes and used to quantify 
changes in active force development under consideration of passive forces. A high spatial 
resolution (< 5 nm) was achieved by using a FFT algorithm and the Nanophysiometer. 
The microfluidic device stabilized single cardiac myocytes during long term sarcomere 
length measurements and permitted the recording of a large number of contractions 
(>100). Averaging of multiple contraction transients significantly increased the S/N ratio 
and improved the spatial resolution of the measurement compared to a culture dish 
experiment. Calcium and contraction measurements were combined by using the electric 
field stimulus as a reference time point. 
Aim 4. Measure force – excitation coupling in single cardiac myocytes isolated from 
PLN deficient mice. Phospholamban ablation has been shown to increase the rates of 
contraction and relaxation in isolated cardiac myocytes. However, in the literature, the 
increased contractility (positive inotropic effect) observed in phospholamban deficient 
cardiac myocytes (PLN-/-) has been consistently attributed to an increased Ca2+ release. 
The optical imaging techniques described in aims 1-3 were applied to test the hypothesis 
that the positive inotropic effect of PLN ablation is amplified by an increase in the 
response of the myofilaments to changes in cytosolic Ca2+ concentration. 
Aim 5. Measure the frequency response of the SR Ca2+ release and uptake in single 
cardiac myocytes isolated from PLN and CaMKII deficient cardiac myocytes.  
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PLN phosphorylation by CaMKII has previously been shown to occur in vivo in a 
frequency-dependent manner and was therefore suggested to play an important role in the 
frequency-dependent acceleration of relaxation (FDAR). The fluorescence techniques 
developed in aim 1 were used to quantify the frequency-dependent adaptation of the Ca2+ 
transient in PLN and CaMKII deficient cardiac myocytes. 
Aim 6. Use the Nanophysiometer to measure extracellular potentials in single cardiac 
myocytes. Extracellular potentials resulting from spontaneously initiated calcium waves 
were measured in single nonattached cardiac myocytes using integrated thin film 
microelectrodes. The microelectrodes were also used to measure extracellular pH in a 
microfluidic device. When the techniques described in aims (1-3 and 6) are combined, 
the Nanophysiometer will allow for rapid extracellular volume exchange, selective 
perfusion of single cells, electrical recordings of extracellular potentials, ion- and 
metabolite concentrations in the extracellular space (e.g. pH, K+,O2, glucose, lactate, 
etc.), and simultaneous optical measurements of intracellular ion concentrations (e.g. 
[Ca2+]i and pHi) and sarcomere length in field stimulated cardiac myocytes at 
physiological pacing frequencies. 
 9
CHAPTER II 
 
BACKGROUND 
 
2.1 Force – excitation coupling in ventricular cardiac myocytes 
Anatomy of the heart and the conducting system 
It will be helpful for the following account to introduce some elementary anatomy 
and to define a few important terms in cardiac electrophysiology. The heart is composed 
of four chambers (Figure 1), two of which are large with thick walls. These are the 
ventricles, which pump blood into the two main arteries. The right ventricle pumps blood 
into the pulmonary artery that supplies the lung circulation, and the left ventricle pumps 
 
Figure 1. Cross section of a human heart.  
Adapted from www.texasheartinstitute.org 
Sino-atrial (SA) node
Atrio-ventricular  
(AV) node 
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blood into the aorta which supplies the systemic circulation. The other two chambers are 
small with thin walls and are called atria. The right atrium receives blood from the 
systemic circulation and passes it onto the right ventricle to enter pulmonary circulation. 
The left atrium receives blood from the pulmonary circulation and passes it onto the left 
ventricle to enter the systemic circulation. Electrical activity is initiated in the sino-atrial 
(SA) node which is a band of fine muscle fibers lying near the junction of the superior 
vena cava and the right atrium. Cells in this region (the SA node) are able to generate 
spontaneous action potentials by a mechanism known as the pacemaker mechanism. 
Although it is not the only region of the heart to possess pacemaker mechanism, its 
beating rate is higher than that of any of the other pacemaker regions so that it sets the 
pace of the heart as a whole. The action potential (AP) is the transmembrane potential 
waveform Em that initiates cardiac excitation contraction coupling (see below). The AP is 
responsible for the propagation of excitation information from cell to cell and allows the 
heart to function as an electrical and mechanical syncytium. After initiated at the SA 
node, the AP spreads through the atrial muscle to produce atrial contraction. Atrial and 
ventricular muscles are not continuous. Electrical activity spreads to the ventricles 
through one point, the atrio-ventricular (AV) node, a small band of tissue connecting the 
two kinds of cardiac muscle. Cells in the AV node transmit the electrical impulse slowly 
to ensure a significant delay between atrial and ventricular contraction. The bundle of His 
are specialized fibers in and beyond the AV node that conduct the electrical excitation 
rapidly to the apex and to the surfaces of the two ventricles. Therefore, the large 
ventricles are excited almost simultaneously. A more comprehensive treatment of action 
potential generation and propagation in the heart can be found in some excellent reviews 
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by Yellen (1998) [38], Carmeliet (1999) and Kléber (1997, 2004) [9, 39]. All 
experiments described here are performed on cardiac myocytes isolated from the left and 
right mouse ventricles. 
 
Calcium cycling in ventricular cardiac myocytes 
 
 
 
Figure 2 Scheme of the Ca2+ cycle in a cardiac ventricular myocyte. Ca2+ ions enter via 
the L-type calcium channel (LTCC, ICa) or Na+/Ca2+ exchange (NCX). Calcium influx 
regulates intracellular SR Ca2+ release by the ryanodine receptor (RyR). Ca2+ is removed 
from the myofilaments and cytosol by the SR Ca2+ – ATPase pump which is modulated 
by phospholamban (PLB, PLN), transmembrane Ca2+ – ATPase pump, NCX and 
mitochondrial uniporter. Insert: action potential (Em), calcium transient ([Ca]i) and 
contraction in a rabbit cardiac myocyte. Figure adapted from [41]. 
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The transmembrane potential controls ion channels and transporters, and a depolarization 
leads to the influx of calcium and the genesis of the calcium transient. Calcium is 
considered perhaps the most important ion involved in the intricate workings of the heart. 
It is crucial to the process of excitation contraction coupling (ECC) in cardiac myocytes. 
ECC is defined as the process from electrical excitation to the mechanical contraction of 
the heart, whose purpose is to propel blood out [40-42]. Calcium currents are main 
contributors to the electrical activity of the heart and a direct activator of the 
myofilaments causing contraction. Contractile dysfunction and arrhythmias in 
pathological conditions are very often the consequence of alterations in the Ca2+ handling 
of the cardiac myocyte [43-45].  
Figure 2 shows a schematic of calcium signaling in a ventricular cardiac myocyte. 
Depolarization of the cell membrane during an AP (insert of Figure 2) opens voltage-
dependent trans-sarcolemmal L-type calcium channels (LTCC, ICa). Calcium enters the 
cell during the action potential mainly through the LTCC and through the reverse-mode 
Na+/Ca2+ exchanger (NCX). The inward transmembrane Ca2+ current triggers massive 
release of Ca2+ ions from the sarcoplasmic reticulum (SR) in a process called “calcium 
induced calcium release” (CICR). Together, sarcolemmal Ca2+ influx and SR Ca2+ release 
raise the intracellular free calcium concentration about five fold to ~1 µM, allowing Ca2+ 
to bind to the myofilament protein troponin C (TnC), which subsequently causes 
contraction of the myofilaments [6, 42]. Relaxation occurs when Ca2+ is removed from 
the cytosol. This is achieved through several routes, the importances of which are species 
dependent. In rabbit ventricular myocytes, 70 % of the activator Ca2+ is removed by the 
ATP-dependent SR Ca2+ pump (SERCA2a), 28 % by NCX, and only 1 % by the “slow” 
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systems – sarcolemmal Ca2+ ATPase and mitochondrial Ca2+ transport. The balance of 
Ca2+ fluxes is similar in rabbit, ferret, dog, cat, guinea pig and human. In mouse and rat 
myocardium, Ca2+ removal is directed more towards the SR due to a higher density of 
pump molecules [46], resulting in a balance of 92 % for SERCA2a, 7 % for NCX and 1 
% for the slow systems. Therefore, in the intact mouse cardiac myocyte, Ca2+ removal 
from the cytosol is mainly governed by Ca2+ uptake into the SR. 
Human hearts have a larger cardiac reserve than mice because they are able to elevate the 
amount of Ca2+ stored the SR by increasing SERCA2a activity (e.g. during beta-
adrenergic stress), leading to an increase in fractional Ca2+ release and in the rate of 
contraction. For the cardiac myocyte to be at steady state, the amount of Ca2+ extruded or 
compartmentalized from the intracellular space during twitch relaxation must be the same 
as the amount of Ca2+ that enters the cytoplasm or is released from intracellular 
compartments during each beat, otherwise the cell would gain or loose Ca2+. Therefore, 
in steady state, the same amount of Ca2+ that is released from the SR is taken back up into 
the SR via the SR Ca2+ pump. Similarly, the same amount of Ca2+ that enters the cell 
through the LTCC is removed from the cytosol via NCX.  
 
Regulation of contractility by phospholamban 
The trigger for relaxation of the ventricular cardiac myocyte is the lowering of the 
cytosolic Ca2+ concentration mainly by the activity of SERCA2a. Phospholamban (PLN) 
is a 52-amino acid protein of 6.1 kDa that forms a homopentamer with an apparent mass 
of 22-kDa which colocalizes with SERCA2a in the cardiac SR membrane as indicated in 
Figure 2 (see reviews by Simmerman and Jones [21] and MacLennan and Kranias [22]). 
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Kinetic analysis showed that in its unphosphorylated state, PLN diminishes the apparent 
affinity of SERCA2a for Ca2+ with little or no effect on the maximum Ca2+ transport rate 
(Vmax). Unphosphorylated PLN limits the rate of Ca2+ uptake into the intracellular store. 
In contrast, phosphorylation of PLN by cAMP and cGMP dependent protein kinase A 
and C (PKA and PKC), respectively, at Ser-16 [47], and by Ca2+/Calmodulin dependent 
protein kinase II (CaMKII) at the distinct site Thr-17 [35, 48] relieve this inhibition 
thereby increasing the rate of SR Ca2+ uptake. As a result, the relief of the inhibitory 
function of PLN on SERCA2a is considered the principal contributor to the positive 
inotropic and lusitropic effects of β-agonists [49-51]. The PLN gene was targeted in 
numerous studies to gain insight into the role of this protein in the regulation of cardiac 
contractility. Heterozygous and homozygous gene deletion was used as a tool to study 
cardiac contractility mice in which PLN levels were reduced by 60 % and 100 %, 
respectively  [24, 28]. The reduced level of PLN expression was associated with a linear 
increase in the affinity of SERCA2a for Ca2+ and with a linear increase in rates of 
myocyte relaxation [28, 52]. Interestingly, the rates of contraction were significantly 
increased in whole hearts [53] and in isolated cardiac myocytes [54]. It was reported that 
“[..] Changes in cardiac myocyte contractility reflect increases in the amplitude and rates 
of the rising and falling phases of the Ca2+ transient, which, in turn, reflect the fact, that 
the size of the Ca2+ store is increased in PLN null animals.[..]” [22]. Indeed, an increased 
SR Ca2+  load was consistently reported in PLN deficient cardiac myocytes [52, 55] 
which may have caused the higher Ca2+ release [54, 55]. However, changes in contractile 
protein expression and phosphorylation observed in PLN deficient mice [56, 57] that are 
known to affect the activation of contraction in PLN deficient hearts suggest that an 
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increased systolic Ca2+ concentration may not be the only cause of the positive inotropic 
effect of chronic PLN gene deletion. The data presented in Chapter IV show that the post-
translational changes in the contractile machinery have increased the response of the 
myofilaments to changes in [Ca2+]i in PLN deficient cardiac myocytes. This question is 
addressed in great detail in Chapter IV. 
 
 
 
 
 
 
Figure 3. Electron-microscope images from cardiac muscle showing the sarcomere 
appearance. (Bottom) Schematic of the ultra structure of the myofilaments in one 
sarcomere which underlies the striated appearance of the sarcomere.  
Figure adapted from: Ion Wizard SarcLen Data Acquisition User's Guide, Ionoptix 2000. 
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Activation of contraction by cytosolic [Ca2+] 
The contractile apparatus is built of repeating sarcomeres which occupy 45 - 60 % of the 
cell volume in the mammalian ventricle. Myofilaments are composed of mainly four 
different proteins: myosin (thick filaments), actin, tropomyosin and troponin (thin 
filaments) [52, 58]. The myofilaments are the contractile machinery of the cell and 
indeed they represent the end effector responsible for converting chemical energy into 
mechanical energy. Figure 3 shows two electron-microscope images and a schematic of 
the sarcomere structure. The thin filaments are anchored at the Z-line, which defines both 
ends of the sarcomere with the thick filaments in between. The sarcomere is only 1.5 to 4 
µm long, depending on muscle type and degree of stretch. The optical properties of the 
 
 
 
 
Figure 4. Schematic diagram of the thick filaments (red, bottom) composed of myosin 
heavy chains and the thin filaments (blue, top) composed of actin, tropomyosin and 
troponin (I, C and T domain). Figure adapted from [58]. 
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thick and the thin filaments are strikingly different. The region characterized by a higher 
density of thin filaments is almost transparent and has therefore been labeled the 
isotropic, or I-band. The regions of high densities of thick filaments have a dark 
appearance and are therefore labeled the anisotropic, or A-band (Figure 3). Between the 
thin filaments there are thick filaments which are composed of myosin. The rise in 
cytosolic Ca2+ concentration is the event which activates the myofilaments, and a fairly 
clear picture (though not complete) of the molecular basis for this regulation has been 
developed [59]. 
Figure 4 shows a more detailed schematic of the thick and thin myofilaments. Each thick 
filament is composed of ~300 myosin molecules. Each myosin heavy chain has a long (~ 
130 nm) α-helical tail (S-2 domain) and a globular head (S-1 domain). The S-2 regions of 
the myosin heavy chain form the main axis of the thick filament. The S-2 heads form the 
crossbridges to actin on the thin filaments, contain the site of ATP hydrolysis, and have 
two light chains associated with each head. The backbone of the thin filament is 
composed of two chains of the globular protein G-actin, which form a helical double 
stranded F-actin polymer. Tropomyosin is a long flexible protein which lies in the groove 
between the actin strands and spans about 7 acin monomers. The troponin complex is 
made of three subunits: troponin C (TnC, Ca2+ binding subunit), troponin I (TnI, 
inhibitory subunit, which also binds to actin). TnT has a globular carboxy region and an 
elonagated shape that lies along tropomyosin over about 3 actin monomers.  
In the resting cardiac myocyte, tropomyosin covers the binding sites for myosin on actin.  
When [Ca2+]i rises, Calcium binds to the Ca2+ specific site of TnC causing tropomyosin 
to move away from its blocking position on the thin filament and allowing myosin to 
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bind to actin and form crossbridges (myosin S-1 head portions protruding from the 
myosin filament). Upon activation, the crossbridges can interact with the thin filament 
and produce either force or relative filament movement by a rotation of the myosin S-1 
head under ATP hydrolysis. Isometric force would be analogous to storing the potential 
energy of the myosin head rotation temporarily in an elastic component of the myosin 
molecule. Alternatively, the rotational movement can produce relative motion of the thick 
and the thin filaments (i.e. sarcomere shortening) if the muscle force exceeds load. A 
single crossbridge may develop a force of 0.2-1 pN and the physical filament translation 
from a single crossbridge cycle is 5-10 nm or 0.25-25 % of sarcomere or muscle length. 
The chemical steps involved in the crossbridge cycle have been extensively characterized  
[42]. In the non-attached cardiac myocytes crossbridge cycling can be monitored by 
measuring sarcomere shortening (Section 3.2). At resting lengths, the amount of Ca2+ 
released from the intracellular stores during a twitch is typically insufficient to saturate 
all thin filament sites. Thus, maximum force or power under physiological conditions is 
not fully utilized. Increases in twitch force and power can be achieved by increasing the 
likelihood of crossbridge formation between myosin and actin, e.g. by increasing the 
delivery of Ca2+ to the myofilaments, accelerating crossbridge formation kinetics, or 
increasing the responsiveness of TnC to Ca2+  [41, 58, 60, 61]. 
The relationship between force and [Ca2+]i is highly nonlinear as a result of the strong 
myofilament cooperativity with respect to [Ca2+]i  [10, 58, 62, 63]. A decrease in 
myofilament Ca2+ sensitivity is observed during acidosis, when phosphate and Mg2+ 
concentrations are elevated, as well as during beta-adrenergic stimulation [64]. An 
increase in myofilament Ca2+ sensitivity occurs dynamically during diastole, when the 
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heart fills with blood, resulting in a stronger contraction with increasing volume (Frank-
Starling mechanism) [65]. The sensitivity of the myofilaments to cytosolic Ca2+ is further 
enhanced by caffeine and certain inotropic drugs. Half-maximal activation of contraction 
requires about 70 µmol of Ca2+ per liter of cytosol to raise [Ca2+]i to about 600 nM. This 
indicates strong cytosolic Ca2+ buffering (~ 100:1). 
 
2.2 Force measurements in single cardiac myocytes 
Limitations of existing techniques 
The isolated heart cell is free of collagen and contains relatively few 
myofilaments in a single cohesive structure. It allows almost direct access to the 
measurement of activator [Ca2+]i, sarcomere length, cross-bridge contractile responses 
and is therefore ideally suited for mechanical studies. In contrast to the structural 
simplification is the inherent challenge of noninjurious cell attachment to a force-
transducing device. The major limitation in attachment of intact cells to a force 
transducer is the extreme sensitivity of the sarcolemma to applied stress. Isolated cardiac 
myocytes were attached to a force transducer using single-barreled suction micropipettes 
[66, 67]. However, the success rate was extremely low because of the high stress on the 
sarcolemma at the tips of the micropipettes. Other technique have been developed using 
compliant fibers or glass beams attached to each end of the cell [68-70], but the 
procedures described are time consuming and require a unique experimental setup. 
Commercial force transducers are available that can be used to resolve the ~ µN forces 
generated by a single cardiac myocyte. However, in cases where the force detection 
system is not submersible, some part of the force sensing system must pass through a 
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liquid-air interface. The surface tension of the meniscus around the connecting element 
though this interface can be of ~10µN, and thus way above the level of the forces 
generated by the single cardiac myocyte. [71] Therefore, extreme interface stability and 
reproducibility are required to measure myocyte forces with these transducers.  
 
Sarcomere acceleration as an index of contractility  
Cell shortening and sarcomere length in intact nonattached cardiac myocytes are readily 
measured using noninvasive optical techniques. However, several assumptions are 
necessary to interpret the sarcomere shortening in terms of contractility. The active 
contraction of an unattached myocyte reveals the maximum degree of shortening of the 
 
 
 
 
Figure 5 Mechanical model of the sarcomere with directions of active force and passive 
and viscous resistance during shortening 
Figure adapted from: Ion Wizard SarcLen Data Acquisition User's Guide, Ionoptix 
2000. 
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minimally loaded cell. In the absence of external force, cardiac myocytes attain an 
equilibrium sarcomere length of ~1.9 µm. Figure 5 shows a mechanical model of the 
sarcomere. Sarcomere compression or stretch is opposed by passive elastic and viscous 
forces FP and FV. The passive force FP is largely dominated by the extensible region of 
the large protein titin that runs from near the Z-line to the edge of the A band and is 
indicated symbolically by the springs in Figure 5. When the sarcomere shortens to a 
degree below the slack length, the thick filament moves into titin’s near Z-line region. As 
a result, titin’s extensible region is compressed, generating the so-called restoring or 
passive force FP that pushes the Z-lines back toward their slack length position (Figure 
5). Additionally, a viscous resistance, FV, provides a damping force during contraction 
and re-extension which is proportional to the shortening velocity dl/dt. The mechanical 
model of the sarcomere shown in Figure 5 is comparable with and overdamped pendulum 
returning to its equilibrium position from a mechanical excursion (viscoelastic vibration 
model). 
The second time derivative of the sarcomere length l during the contraction process is a 
measure of the total force FT which is the sum of all forces, which are time t and length 
dependent: 
2
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Equation 2.6 shows that measuring of sarcomere shortening alone is not sufficient to infer 
changes in the active component of the contractility because an increase in sarcomere 
acceleration may be a result of a softer sarcomere rather than a result of an increase in the 
active force. Therefore, passive elastic and viscous forces need to be considered when 
sarcomere length us used as a measure of contractility in single cardiac myocytes. In the 
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following discussion, the components of the overall resistance are presented in more 
detail. Molecular force spectroscopy and atomic force microscopy (AFM) have been used 
to measure the passive force directly in isolated polymer solutions.  
Kellermayer et al. found that the elastic properties of titin could be described by a 
wormlike chain (WLC) model [72]. The exact solution of this model yields its potential 
energy as a function of the relative length change, s = l/L, where l is the time-dependent 
length and L the maximum, time independent length of the unfolded molecule (i.e. l<L). 
An algorithm to calculate the exact solution of the WLC model by numerical iteration 
was presented by Bouchiat et al. [73]. A good analytical approximation of the WLC 
model suitable for fitting of experimental force-length relationships of titin was given by 
Bustamante et al.: 
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where kB is the Boltzmann constant and T the absolute temperature. LP is the persistence 
length which is defined as the length along the polymer chain over which the tangent 
vectors of the chain become decorrelated. The persistence length of a polypeptide chain 
measures the elastic stiffness of the chain and decreases with increasing stiffness. For the 
rigid native folded titin molecule, LP is on the order of 15 nm [72]. The WLC force-
extension curve is a highly nonlinear function: at low extension (s<<1), force grows 
linearly with s with a slope of kBT/LP ~ 0.3 pN per molecule. At high extension, the force 
diverges as (kBT/LP)[4(1-s)2]-1.  
Information about possible changes in passive forces caused by an intervention may be 
obtained by comparing contraction and relaxation. Figure 5 and equation 2.7 indicate that 
a change in the passive loading of the sarcomere would affect contraction and relaxation 
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differently. In fact, compression of crossbridges or stress on the cytoskeleton as may 
occur in the anoxic heart [74, 75] decreases the persistence length LP thereby increasing 
the passive loading FP of the sarcomere at any given fractional shortening s. As a result, 
during ischemia, the rate of shortening is slowed, while the rate of relengthening is 
accelerated. On the other hand, isoproterenol, a beta-adrenergic agonist, increases the 
active force of shortening, FA, with no influence on the passive loading as evidenced by 
an increase in both the rates of shortening and relaxation [76]. A change in the passive 
loading of the sarcomere may also be identified by comparing the sarcomere length at the 
times when the maximum acceleration is reached during contraction and relaxation. A 
softer sarcomere would be characterized by a decreased passive resistance FP (equation 
2.7) at all extension levels and would thus be shorter during contraction and longer 
during relaxation at the time when the maximum acceleration is reached (Chapter IV).  
The contribution of the viscous force FV to the overall mechanical resistance was 
measured by Niggli and Lederer [77]. They found that viscous damping was proportional 
to the velocity of sarcomere contraction: 
dt
dsBFV = ,          (2.8) 
 
where B is the viscous damping constant (in units of Ns m-1). Under the assumption that 
an intervention does not change the viscosity constant, ratios of viscous force equal ratios 
of contraction rates.  
 
In summary, when assessing the mechanism of an intervention, passive restoring force 
and viscous damping must be considered when relative sarcomere shortening is used as 
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an index of contractility. Important information about the passive forces may be obtained 
by comparing rates of contraction and relaxation or by measuring the sarcomere length 
reached at the time of maximum acceleration during contraction and relaxation, as 
discussed in more detail in Chapter IV. 
 25
CHAPTER III 
 
THE NANOPHYSIOMETER 
 
3.1 Device concept, design and fabrication 
The integration of Bio-Micro-Electro-Mechanical Systems (BioMEMS) with 
biology and the development of self-contained lab-on-chip devices will provide powerful 
tools to study novel aspects of cell physiology. Large scale in vivo like biological 
experiments on a chip are possible through the introduction of microfluidics technology 
and mass fabrication techniques, which permit the fabrication of microfluidic channels, 
reservoirs, valves and pumps using bio-compatible materials [78, 79]. Miniaturized on-
chip cell cultures have been developed as part of cell-based toxin detectors [80-84] and 
micro- or nanoscale devices for novel experiments in cell biology [85]. Microfluidics 
technology offers tremendous potential for rapid biological analysis in quantitative 
systems biology, complementing or replacing traditional single cell measurement 
techniques such as patch-clamp [86-90] or fluorescence microscopy [84, 91, 92]. 
However, the development of microfluidics technology for scientific research is still in its 
early stage, as indicated by the small number of commercially available systems. 
Furthermore, the use of microfluidics for single cell manipulation and measurement is 
most often presented as “proof of concept” rather than being widely utilized as a research 
tool in mainstream life sciences. Microfluidic cell retention structures have been used to 
position and stabilize single cells during physiological recordings. Results obtained from 
cells confined in a restricted extracellular space provided by the microfluidic 
 26
environment seemed to be consistent with those obtained from cells in larger volumes as 
long as continuous solution exchange was provided. Klauke et al. demonstrated electrical 
field stimulation of single adult cardiac myocytes in an open architecture microchannel 
array [93]. Prolonged pacing of single cardiomyocytes in a 100 pl volume bath did not 
affect calcium transients although it reduced the sarcomere contraction amplitude after 40 
minutes. The reduction in contractility in the small volumes could be partially rescued by 
replacing the bath solution and did not occur in a larger, 5 nl volume. This observation 
shows that metabolite accumulation occurs in a restricted extracellular space thereby 
affecting the amplitudes of contraction. Other studies showed that prolonged electrical 
stimulation of isolated adult cardiac myocytes in micro-chambers did not impair 
excitation-contraction coupling as verified by optical recordings of action potentials, Ca2+ 
transients and cell shortening [94-96].  
The Nanophysiometer is a microfluidic-based device and a tool for physiological 
measurements on single isolated cardiac myocytes. The advantage of the microfluidic 
approach is that cells can be automatically positioned and confined under the microscope 
without damaging the sensitive cell membrane. Furthermore, the design of the 
microfluidic network permits the continuous perfusion of the entire cell, rapid 
extracellular volume exchange or selective perfusion of a membrane patch and the 
creation of well defined concentration gradients along a single cardiac myocyte. 
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Device fabrication using soft lithography 
The Nanophysiometer is a microfluidic device based on microscopic channels and made 
of Poly(dimethylsiloxane) (PDMS), a biocompatible polymer.  
PDMS is flexible, optically transparent (and therefore compatible with fluorescence 
microscopy) and inexpensive. It is also impermeable to water and highly permeable to 
gases [97]. It can be formed with ease by a molding process and bonded to other 
materials, which is an important advantage over glass and silicon, especially when rapid 
prototyping is required.  
The technique used to manufacture the Nanophysiometer is called “soft lithography” and 
was pioneered by George M. Whitesides [78, 98-101].  
 
 
Figure 6. Layout of a chrome mask with microfluidic structures (left) and 
microelectrodes (right). 
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It was later adapted by Stephen R. Quake who demonstrated the fabrication of complex 
microfluidic channel structures, including on-chip active valves and peristaltic pumps 
using a multilayer PDMS fabrication process [79, 102-105].  
The design of the microfluidic structure is drawn using a standard computer-aided design 
(CAD) program. Once the desired design is available in form of a digital drawing, 
commercial services transfer the patterns onto film transparencies (for > 25 µm size 
structures) or chrome masks (for > 2 µm size structures).  
The layout of a typical chrome mask is shown in Figure 6 with patterns for the fabrication 
of microfluidics (left) and microelectrodes (right). The mask is then used in an UV 
photolithography process to generate a master mold as shown in Figure 7. A thick layer 
of photoresist (e.g. the photo curable epoxy SU-8) is spin-coated onto the surface of a 
silicon wafer. Using different types of SU-8 with various viscosities in combination with 
different spin-coating velocities, thicknesses of 1-300 µm can be reliably achieved. The 
 
 
 
Figure 7. Photolithographic and molding process to fabricate microfluidic devices. 
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photoresist is then exposed to UV light through the chrome or film mask. A film mask 
has a lower spatial resolution with a typical smallest feature size of 25 µm. In order to 
achieve a higher resolution, additional size reduction can be achieved by placing a 
microscope objective in the light path between the photo mask and the silicon wafer 
(Figure 7B). It is important to note that objectives and optical elements used for size 
reduction in the exposure process reduce the effective area available for the microfluidic 
structure. Unexposed areas are removed in a chemical development process leaving only 
the channel relief structure on the surface of the wafer, which serves as a replica master 
mold. A PDMS/curing agent mixture (typically 10/1) is then cast onto the master and 
cured for 60 min at 70 ºC. The elastomer is then peeled off the master, producing the final 
replica bearing the designed microstructures. Small access holes are punched into the 
elastomer before it is sealed onto a glass substrate containing a thin-film microelectrode 
array. Further details about the design and application of the Nanophysiometer are 
presented in Chapter III. A more detailed description of the soft lithographic 
microfabrication process can also be found in the literature [78, 79, 98, 103]. 
 
Chemical control of the extracellular environment 
Cells and reagents are moved through the microfluidic channels of the Nanophysiometer 
by manually applied pressure gradients.  
The directions of the pressure gradients used to confine and perfuse single cardiac 
myocytes inside the Nanophysiometer are indicated by the arrows in Figure 8A. 
Chemical control of the extracellular space around a cardiac myocyte is achieved by 
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rapid solution exchange through microchannels leading into the measurement volume as 
shown in Figure 8A.  
The pressure gradients along the smaller perfusion channels in the Nanophysiometer 
allow continuous perfusion of the entire cell or parts of the membrane. In Figure 8B, the 
selective perfusion of a membrane patch is demonstrated. In this experiment, one end of 
the cell was perfused for 10 s through a microfluidic channel by a 1 µM fluorescent 
solution (Sulforhodamine 101), while the fluorescence was measured at six different 
positions along the myocyte. The position of the fluorescence detectors are indicated by 
the white circles in Figure 8C. The resulting fluorescence intensities were well described 
by the solution of the one-dimensional diffusion equation indicating laminar flow through 
the perfusion channels and diffusion-limited mixing along the cell [106].  
Figure 8. (A) Bright field microscope image of a cardiac myocyte confined inside the 
Nanophysiometer. The black lines are thin film microelectrodes used for field 
stimulation. Arrows indicate the directions of pressure gradients for continuous 
perfusion. (B) Concentration gradient measured by 6 PMTs along a single cardiac 
myocyte. (C) Bright field microscope image of the cardiac myocyte used in the 
experiment. 
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Stimulation of cardiac myocytes in the Nanophysiometer 
Thin-film microelectrodes are suitable for field stimulation of cardiac myocytes in the 
Nanophysiometer. In order to avoid changes in pH due to electrolysis during prolonged 
stimulation, electrode potentials must be kept below the reduction potential of water, i.e. 
0.83 V. This requirement can be achieved by using microelectrodes with small inter-
electrode distances. These microelectrodes require small electrode potentials to yield high 
electric fields. An approximate electric field strength on the order of 100 V/cm may be 
established by applying just 1 V across two parallel microelectrodes which are located 
100µm apart (Chapter IV). Cell membranes have a relatively small conductance 
compared with the extracellular medium. Therefore, the imposed electric field produces a 
flow of current primarily around the cell, resulting in a highly inhomogeneous electric 
field gradient along the cell surface. Given that the interior of the cell is essentially 
isopotential, the surface potential gradient results in a spatially varying transmembrane 
potential which can activate transmembrane currents through voltage-gated ion channels. 
Theoretical and experimental descriptions of electric field stimulation of single cardiac 
cells can be found in the published work of Leslie Tung et al. [107] and Vinod Sharma et 
al. [108, 109]. 
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3.2 Optical measurements of cytosolic calcium concentration and sarcomere length 
in the Nanophysiometer 
 
Fiber – optical system for high-resolution multi-parameter recordings 
 
 
 
Figure 9. (A) Schematic representation of the optical setup for intracellular calcium 
and sarcomere length measurements on single cardiac myocytes in the microfluidic 
device. (B) Screenshot of the Labview data acquisition software. (C) Optical mapping 
of 6 fibers positioned along a single cardiac myocyte in the Nanophysiometer. 
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Figure 9 shows the optical setup which was designed for the measurement of 
intracellular calcium concentration and sarcomere length from isolated single cardiac 
myocytes trapped in the Nanophysiometer. It was built around an inverted microscope 
(Axiovert 200, Carl Zeiss, Germany) equipped with an epi-fluorescence light train. A 
monochromator (Optoscan, Cairn Research Ltd., Kent, UK) was used to select the 
wavelength for dye excitation. It permitted wavelength selection from the 100 W Hg/Xe 
lamp emission in the range of 300-800 nm with a variable bandwidth of 1-30 nm which 
was controlled via galvano-driven input and output slits. The monochromator was also 
capable of fast wavelength-switching allowing ratiometric excitation (e.g. using fura-2) 
with switching times dependent of the wavelength range of less than 2 ms. Red light 
which did not excite the Ca2+ sensitive dyes was generated by a halogen lamp above the 
Nanophysiometer and used for whole-cell-high-speed sarcomere imaging via a 240 
 
 
 
 
Figure 10 Fiber - PMT connection. 
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frames-per-second CCD camera (Myocam, Ionoptix Corp., Milton, MA). The halogen 
light was transmitted by the dichroic mirror 1 and reflected by the mirror 2 onto the 
sarcomere camera which was connected to a frame grabber card installed in the computer 
1 for the measurement of sarcomere length. Alternatively, turning the mirror 2 by 90 º 
allowed indo-1 fluorescence detection via wavelength separation of the free dye 
(maximum emission at 405 nm) and the Ca2+-bound dye (maximum emission at 495 nm). 
The principle of ratiometric [Ca2+]i detection is described in more detail below. Replacing 
mirror 2 by a dichroic mirror permitted the simultaneous measurement of [Ca2+]i and 
sarcomere length. The fluorescence light was collected alternatively by six 1 mm 
diameter optical fibers selected from a 80-fiber array at the base port of the microscope or 
by two optical fibers at a side port of the microscope which were optically aligned to 
collect the fluorescence light from the same spot on the cell at two different emission 
wavelengths (for calibrated indo-1 measurements, Figure 9C). Each fiber was connected 
to a photomultiplier (PMT, H6780-20, Hamamatsu) via a custom designed connection as 
shown in Figure 10. The PMTs were mounted inside a shielded aluminum box and 
powered by batteries to reduce noise.  
The optical fiber connections were designed to accommodate 8 mm diameter filters to 
allow multiple-wavelength fluorescence detection.  
Optical mapping of the six fiber positions was accomplished by means of a scan 
converter which allowed mixing of the video feed with a computer drawing of the fiber 
geometry. Figure 9C shows the outlines of the 6 optical fibers on a single cardiac 
myocyte in the Nanophysiometer. Measurements of [Ca2+]i and sarcomere length were 
accomplished by using two separate data acquisition systems, i.e. computer 1 and 
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computer 2, equipped with A/D converter boards, with scan rates of 20 KHz and 1 KHz, 
respectively. Calcium and sarcomere length measurements were synchronized by the 
stimulus. To limit the exposure of stained cells to the phototoxic excitation light, shutter 
opening and stimulus were precisely controlled by a third computer.  
Computer 3 (Figure 9A) was used to generate a pulse train that opened the shutter 40 ms 
before the stimulus as shown in Figure 11. Additionally, when the pre-amplifier was 
operated in AC-coupled mode, a 30 ms sample and hold pulse (s+h) was initiated 5 ms 
after the opening of the shutter to temporarily reduce the output feedback resistor of the 
amplifier from 10 MΩ to 1 KΩ which shortened the time constant of the high-pass filter 
from 10 s to 1 ms, thereby avoiding saturation of the amplifier at high background 
fluorescence intensities. For calibrated indo-1 calcium measurements, however, the 
 
 
 
 
Figure 11 Control signals for fluorescence detection. 
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amplifier was operated in DC mode to allow recording of diastolic [Ca2+]i and 
background fluorescence. 
 
Measurement of cytosolic Ca2+ concentration 
The most popular method for measuring cytosolic [Ca2+]i in mammalian cells is to 
monitor the fluorescence of a calcium-sensitive indicator. Fluorescent probes for calcium 
are moderate to high-affinity calcium-binding molecules [110, 111]. They emit light upon 
excitation at a given wavelength. The intensity of the emitted light is a function of the 
amount of calcium bound to the dye molecules. Under the assumption that the dye 
concentration is small enough so that the fluorescence contribution induced by a given 
molecular species is proportional to the concentration of that species, the measured 
fluorescence intensity of a mixture of free and Ca2+ - bound indicator is given by: 
bbff cScSF ⋅+⋅= ,         (2.1) 
where cf and cb are the concentrations of the free and Ca2+ bound indicator, respectively. 
The two states of the dye are described by two proportionality coefficients, symbolized 
by Sf and Sb for the free and the Ca2+ bound dye. The S factor depends on the excitation 
intensity, extinction coefficient, path length, quantum efficiency and the instrumental 
efficiency of collecting emitted photons. Assuming 1:1 complexation, cf and cb are 
related by cb = cf [Ca2+]i / Kd, where Kd is the effective dissociation constant of the dye. 
Defining Fmin := Sf (cf +cb) and Fmax:=Sb (cf + cb) and solving equation 2.1 for [Ca2+]i 
yields the calibration equation for a single wavelength dye: 
FF
FFKCa di −
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min2 ][ .        (2.2) 
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Equation 2.2 clearly shows that [Ca2+]i is not directly proportional to the fluorescence 
intensity, but depends on Fmin and Fmax which are the minimum fluorescence in a Ca2+-
free environment and the maximum fluorescence at saturated [Ca2+], respectively. Under 
these conditions any given fluorescence reading from the intracellular dye may be 
compared with a calibration in which the dye is forced into known states of high and low 
Ca2+ saturation. However, Fmin and Fmax each depend on dye distribution and detector 
sensitivity. Hence, any intervening loss of dye or change in instrument sensitivity 
jeopardizes the calibration and may be mistaken for a change in [Ca2+]i. Therefore, 
calibration of single wavelength dyes is not reliable, although several approaches have 
been reported [112, 113]. The uncalibrated fluorescence intensity may be used to 
qualitatively identify transient changes in [Ca2+]i. To avoid these complications, 
ratiometric fluorescent indicators have been developed that are characterized by a shift in 
excitation or emission wavelength upon binding to Ca2+ ions. The ratio of the 
fluorescence intensities F1 and F2 at two excitation (or emission-) wavelengths λ1 and λ2 is 
in principle sufficient to calculate absolute [Ca2+]i independent of total effective dye 
concentration or instrument sensitivity: 
bbff
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With R:=F1/F2, the fluorescence ratio at the two wavelengths is given by: 
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Solving equation 2.4 for [Ca2+]i and substituting Rmin:=Sf1/Sf2 and Rmax:=Sb1/Sb2, one 
obtains 
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Equation 2.5 is analogous to the calibration equation 2.2 for a single wavelength dye, but 
independent of total dye concentration and instrument sensitivity. In order to quantify 
absolute [Ca2+]i concentration, we have established a protocol for in vivo calibration of 
the Calcium indicator dye indo-1, which is presented in Chapter IV.  
 
Measurement of sarcomere length 
Due to the periodic repetition of sarcomeres in the muscle, the dark A-band and light I-
band alterations result in a striated appearance. One sarcomere length would be defined 
as the distance from the middle of one I-band to the middle of the next when viewed 
under the light microscope. This distance may not be measured accurately. Therefore, 
alternative methods have been developed to get a good estimation of sarcomere length. 
 
 
 
 
Figure 12. (Top) microscope image of a single cardiac myocyte with the ROI defined 
by the yellow rectangle. (Bottom) average density trace (black) derived from the ROI 
and powerspectrum (red).  
(Adapted from Ionoptix Corporation, Ion Wizard SarcLen Data Acquisition User's 
Guide, 2000) 
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The approach used by the Ion Wizard SarcLen data acquisition software is to estimate the 
frequency of the striation pattern, i.e. how many sarcomeres can be found per length. The 
sarcomere length is measured from a user-defined region-of-interest (ROI) which is a box 
enclosed by four yellow lines as shown in Figure 12. All calculations are performed on a 
density trace derived from the ROI. Each pixel is assigned a value of brightness and 
because of the periodic repetition of the sarcomere the density trace has a sinusoidal 
appearance with the wavelength representing the sarcomere length. The density trace is 
transformed via a fast Fourier transform (FFT) algorithm from the spatial domain into the 
frequency domain. The output of the FFT is presented in form of the power spectrum in 
the lower part of Figure 12. The power spectrum is a representation of the relative 
contribution of each spatial frequency in the density trace. The most dominant pattern in 
the density trace, the dark-light transitions of the sarcomeres, appears as a sharp peak in 
the power spectrum. The average sarcomere length can then be derived from the peak of 
the power spectrum. Finally, the reciprocal value of the peak in the power spectrum (in 
units of pixels/sarcomere) is multiplied with a calibration factor (in length/pixel) to yield 
an average value of the sarcomere length in the ROI. The great advantage of this method 
is that it provides sub-pixel spatial resolution.  
 
Analysis of Ca2+ and sarcomere length recordings 
The time dependent changes of intracellular calcium concentration and sarcomere length 
were fit to empirical functions to calculate time constants and multiple time derivatives. 
All calculations were performed using Matlab (R14, The MathWorks, Inc.). During the 
action potential, calcium ions enter the cell through LTCC and trigger massive release of 
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Ca2+ through the intracellular Ca2+ release channels. The intracellular Ca2+ release 
channels are called ryanodine receptors (RyR) and are located in the membrane of the SR 
[114-116]. When a RyR opens, [Ca2+]i in its vicinity rises immediately to levels above 
10µM, resulting in the activation of neighboring RyRs. When the channel closes, the 
local Ca2+ transient dissipates rapidly (~ microseconds) due to the diffusion of Ca2+. 
Models of RyR kinetics have been derived from experiments performed on isolated 
channels in lipid bilayers using flash photolysis of caged Ca2+ (such as DM-nitrophen) to 
simulate fast changes in [Ca2+] in the microenvironment of the reconstituted channel. The 
apparent calcium sensitivity of the open probability, Po, in response to a Ca2+ spike was 
described by a Hill equation [117], based on binding of nH Ca2+ ions to channel [118]: 
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Where HnCaK describes the calcium sensitivity of the RyR, i.e. the Ca
2+ concentration 
required to activate 50 % of the channels, which was found to be on the order of 40 µM  
[118-120]. The time course of RyR activation was best fit by an exponential association 
function raised to the power of na  [121]: 
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Interestingly, although equations 2.8 and 2.9 were originally derived to fit RyR activation 
in isolated channels, they were well suited to fit the rising phase of the Ca2+ transient in 
the intact cell as presented in Figure 13.  
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The Hill slope nH was between 2 and 4 in isolated RyRs, strongly suggesting that binding 
of several Ca2+ ions must occur before the channel can open. In the intact cell, however, 
RyRs are organized in clusters of ~100 release units with strong interactions between 
them [40]. Therefore, the hill coefficient in equation 2.6 cannot be expected to represent 
single channel binding kinetics [122]. In fact, nH was consistently smaller than 1 in the 
 
 
Figure 13. Top: Fit of Ca2+ release (red) to the rising phase of the Ca2+ transient 
(grey line) and first time-derivative (blue). Bottom: Fit of sarcomere contraction 
(red) to the data (grey circles) and first time-derivative (blue). 
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intact cells. Nevertheless, the model provided a good fit to the data allowing the 
calculation and analysis of multiple time derivatives without amplifying noise 
contributions in the experimental data. The same equations used to model SR Ca2+ release 
provided a good fit to the sarcomere contraction data as shown in the bottom portion of 
Figure 13. 
During relaxation in mouse myocardium, more than 90 % of activator Ca2+ is taken up by 
the ATP-dependent SR Ca2+ pump, SERCA2a [41].  
Calcium uptake and sarcomere relaxation at the time t were best fit by a linear 
combination of two exponential 
functions: [ ]
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Measurements of the time constants τ1 and τ2 in equation 2.10 have been used previously 
to characterize the falling phase of the Ca2+ transient [33, 52, 123-125] and therefore, 
unique solutions were desired. However, five free parameters in equation 2.10 did not to 
allow a unique fit, so that a reduction of free parameters was required. The number of 
free parameters could be reduced to three by normalizing the Ca2+ transients at the 
maximum cytosolic [Ca2+]i: 
With  [ ] 02 =+
dt
Cad  and [Ca2+] = 0 at the time t = 0, one obtains: 
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A representative fit of Ca2+ uptake and sarcomere relaxation using equations 2.11 and 
2.12 is shown in Figure 14. 
 
 
 
 
 
 
Figure 14. (Top) Fit of Ca2+ uptake (red) to the falling phase of the Ca2+ transient 
(grey line) and first time-derivative (blue).(Bottom) Fit of sarcomere relaxation (red) 
to the sarcomere length measurement during relaxation (grey circles) and first time-
derivative (blue). 
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CHAPTER IV 
 
SARCOMERE ACCELERATION IN PHOSPHOLAMBAN DEFICIENT CARDIAC 
MYOCYTES REVEALS AN ALTERED MYOFILAMENT RESPONSE TO 
CYTOSOLIC CALCIUM CONCENTRATION 
 
4.1 Abstract 
 
Abnormal calcium cycling in animal models of heart failure and in human failing 
hearts is characterized by impaired sarcoplasmic reticulum (SR) Ca2+ uptake and 
diminished SR Ca2+ stores. A reduced level of SR Ca2+ ATPase pump (SERCA2a) 
molecules and a reduced degree of phosphorylation of phospholamban (PLN) is believed 
to contribute to the depressed SR Ca2+ uptake in heart failure. Interventions that target the 
SERCA2a – PLN interaction hold therapeutic promise by restoring cytoplasmic Ca2+ 
transients and contraction. In mice, PLN ablation is associated with elevated SR Ca2+ 
load and with a linear increase in the extent and rate of myocyte shortening and 
relaxation. These positive inotropic and lusitropic effects of genetic PLN deletion have 
been attributed to the upregulation of Ca2+ transients. However, PLN knock out results in 
significant reordering of contractile proteins, leading us to hypothesize that an increase in 
the myofilament Ca2+ sensitivity contributes to the faster sarcomere contraction in 
cardiomyocytes lacking PLN. We used a microfluidic device to trap myocytes in a 
physiologically realistic space that facilitates sarcomere shortening and Ca2+ transient 
measurements.  
We measured sarcomere acceleration from free contracting wild type (WT) and PLN 
knock out (PLN-/-) ventricular myocytes and used it as an index of cellular inotropy. The 
maximum sarcomere acceleration was 9.1 ± 2.1 fold increased (P<0.001) while Ca2+ 
release was moderately increased (1.65 ± 0.30 fold, P<0.01) in PLN-/- compared to WT 
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cardiomyocytes. Furthermore, at the time minimum sarcomere length, cytosolic Ca2+ 
concentration was almost 50% smaller in the PLN-/- cells. Our data add a physiological 
dimension to a previously published proteomic analysis showing that chronic PLN 
ablation changes myofilament composition. PLN-/- ventricular myocytes have 
significantly enhanced myofilament responses to systolic Ca2+i. Our results provide novel 
insight into myofilament contractile responses to chronic PLN gene deletion. 
 
4.2 Introduction 
Heart failure remains the leading cause of mortality and morbidity in developed 
countries. Diminished calcium transient amplitude, reduced sarcoplasmic reticulum (SR) 
Ca2+ content and impaired Ca2+ re-uptake are observed in cardiac myocytes from failing 
human hearts. Furthermore, altered protein expression profiles and phosphorylation states 
of key sarcoplasmic reticulum (SR) components were found in failing cardiac myocytes 
[6, 44, 126]. The reduced cardiac output observed in failing human hearts has been 
attributed to changes in the calcium transient  [16, 50]. Correcting the calcium transient is 
therefore a rationale to recover cardiac contractility in heart failure patients. 
Phospholamban (PLN) is one critical regulator of calcium homeostasis in the heart and a 
key therapeutic target in the treatment of heart disease. The PLN monomer is a 6.08 kDa, 
52 amino acid transmembrane protein that is located in the cardiac SR (see reviews by  
[21-23]). It binds to and inhibits the activity of the SR Ca2+ pump (SERCA2a), which 
actively transports Ca2+ into the SR to lower cytosolic calcium concentration allowing 
relaxation to occur. PLN inhibits SERCA2a by decreasing Ca2+ transport and ATPase 
activity at low intracellular calcium concentrations. Phosphorylation by cAMP-dependent 
 46
protein kinase (PKA) and Ca2+/Calmodulin-dependent protein kinase II (CaMKII) at high 
cytosolic intracellular calcium concentration relieves this inhibition allowing greater Ca2+ 
transport across the SR  [127-129]. Mice engineered for PLN deletion (PLN-/-) have an 
increased rate of ventricular relaxation in whole hearts  [130], in papillary muscle 
preparations  [36] and in single cells  [54]. Most strikingly, PLN ablation prevented the 
functional, structural and histological abnormalities in a mouse model of dilated 
cardiomyopathy that shows characteristics of heart failure [131]. Several other studies 
have clearly shown the beneficial effects of chronic PLN suppression on cardiac function 
and remodeling in myocardial cells isolated from human failing hearts  [132] and in 
animal model of heart failure  [132-135]. However, other reports indicate that correcting 
the Ca2+ transient alone might not translate into improved cardiac function or into 
reversal of remodeling  [136, 137]. Furthermore, the inheritance of two copies of the 
human PLN mutation, Leu39stop, which can be considered the equivalent to a PLN-null 
genotype, led to dilated cardiomyopathy and heart failure  [138]. Discrepancies between 
the cardiac phenotypes in mice and in humans may originate from differences in the 
balance of myocyte Ca2+ fluxes because humans have a larger cardiac reserve, i.e. a 
potential for a gain in SR Ca2+ content  [41].  
There is evidence that genetic PLN ablation leads to systemic biochemical remodeling 
which might affect mice differently than humans. Proteomic analysis of hyper-dynamic 
PLN knockout mouse hearts revealed alterations in the expression level of more than 100 
ventricular proteins, along with changes in the phosphorylation state of important 
regulatory proteins  [56, 139]. Interestingly, the proteins affected by phospholamban 
ablation could be divided into two groups: metabolism and contractile apparatus. 
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Quantitative Western blotting confirmed changes in the two subunits of the myosin light 
chain (MLC-1 and MLC-2), which associate with the heavy chains to form a functional 
contractile unit. The atrial isoform of MLC-1 was down-regulated while its ventricular 
isoform was upregulated. In addition to the MLC-1 isoform switching, MLC-2a protein 
levels were higher in the PLN-/- than in the wild-type control hearts. Two dimensional 
32P autoradiography also showed that phosphorylation of MLC-2v was significantly 
increased in the PLN-/- ventricles. Phosphorylation of MLC-2v accompanies sarcomere 
organization and may facilitate the incorporation of additional actin/myosin crossbridges 
into the sarcomere allowing for higher organization of the sarcomeric architecture  [140]. 
It has been shown in rat and human cardiac muscle to increase the calcium sensitivity of 
the myofilaments leading to an increased contraction at a given amount of cytosolic 
calcium concentration  [141, 142]. Thus, these compensatory changes in contractile 
proteins may result in enhanced myocardial contractility, but they had never been 
considered as major contributors. In fact, the positive inotropic effect of PLN deletion 
was attributed to the increased SR Ca2+ load leading to increased amplitudes and rates of 
intraventricular pressure in isolated whole heart preparations  [24, 53, 139] and increased 
twitch contraction amplitudes and velocities in single cells  [52, 54, 55, 143].  
We investigated the time course and the amplitude of the Ca2+i transients in relation to the 
amplitude and velocity of the sarcomere shortening and relaxation in cardiac myocytes 
isolated from PLN-/- and wild type (WT) control hearts. The aim of the study was to test 
whether or not the Ca2+ sensitivity of contractile machinery is changed in phospholamban 
deficient cardiac myocytes. Furthermore, we present a novel microfluidic based 
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technique to confine single cardiac myocytes and thereby reducing motion artifacts 
during prolonged optical recordings.  
4.3 Methods 
Microfluidic device fabrication and cell manipulation 
  The microfluidic cell trap is based on a previously published device  [144]. Briefly, 
an inverted relief microchannel structure was produced by photolithography in a 30 µm 
thick layer of photoresist (SU8-2050, Microchem) on a 3 ” diameter silicon wafer 
(master) by exposing it to UV light through a metal mask (Advance Reproductions) using 
a contact mask aligner. The photoresist was developed according to the manufacturer’s 
instructions. A 5 mm layer of PDMS, poly-dimethylsiloxane was cast onto the master in a 
plastic culture dish at the standard PDMS/curing agent mixing ratio of 10/1 [98]. After 3 
h of curing in a 60 ºC convection oven, PDMS devices were cut out and separated from 
the master. Microchannel access holes were punched through the elastomer by means of 
1mm diameter sharpened stainless steel capillaries. The PDMS structure was manually 
aligned and sealed by auto-adhesion on the microelectrodes which were deposited on #1 
cover glass by ion beam evaporation [145]. Stainless steel capillaries were inserted into 
the PDMS access holes and connected to 1 ml syringes via 0.5 mm inner diameter 
microtubing (Cole Parmer). The cell trap consisted of a 25 µm wide and 220 µm long 
channel with a 5 µm wide restriction at the one end where the cell was held by suction as 
shown in Figure 15B. Occasional cell damage caused by the trapping procedure could be 
identified immediately by hyper contracture followed by cell death. However, more than 
80 % of the cells showed no sings of cell damage with sharp edges and clear striation 
patterns. These cells remained viable and could be electrically stimulated in the 
 49
microchannel for at least one hour. The voltage required to pace the cells was less than 
500 mV, which prevented gas formation due to electrolysis, a common problem in 
culture dish experiments with electrode separations on the order of millimeters.  
 
Isolation of ventricular cardiac myocytes  
Animal studies conformed to the guidelines of the Vanderbilt University Institutional 
Animal Care and Use Committee and to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996). Male phospholamban knockout mice, 3-4 months of age, and their wild-
type littermates were anesthetized by intraperitoneal injection of 3 mg/10ml Avertin 
solution (5 mg Avertin per 10 g body weight, T48402, Sigma-Aldrich) containing 
Heparin (H9399, Sigma-Aldrich). The heart was rapidly excised and placed into ice-cold 
Ca2+-free Hepes-buffered normal Tyrode (NT) solution. The NT solution contained (in 
mM): Na+ 140, K+ 4.5, Mg2+ 0.5., Cl- 150, H2PO4- 0.4, HCO3- 10, Hepes 10, glucose 10 
and no Ca2+. Calcium chloride was added where specified. The aorta was cannulated and 
the heart was perfused with NT solution at room temperature for 10 min to stop 
contractions. The perfusion was then switched to NT solution containing 10 µM Ca2+, 
178 U/ml collagenase (CLS2, Worthington Biochemical) and 0.64 U/ml protease (P5147, 
Sigma-Aldrich) for 8 to 10 min at 37 ºC. Ventricles and septum were cut away, coarsely 
minced, and placed into NT solution. Myocytes were dispersed by gentle agitation and 
the Ca2+ concentration was gradually increased to 0.5 mM. After 15 min, 10 mg/ml 
bovine serum albumin (A9647, Sigma-Aldrich) was added to the solution in which cells 
were stored until used, usually within 3 hours after isolation. 
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Measurement of indo-1 calcium transients 
Cells were loaded with the cell-permeant acetoxymethyl ester form of the calcium 
sensitive dye indo-1 (I1203, Molecular Probes-Invitrogen). Stock solutions were prepared 
by dissolving 1 mg of the dye in 200 μl anhydrous DMSO (276855, Sigma-Aldrich) 
yielding a stock concentration of 5 mM. The stock solution was stored in 20 μl aliquots 
desiccated and frozen at -20 ºC until used. For each experiment, one aliquot (20 μl) of the 
stock solution of the dye was added to 5 ml of cell suspension to yield a final 
concentration of 20 μM. Cells were kept in the staining solution for 5 min at room 
temperature and then centrifuged at 27 g for 10 min. The supernatant was removed and 
the cells were re-suspended in Tyrode solution containing the final calcium concentration 
of 1.0 mM. Cells were incubated in Tyrode solution for another 30-40 min to allow 
complete intracellular indo-1 de-esterification. To reduce phototoxic effects, only 200 μl 
of stained cells were pipetted into the bath solution for each fluorescent measurement 
after which the bath solution was completely replaced. The bath solution contained 
Tyrode solution at 1.0 mM CaCl2.  
 
Microscope configuration 
The microfluidic device was mounted on the stage of an inverted microscope (Axiovert 
200, Carl Zeiss, Germany) and the trap was magnified by a 63X, 1.4 NA oil immersion 
lens (Plan Apochromat, Carl Zeiss, Germany). The Indo-1 dye was excited by a 
monochromator (Optoscan, Cairn Research Ltd, UK) at a wavelength of 365 ± 15 nm. 
The excitation light was reflected by a 390 nm dichroic mirror (390DRLP, Omega 
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Optical Inc.) onto the cell. A second dichroic mirror (450 DCLP, Omega Optical) in the 
emission path was used to split the fluorescence light into a transmitted (F495) and a 
reflected beam (F405). Each beam was passed through a bandpass emission filter with a 
center wavelength of 495 ± 10 nm (495DF20, Omega Optical) and 405 ± 20 nm 
(405DF43, Omega Optical). The light from the two beams was finally collected by two 1 
mm diameter optical fibers (P1000-2-UV-VIS, Ocean Optics) representing a ~16 μm 
diameter spot on the cell and converted into an electric current by two photomultiplier 
modules (H6780, Hamamatsu). The photo currents were converted into voltages and 
amplified by custom-built DC coupled amplifiers and digitized at a sampling rate of 20 
KHz by an A/D converter board (PCI-6071E, National Instruments) in a standard PC.  
 
Calibration of Indo-1 calcium fluorescence 
Calibration of the indo-1 fluorescence signals was carried out at the end of the 
experiment according to a previously published method [146]. Background and 
autofluorescence were subtracted from the signal before the fluorescence ratios 
(R=F405/F485) were converted to free [Ca2+]i according to the equation [110]: 
[Ca2+]i=Kd·β·[R-Rmin]/[Rmax-R]. The dissociation constant for indo-1 was taken as 
previously published in vivo as Kd = 844 nM [146]. The ratio of the free/bound indo-1 
fluorescence at 485 nm was β = 2.37 ± 0.27. For in vivo measurements of Rmin and Rmax, 
indo-1 loaded cells were washed for 10min in calcium-free Tyrode solution containing 
5mM EGTA and 10 mM caffeine to empty the intracellular Ca2+ stores. Cells were then 
washed for 15 min in NT solution containing 5mM EGTA. To achieve metabolic 
inhibition and to avoid hyper contracture during the increase of the extracellular calcium 
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concentration, 3 µM carbonyl cyanide p-(tri-fluoromethoxy)-phenylhydrazone (C2920, 
Sigma-Aldrich) was added. To obtain Rmin, 10 µM of the nonfluorescent Ca2+ ionophore 
A23187 (B7272, Sigma-Aldrich) was added to the solution and measurements were taken 
after the fluorescence at both wavelengths reached stable values. For Rmax determination, 
the bath solution was EGTA-free and contained 15 mM Ca2+ to saturate the intracellular 
dye. The Ca2+-ionophore was present during all calibration measurements.  
 
Sarcomere contraction measurements 
Sarcomere contraction was measured from cells trapped inside the microfluidic device 
using a commercial contractility system (Ionoptix Corp.) consisting of a 240 frames-per-
second CCD camera (Myocam), a frame grabber PC card (FRGRAB), an analog/digital 
converter (DSI200) to record the stimulus, and the data acquisition software (Ion 
Wizard). The camera was connected to a side port of the microscope. Cells were field 
stimulated (square waves, 8 ms stimulus duration, 25 % above threshold) at 1 Hz until 
steady state was achieved and only those cells exhibiting stable steady-state conditions 
were included in the study. Indo-1 fluorescence and sarcomere contraction were 
determined in separate experiments, although simultaneous measurements are possible. 
However, we decided for separate measurements to avoid  Ca2+ buffering and 
phototoxicity during sarcomere contraction measurements  [147]. The timing of the 
stimulus was recorded for each calcium and contraction transient and used as a reference 
to synchronize both measurements. 
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Data analysis and statistics 
Data were analyzed in Matlab (R14, The MathWorks). The data were fit to empirical 
functions for the purpose of calculating multiple time derivatives. Intracellular calcium 
release [Ca2+]i was best fit by a modified model of isolated RyR activation as previously 
described  [121]: [Ca2+]i=[Ca2+]max· (P/1-P)n, where P is the time-dependence of the Ca2+ 
release, defined by a single exponential function raised to the power of m: P = 0.5·(1-e-
t/τ)m. The parameters n, m, and τ were used as fit parameters. Calcium uptake was best fit 
by a sum of two exponential functions: [Ca2+] i = A·e-t/τ1 + B·e-t/τ2. The parameters A, B, 
τ1 and τ2 were used as fit parameters. [Ca2+]i was replaced by the sarcomere length in the 
above equations to fit the contraction measurements.  
Maximum rates of Ca2+ release and sarcomere contraction were defined as the maxima of 
first time-derivatives of the Ca2+ and the contraction transients, respectively. Sarcomere 
acceleration was defined as the second time-derivative of the sarcomere contraction. The 
duration of the Ca2+ release and the duration of sarcomere contraction were defined as the 
times from 10 % to 95 % of the maxima of the Ca2+ and the contraction transients, 
respectively.  
Data are expressed as means ± S.E.M. Statistical significance was determined by 
Student’s t test for unpaired observations between wild type (PLN+/+) and 
phospholamban deficient (PLN-/-) cells. A p value < 0.05 was considered statistically 
significant. All data presented was taken from four animals in each group. The number of 
cells used in the statistical analysis is indicated in Figure 3. 
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4.4 Results 
 
Microfluidics facilitates cell alignment and reduces motion artifacts 
 
To get reliable, high resolution sarcomere length measurements, the striation 
pattern of the cell had to be aligned in the field of view and the position of the cell 
maintained during the whole time course of the experiment. The microfluidic device 
shown in Figure 15 automatically aligned and stabilized single cardiac myocytes during 
optical recordings.  
 
 
 
Figure 15. PDMS microfluidic cell trap. (A) Schematic overview of the microfluidic 
device sealed on a microelectrode array with cell delivery and perfusion channels that 
can be used to expose the cell to drugs. The cell trap near the center of the device can 
hold and perfuse a single cell during measurements. (B) Microscope image of the cell 
trap occupied by a single cardiac myocyte with microelectrodes for field stimulation 
parallel and perpendicular to the cell. 
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Single cardiac myocytes were pulled into the microfabricated cell trap by a negative 
pressure applied to the vacuum channel as shown in Figure 15B. Figure 16A and B show 
multiple sarcomere contraction recordings from a single cell in a culture dish and in the 
microfluidic cell trap, respectively. The recordings in the culture dish (Figure 16A) could 
only be analyzed during the first seven contractions. A slight rotation induced by the 
contraction led to measurement artifacts indicated by positive contraction amplitudes. In 
contrast, Figure 16B shows stable and highly reproducible recordings of sarcomere length 
from a confined myocyte inside the microfluidic cell trap with an improved signal to 
noise ratio.  
Reproducible recordings over long periods of time allowed us to average 40 to 50 
transients, thereby significantly increasing the S/N ratio and preserving the bandwidth of 
the measurement.  
 56
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Sarcomere contraction measurements in the microfluidic device. (A) 
Sarcomere length measurement from an unattached cardiac myocyte contracting in a 
perfusion chamber. (B) Sarcomere length measurement from a contracting cardiac 
myocyte inside the microfluidic channel, where the movement of the cell is 
restricted. 
 
 57
Phospholamban ablation increases calcium release and sarcomere contraction amplitude 
 
Phospholamban gene ablation has previously been shown to increase the SR Ca2+ content 
resulting in an increased Ca2+ release, leading to an increase in the amplitude of 
 
 
 
Figure 17 Cytosolic Ca2+ concentration and sarcomere length in PLN+/+ and PLN-/- 
cells. (A) Average steady state intracellular indo-1 Ca2+ transient from PLN+/+ cells 
(n=13) and PLN-/- cells (n=17). Every cell was represented by an average of 5-6 
consecutive indo-1 transients. (B) Average steady state sarcomere length transients 
from PLN+/+ cells (n=12) and PLN-/- cells (n=10). Every cell was represented by an 
average of 40-50 consecutive contraction transients. (B) Maximum Ca2+ release in 
PLN+/+ and PLN-/- cells (left) and peak sarcomere contraction amplitude in PLN+/+ 
and PLN-/- cells (right). *,†: p<0.05 
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sarcomere contraction. However, the dynamics of the Ca2+ release in combination with 
the contraction have not been characterized in PLN -/- mice. Figure 17A shows Ca2+ 
transients and dynamic changes in sarcomere length relative to a stimulation pulse during 
a single contraction.  Indo-1 Ca2+ transients from PLN-/- cells were larger in amplitude 
and shorter in duration. Maximum Ca2+ release was increased 1.65 ± 0.30 fold in the 
PLN-/- cells. Peak Ca2+ release was 932 ± 85 nM in PLN-/- cells and 566 ± 88 nM in the 
PLN+/+ cells, as shown in Figure 17B. 
The increased peak Ca2+ release in the PLN-/- cells was accompanied by a 5.12 ± 0.73 
fold increased peak sarcomere contraction amplitude with magnitudes of 174 ± 12 nm in 
the PLN-/- cells and 34.1 ± 4.2 nm in the PLN+/+ cells. The data are shown in Figure 
17B. Diastolic sarcomere length was shorter in the PLN-/- cells with 1.78 ± 0.02 µm 
compared to 1.81 ± 0.02µm in the PLN+/+ cells, while there was no difference in the 
diastolic [Ca2+]i. The fractional sarcomere shortening during contraction was therefore 
1.89 ± 0.24 % in the PLN+/+ and 9.85 ± 0.6 8 % in the PLN-/- cells, respectively. 
 
Phospholamban ablation alters calcium release and the dynamics of sarcomere 
contraction 
 
A large contributing factor in myofilament activation is the rate of rise of intracellular 
calcium concentration [61, 63].  
Therefore, we compared the time courses of the Ca2+ release and the sarcomere 
contraction in more detail as shown in Figure 18.  
Time to maximum Ca2+ release was not significantly changed, with 19.97 ± 0.83 ms in 
the PLN+/+ cells and 19.3 ± 1.0 ms in the PLN-/- cells (Figure 18A).  
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The maximum Ca2+ release rate was increased 1.85 ± 0.15 fold in the PLN-/- cells, with 
6.15 ± 0.37 µM per 100ms in the PLN+/+ cells and 11.39 ± 0.68 µM per 100 ms in the 
PLN-/- cells (Figure 18B).  
Furthermore, the times until the maximum Ca2+ release rate was reached were similar in 
both groups, with 2.89 ± 0.17 ms in the PLN+/+ cells and 2.69 ± 0.24 ms in the PLN-/- 
cells (Figure 18C). These times were measured relative to the time point when the Ca2+ 
 
 
Figure 18. Time course analysis of Ca2+ release and sarcomere contraction in PLN+/+ 
and PLN-/- cells. (A) Time from 10 % to 90 % of the rising phase of the [Ca2+]i 
transient. (B) Maximum rate of the intracellular Ca2+ release. (C) Time from 10 % of 
peak [Ca2+]i to the maximum rate of Ca2+ release. (D) Time from 10 % to 90 % of the 
rising phase of the sarcomere length transient. (E) Maximum contraction velocity. (F) 
Time from 10 % of peak sarcomere contraction to maximum contraction velocity.  
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concentration reached 10 % of the maximum. Since the times to maximum Ca2+ release 
were the same for both genotypes, the increased maximum rate of Ca2+ release in the 
PLN-/- cells could be attributed to the increased Ca2+ release amplitude. 
In contrast, the time it took for the sarcomeres to reach their maximum shortening was 
almost 50 % smaller in the PLN-/- cells compared to the WT control cells. We measured 
a time of 50.7 ± 4.3 ms in the PLN+/+ cells and 27.5 ± 2.2 ms in the PLN-/- cells, 
respectively. Furthermore, our data analysis showed a large increase in the maximum 
sarcomere contraction velocity of 6.8 ± 1.1 fold in the PLN-/- cells compared to control, 
corresponding to a maximum shortening velocity of 0.113 ± 0.017 µm per 100 ms in the 
PLN+/+ cells and 0.764 ± 0.058 µm per 100 ms in the PLN-/- cells.  
The faster sarcomere shortening was also reflected by the time it took the sarcomeres to 
reach the maximum velocity of contraction. The PLN+/+ cells reached the maximum 
velocity of contraction in 4.62 ± 0.77 ms, while the PLN-/- cells only needed 0.48 ± 0.36 
ms, as measured from the time of 10 % contraction (Figure 18D).  
In summary, the sarcomere contraction velocity was increased 6.8 ± 1.1 fold and was 
reached 9.6 ± 1.6 times faster. Calcium release amplitude and rate were increased only 
1.65 ± 0.30 and 1.85±0.15 fold, respectively in PLN -/- mice compared to WT control.  
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Phospholamban ablation accelerates sarcomere shortening 
 
 
Figure 19. Sarcomere acceleration of PLN+/+ and PLN-/- cells (A) Time course of the 
sarcomere acceleration during contraction in PLN+/+ (solid line) and PLN-/- (dotted 
line) cells. The increased sarcomere acceleration was accompanied by a moderate 
increase in Ca2+ release (insert). (B) Sarcomere length at the time at which the 
maximum acceleration was reached during contraction (CONTRACT) and relaxation 
(RELAX). Dotted lines represent the diastolic sarcomere length. 
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In order to compare active and passive forces during contraction and to assess whether 
the increased inotropy in the phospholamban deficient cells could be the result of the 
increased Ca2+ release, we used the acceleration of sarcomere shortening as an index of 
contractility. Figure 19A shows the sarcomere acceleration as a function of time in the 
PLN+/+ and the PLN-/- cardiac myocytes. Sarcomere acceleration was consistently 
increased in the PLN-/- cells during the entire time course of contraction.  
The peak sarcomere acceleration was increased 9.1 ± 2.1 fold in the  PLN-/- cells with 
absolute values of 84 ± 18 μm/s2 in the PLN+/+ cells and 766 ± 67 µm/s2 in the PLN-/- 
cells (Figure 19A).  
The maximum sarcomere acceleration during compression and relaxation is proportional 
to the maximum total force, which is the sum of the positive active force which 
compresses the sarcomeres and the negative passive force that resists shortening (see 
discussion). Peak force was developed at almost diastolic sarcomere length (dotted lines 
in Figure 19A) in the PLN+/+ cells, i.e. at 1.796 ± 0.015 µm during contraction and at 
1.782 ± 0.014 µm during relaxation. In contrast, the sarcomeres of the PLN -/- cells were 
compressed to a much larger extent at the time of maximum force. Sarcomere length at 
peak force was 1.713 ± 0.023 µm during contraction and 1.649 ± 0.018 µm during 
relaxation in the PLN null myocytes.  
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Figure 20. Phase plots of PLN+/+ and PLN-/- cells. (A) Average twitch sarcomere 
length as a function of [Ca2+]i during the cardiac cycle in PLN+/+ and PLN-/- cells. 
Arrows indicate the time direction of contraction and relaxation. The circles and 
triangles represent 5ms time intervals in the PLN+/+ and PLN-/- transients, 
respectively. (B) Intracellular Ca2+ concentration at the maximum sarcomere length 
for PLN+/+ and PLN-/- cells. 
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Phospholamban ablation increases the response of the cardiac myofilaments to changes 
in intracellular calcium concentration 
 
PLN-/- cells showed a large increase in sarcomere acceleration with only a moderate 
increase in the peak calcium release and no significant change in the time course of the 
Ca2+ release. We have used phase plots as a method to identify a change in the Ca2+ 
sensitivity of contraction. This method has been described to investigate shifts in the 
myofilament Ca2+ sensitivity in isolated cardiac myocytes  [148]. Within each contraction 
the phase-plane diagram of sarcomere length and cytosolic [Ca2+]i concentration forms a 
counter-clockwise loop as indicated by the arrows in Figure 20A. The symbols which are 
drawn on top of each phase trajectory represent 5 ms time intervals. The larger mean 
distances of the triangles during contraction and relaxation on top of the PLN-/- trace 
indicate the increased velocities of contraction and relaxation in these cells compared to 
the WT control cells. The PLN-/- phase plot in Figure 20A clearly shows a hysteresis as a 
result of the delay between the peak [Ca2+]i and the onset of sarcomere shortening which 
can also be inferred from Figure 17A. The prominent shift of the PLN-/- phase trajectory 
to the left is consistent with an increase in the myofilament Ca2+ response in these cells, 
as cell shortening and the re-lengthening occurred at lower intracellular calcium 
concentrations compared to the PLN+/+ cells. The shortest sarcomeres were observed in 
the phospholamban deficient cells at a cytosolic Ca2+ concentration which was close to 
the diastolic level, i.e. 347 ± 17 nM, and much smaller than in the PLN+/+ control cells 
(651.1 ± 7.5 nM).  
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The phase plot clearly showed a characteristically different response of the cardiac 
myofilament to a given cytosolic calcium concentration which could explain the 
increased contractility of the PLN-/- sarcomeres. 
 
4.5 Discussion 
Time course of the Ca2+ release and the sarcomere contraction in the PLN-/- cells 
Our quantitative analysis of the time courses of the calcium release and sarcomere 
contraction revealed, that the shorter time-to-maximum contraction amplitude and the 
shorter time-to-maximum contraction velocity were not reflected by corresponding 
changes in the Ca2+ transient (Figure 18). Furthermore, the maximum rate of calcium 
release was increased in the PLN-/- cells due to the higher peak [Ca2+]i which was 
reached in both groups at the same time (Figure 18A). We observed that changes in the 
time course of SR Ca2+ release were not correlated with corresponding changes in the 
time course of sarcomere contraction. The force – [Ca2+]i relationship during a dynamic 
twitch is characteristically different than in the steady state. The steady-state force – 
[Ca2+]i relationships are measured in tetanized mouse and rat cardiac muscle preparations 
and are highly non-linear with hill coefficients between 5 and 10  [63, 149, 150] 
indicating a large increase of force with intracellular calcium concentration. Force – 
[Ca2+]i relationships measured during a twitch are characterized by a much smaller rise in 
force for a given increase in cytosolic [Ca2+]. In intact mouse ventricular muscle during a 
twitch, force increased approximately linearly with systolic Ca2+ concentration [149-
151].  The difference to the steady state is an apparent loss of myofilament Ca2+ 
sensitivity and cooperativity as a result of the fast changing cytosolic Ca2+ concentration, 
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which may not allow the formation of a dynamic equilibrium at any time during the 
transient  [62, 63]. This effect is even more pronounced in mice with PLN deletion 
leading to a further reduction in the force generation due to the extremely short Ca2+ 
transients. Therefore, the increase in the rate of sarcomere contraction in the PLN null 
myocytes may be the result of an increased amplitude (rather than a change in the time 
course) of the Ca2+ release or the result of a change in the Ca2+ sensitivity of the 
myofilaments. 
 
Sarcomere acceleration as an index of myocyte contractility 
We compared the relative changes in sarcomere acceleration in the PLN-/- cells with 
previously published data on the twitch peak force – peak [Ca2+]i relationship in WT 
mouse cardiac muscle to decide if the increased maximum Ca2+ release was indeed 
responsible for the increased contractility in the PLN deficient cells. 
In order to infer relative changes in contraction force from changes in sarcomere 
acceleration several assumptions about restoring forces need to be made. The active 
shortening response of an unattached cardiac myocyte reveals the maximum degree of 
shortening in a minimally loaded cell. The titin network provides the main contribution to 
the contraction opposing restoring force that limits shortening [72, 152, 153]. Therefore, 
the total force acting upon an unloaded sarcomere is the sum of the positive active force 
FA and the negative passive elastic resistance, FP. In addition to the elastic resistance, a 
viscous resistance FV provides a damping force during contraction which is proportional 
to the rate of shortening, i.e. FV = B ds/dt, where B is the damping constant and s the 
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sarcomere length [77]. Altogether, the total force FTOT acting upon the sarcomere during 
contraction can be described as:  
FTOT=FA  - FP - FV, where FA, FP are the time and length-dependent active and passive 
elastic forces, respectively, and FV is the time and velocity dependent viscous resistance. 
The total contraction force per sarcomere unit, FTOT, is proportional to the sarcomere 
acceleration, i.e. FTOT = m ·a, where m and a are the mass and acceleration of the 
sarcomere, respectively. Because sarcomere acceleration measures total force per 
sarcomere, both an increase in the active force and a decrease in the passive resistance 
would increase acceleration during contraction.  
The comparison of contraction with relaxation suggests that PLN deletion did not 
decrease the passive forces opposing shortening during sarcomere contraction. 
Interventions that increase the effective elastic constant were shown to slow down the 
rate of shortening but accelerate the rate of re-lengthening  [74, 75] in the anoxic heart 
(due to compression of crossbridges). Likewise, a softening of the elastic properties of 
the sarcomere would lead to increase the rate of contraction but decelerate relaxation. 
Therefore, a softer sarcomere would be shorter during contraction and longer during 
relaxation at the time of maximum force development.  
The data in Figure 19 show that the sarcomere length at the time of maximum 
acceleration was shorter in the PLN null myocytes during contraction and relaxation 
compared to the WT control. Since we observed a shorter sarcomere length both during 
contraction and relaxation we cannot assume that the passive forces opposing sarcomere 
contraction are decreased in the PLN -/- at maximum acceleration. In fact, the 
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significantly smaller sarcomere length during relaxation compared to contraction in the 
PLN-/- cells is indicative of an increase in stiffness of the sarcomeres.  
This was also reflected by the 12.14 ± 2.4 fold increased maximum relaxation velocity 
(data not shown) compared to the 6.8 ± 1.1 fold increase in maximum contraction 
velocity. Furthermore, the shorter diastolic sarcomere length in the PLN-/- cells 
contributed to an increase in the passive forces at all sarcomere lengths as predicted by 
the classical Frank-Starling effect  [154]. 
Therefore, we found that the assumption was justified that the passive sarcomere 
restoring force in phospholamban deficient cells, FPPLN, at the time of maximum 
acceleration, tmax, was not smaller than in WT control, so that FPWT(tmax) ≤  FPPLN(tmax). 
Under this assumption, the total force per sarcomere at the time tmax can be estimated as:  
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Assuming that genetic phospholamban deletion did not change the intracellular viscosity, 
the ratio of viscous forces may be replaced by the ratio of contraction velocities, i.e. 
WTPLNWT
V
PLN
V vvFFV // == , where V denotes the ratio of the PLN-/- and WT 
contraction velocities at the time tmax. The sarcomere mass, mPLN, is comparable in the 
PLN-/- and wild-type hearts, as no difference in the heart/body weight ratio was found  
[24]. Therefore, we assume that the sarcomere mass of the PLN-/- cells can be 
approximated by that of the WT cells: 
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We defined R as the ratio of PLN -/- and WT sarcomere accelerations.  
Taking equations 4.1 and 4.2 together yields a relationship between the ratios of 
sarcomere acceleration and active force in the unloaded cardiac myocytes: 
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The data presented in Figure 19B indicates that the passive force in the wild-type cells, 
FPWT, was small compared to the active force, FAWT, because the maximum acceleration 
was reached at a sarcomere length which was (within the standard error interval) equal to 
the diastolic value, while the contraction velocity reached nearly 20% of its maximum 
value at that time. This indicates a considerable active force development at almost 
diastolic sarcomere length. Therefore, the passive component of the total force at the time 
tmax, FPWT, may be neglected in first approximation compared to the active force, FAWT. In 
fact, Helmes et al. [153] directly measured the passive restoring forces in rat cardiac 
myocytes by selectively digesting titin. They found that the passive force decreased 
approximately linear during relaxation and that it was negligible at the diastolic value. 
Taken together, the ratio of the active forces developed in unloaded PLN-/- and WT 
cardiac myocytes can be estimated by: 
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If an intervention is known not to influence the elastic properties of the titin network, the 
inequality sign in equation 4.4 may be replaced by and equal sign, yielding a direct 
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relationship between ratios of active force and ratios of sarcomere shortening velocity 
and acceleration. 
The PLN-/- sarcomeres showed an R = 9.1 ± 2.1 fold increase in the maximum 
acceleration and a V = 28.6 ± 2.0 increase in the shortening velocities at the time tmax 
when the maximum total force was reached. The ratio of viscous damping to active force, 
FVWT/FAWT, can only take values between 0 and 1. Niggli et al. found that this ratio may 
likely exceed 30 % in the range of experimentally observed twitch shortening velocities  
[77]. On the other hand, Peak Ca2+ release was only slightly increased (1.65 ± 0.30 fold). 
The relationship 4.4 allowed us to compare our data to twitch-force peak-[Ca2+]i  
measurements in isolated intact mouse trabeculae and small papillary muscles [149, 150]. 
In these preparations, a two fold relative increase in the active force of shortening 
corresponded to an increase in [Ca2+]i concentration in the rage from 0.5 to 1.0 μM.  
Therefore, based on our [Ca2+]i measurements, the ratio of the active forces in PLN-/- and 
WT is expected to be smaller than 2. However, in the PLN-/- cardiac myocytes we 
measured an overwhelmingly a nine fold increase in the sarcomere acceleration along 
with a 28 fold increase in viscous loading which clearly indicates a change in the force-
[Ca2+]i relationship in the phospholamban deficient cardiac myocytes. 
  
Myofilament response to intracellular [Ca2+] 
A further indication for a change in the myofilament response to intracellular Ca2+ in the 
PLN null myocytes can be visualized by plotting sarcomere length as a function of Ca2+ 
release, as presented in Figure 20.  The shift in the PLN-/- phase plot to the left shows a 
much smaller cytosolic calcium concentration at the onset of contraction and relaxation 
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than in the WT cells (Figure 20B), which is characteristic for an increase in the Ca2+ 
myofilament sensitivity [148] in these cells. 
 
Summary and Implications 
In summary, our results showed a significant change in the force – Ca2+ relationship in 
cardiac myocytes isolated from phospholamban deficient mice. The smaller cytosolic 
calcium concentrations at the onset of contraction and relaxation are indicative of an 
increase in Ca2+ myofilament sensitivity. As a consequence, therapeutic interventions that 
target on the SERCA2a – PLN interaction may alter the myofilament response to 
cytosolic [Ca2+]. 
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CHAPTER V 
 
DIFFERENTAIL EFFECTS OF PHOSPHOLAMBAN AND CAMKII ON CALCIUM 
UPTAKE AND RELEASE IN ISOLATED CARDIAC MYOCYTES AT 
PHYSIOLOGICAL PACING RATES 
 
5.1 Abstract 
Phospholamban (PLN) is a critical regulator of sarcoplasmic reticulum (SR) Ca2+ 
uptake and a known target of the multifunctional Ca2+ and calmodulin-dependent protein 
kinase II (CaMKII). CaMKII activity has been shown to hasten both SR Ca2+ uptake and 
release via phosphorylation of PLN and the SR Ca2+ release channel (RyR2) in a 
frequency-dependent manner. However, most studies in mice were performed at low 
frequencies and at room temperature using pharmacological CaMKII inhibitors.  
We tested the role of PLN and CaMKII in the regulation of SR Ca2+ uptake and release in 
500 isolated cardiac myocytes using transgenic mice expressing a CaMKII inhibitor in 
the presence and absence of PLN and at pacing frequencies ranging from 0.2 Hz to 10 
Hz. In PLN deficient cardiac myocytes, Ca2+ uptake significantly shortened with pacing 
frequency but was not affected by chronic CaMKII inhibition. Ca2+ release increased 
with pacing frequency but was not affected by genetic CaMKII inhibition in the presence 
of PLN. However, PLN ablation alone and in combination with chronic CaMKII 
inhibition slowed Ca2+ release by 16+-7 % and 37+-10 %, respectively at 10 Hz. Our data 
provide novel insight into Ca2+ responses to chronic in vivo PLN gene deletion and 
CaMKII inhibition at physiological pacing rates. 
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5.2 Introduction 
Calcium ions enter the cell via voltage-gated sarcolemmal Ca2+ channels during 
depolarization, triggering massive Ca2+ release from the sarcoplasmic reticulum (SR) into 
the intracellular space [41]. The increase in free intracellular calcium concentration 
([Ca2+]i) initiates the contraction of the myofilaments. For relaxation to occur, most of the 
cytosolic calcium is transported back into the SR by the ATP driven calcium pump 
(SERCA2a). The rate at which SR Ca2+ uptake occurs is modulated by phospholamban 
(PLN), a 52-kDa SR protein which inhibits Ca2+ uptake into the intracellular stores in its 
unphosphorylated state. In vivo, phosphorylation of PLN by cAMP dependent protein 
kinase (PKA) and Ca2+- calmodulin-dependent protein kinase (CaMKII) relieves this 
inhibition leading to a higher calcium pump activity  [21, 22]. When the heart rate 
increases, an increase or decrease of the developed force (positive or negative force-
frequency relationship) may occur paralleled by an acceleration of relaxation (frequency-
dependent acceleration of relaxation, FDAR). While the force-frequency relationship can 
be either positive or negative, depending on many factors such as species, origin of the 
tissue, range of frequencies, temperatures or calcium concentration, the time course of 
contraction and relaxation is unanimously accelerated with increased pacing frequency 
and thus preserved across all preparations and species [124]. The frequency-dependent 
acceleration of relaxation (FDAR) is a purely SR related phenomenon, because it is 
abolished by inhibition of the SR Ca2+ uptake  [32, 155, 156]. Phospholamban can be 
phosphorylated by CaMKII, which itself is active along the SR and in vivo known for 
affecting PLN [157], the L-type Ca2+ channel (LTCC) [158] and the cardiac Ca2+ release 
channel (RyR2) [159]. CaMKII phosphorylates PLN at Thr17, a site which is distinct 
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from the PKA phosphorylation site at Ser16. The frequency dependence of CaMKII 
activity was first discovered by De Konick and Schulman, who showed in an elegant in 
vitro experiment that CaMKII is capable of decoding the frequency of repetitive calcium 
spikes [160]. Others confirmed the hypothesis of a frequency-dependent activation of 
CaMKII activity in the heart showing that an increased pacing rate not only elevated the 
CaMKII activity in whole heart preparations  [159], but specifically increased PLN Thr17 
phosphorylation without altering the PKA-mediated Ser16 phosphorylation  [33, 35, 37]. 
In contrast, pharmacological or genetic CaMKII inhibition reduced phospholamban 
Thr17 phosphorylation  [48, 161, 162] and slowed SR Ca2+ uptake in isolated ferret  
[125] and rat  [156] cardiac myocytes. FDAR was markedly reduced in mice expressing 
Thr17-Ala mutant PLN in a PLN null background [37]. The pharmacological CaMKII 
inhibitor KN-93 completely abolished FDAR in isolated mouse muscle and prevented the 
frequency-dependent shortening of the Ca2+ transient in isolated rat myocytes  [123]. 
However, other reports clearly show that the role of CaMKII phosphorylation of PLN is 
still a controversy. In a recent study, Valverde et al. showed that FDAR occurred without 
a significant change in the phosphorylation state of PLN residues in the intact rat heart 
and in isolated cat papillary muscle preparations, and concluded that CaMKII 
phosphorylation pathways were not involved in FDAR  [33]. Furthermore, the force-
frequency relationship was flat and FDAR was absent in papillary muscles isolated from 
PLN null mice  [36]. Other studies showed that the frequency-dependent acceleration of 
SR Ca2+ uptake was still present in PLN null myocytes, but could be prevented by adding 
KN-93 to the medium in these cells  [52, 123]. As a consequence, a phospholamban 
independent mechanism of FDAR was suggested via direct SERCA2a phosphorylation  
 75
[163, 164], but this hypothesis was strongly challenged by other reports that refused this 
possibility  [165, 166]. CaMKII may also play a role in the regulation of the cardiac SR 
Ca2+ release channel (RyR2). CaMKII phosphorylation of RyR2 at the CaMKII specific 
site (Ser2815) increased the open probability of the isolated channel  [167, 168] and 
increased SR Ca2+ release in intact cardiac myocytes  [125, 169, 170]. RyR2 
phosphorylation was increased after pacing, suggesting a frequency-dependent regulation 
of SR Ca2+ release in the heart  [159]. However, the effect of CaMKII on the RyR2 is 
controversial because other studies showed that CaMKII activity may decrease the open 
probability of the RyR2  [171, 172]. The interpretation of previously published studies on 
the frequency dependence of Ca2+ uptake and cardiac muscle relaxation may be 
complicated by the different experimental conditions and unspecific side effects of 
pharmacological CaMKII inhibitors. Most studies in mice were performed at room 
temperature and at maximum pacing rates ranging from 2 to 5 Hz, while the physiologic 
heart rate of mice is in the range of 10 to 12Hz. Because calcium transients are short in 
mouse myocytes, intracellular [Ca2+]i levels and CaMKII activity are expected to rise 
significantly with increasing pacing frequency  [160]. Furthermore, pharmacologic 
CaMKII inhibitors, such as KN-93, KN63 or W-7 are known to have unspecific side 
effects on cardiac ion channels  [173, 174]. Clearly, the current literature shows that the 
role of CaMKII in the frequency-dependent regulation of calcium uptake and release is 
not resolved. The goal of this study was to determine whether CaMKII activity or the 
presence of phospholamban is required for the frequency-dependent acceleration of Ca2+ 
uptake at physiological pacing frequencies and temperatures. Furthermore, we 
investigated the effects of CaMKII activity on the time course of the intracellular Ca2+ 
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release in the presence and absence of PLN. We used a previously published model of 
chronic cardiac CaMKII inhibition by cardiomyocyte delimited expression of a specific 
CaMKII inhibitory peptide (AC3-I) that targets a conserved region of the CaMKII 
regulatory domain as well as a transgenic control mouse expressing an inactive scrambled 
version of the peptide (AC3-C)  [162, 175].  Transgenic AC3-I and AC3-C mice were 
interbred with PLN-/- mice to eliminate PLN-dependent CaMKII contributions to the SR 
Ca2+ uptake and release. 
 
5.3 Methods 
Mice with genetic CaMKII inhibition 
The AC3-I and AC3-C mice were generated by synthesis of a minigene based on 
the peptide sequence of AC3-I (KKALHRQEAVDCL) or AC3-C 
(KKALHAQERVDCL)  [176] and was described earlier  [162].  Both AC3-I and AC3-C 
were fused to enhanced green fluorescence protein (eGFP) for stabilization and to label 
the cellular tissue distribution for the transgenically expressed proteins. 
PLN null mice  [177] were interbred with AC3-I and AC3-C mice for > 4 generations and 
the genetic identity of PLN-/- pubs with transgenic expressing of AC3-I or AC3-C was 
confirmed using PCR  [162]. There was no evidence of cellular hypertrophy in isolated 
ventricular myocytes, based upon equivalent cell membrane capacitance measurements. 
We isolated single cells from 3 to 5 months old male and female mice (about half of the 
cells originated from female mice). Wild-type (WT), AC3-C, AC3-C x PLN-/- and PLN-
/- littermates served correspondingly as controls. 
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Isolation of ventricular cardiac myocytes  
Animals were cared for according to PHS Guide for the Care and Use of Laboratory 
Animals. All animal protocols were approved by the Institutional Animal Care and Use 
Committee, IACUC at Vanderbilt University. Mice were anesthetized by intraperitoneal 
injection of a 25 mg/ml Avertin solution (5 mg Avertin per 10 g body weight, T48402, 
Sigma-Aldrich) containing 3 mg/10ml Heparin (H9399, Sigma-Aldrich). The heart was 
rapidly excised and placed into ice-cold Ca2+-free Hepes-buffered Tyrode solution (NT). 
The aorta was cannulated and the heart was perfused retrograde with Ca2+-free NT 
solution at room temperature for 10 min to stop contractions. The NT solution contained 
(in mM): Na+ 140, K+ 4.5, Mg2+ 0.5., Cl- 150, H2PO4- 0.4, HCO3- 10, Hepes 10. Calcium 
was added when specified. The perfusion was switched to NT solution containing 10 µM 
Ca2+, 178 U/ml collagenase (CLS2, Worthington Biochemical) and 0.64 U/ml protease 
(P5147, Sigma-Aldrich) for 8 to 10 minutes at 37 ºC. Ventricles and septum were cut 
away, coarsely minced, and placed into Ca2+ -free Tyrode solution containing 0.5 % BSA 
at room temperature. Myocytes were dispersed by gentle agitation and Ca2+ concentration 
was gradually increased within 30 min from 0 mM to 0.5 mM to obtain calcium tolerant 
cardiac myocytes. Cells were stored in the BSA solution until used. All experiments were 
performed within the first three hours after isolation. 
 
Measurement of x-rhod-1 calcium transients 
We measured absorption spectra of AC3-I and AC3-C cells and found intense 
autofluorescence peaks in the wavelength range of 350 to 380 nm, likely originating from 
the AC3-I – EGFP construct. Therefore, the ratiometric dye fura-2 was not suitable for 
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this study. We considered other ratiometric dyes and found that the fluorescence of the 
red-shifted version of fura-2, fura-red, was contaminated by the AC3-I – EGFP protein as 
well  [178]. The ratiometric-emission dye indo-1 was compatible with EGFP, but showed 
a poor signal-to-noise ratio (S/N) due to the wavelength separation of the fluorescence 
intensity  [110, 111]. We decided to use the single wavelength dye X-Rhod-1 for this 
study (4 μM, X14210, Molecular Probes-Invitrogen) which displayed a good separation 
of both excitation and emission wavelength from that of the AC3-I – EGFP protein and a 
very bright fluorescence resulting in a good S/N ratio [179]. For every cell, AC3-I or 
AC3-C expression was confirmed by green fluorescence after the acquisition of the Ca2+ 
transient. The dye was purchased in 50 μg aliquots. For each experiment 25 μg dye in 20 
μl DMSO (276855, Sigma-Aldrich) was added to 5 ml of cell suspension.  
Cells were kept in the staining solution for 5 min at room temperature and then 
centrifuged at 27 g for 10 min. The supernatant was removed and the cells re-suspended 
in NT solution containing 1.0 mM CaCl2.The bath solution was kept at 37 ºC and 
contained NT solution with 1.0 mM CaCl2, supplemented with 10 μg/ml insulin, 5.5 
μg/ml transferring and 6.7 ng/ml sodium selenite (100X medium supplement, 41400, 
Gibco-Invitrogen).  
The medium supplement had previously been shown to benefit mouse myocyte cultures 
by promoting glucose uptake and monovalent cation and phosphate transport and allowed 
prolonged high-speed stimulation in the serum free bath solution. Myocytes were 
stimulated by two parallel platinum wires connected to a field stimulator (701B, Aurora 
Scientific, Inc.) at six different rates of 0.2; 1; 2; 4; 8 and 10 Hz.  
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Cells were stimulated for at least 60 contractions until they reached steady state.  
Multiple exposures were avoided in order to minimize phototoxic effects. This was 
accomplished by replacing the entire bath solution with cells after each exposure. The 
data presented in this study was taken from 495 cells. The number of cells and the 
number of animals are shown for each frequency and genotype in Table 1.  
 
 
 
Table 1. Number n of cells (animals) used in the study that involved 6 genotypes and 6 
different stimulation frequencies. For each cell, only one fluorescence measurement was 
taken to minimize phototoxic effects. About half of the cells in each group were isolated 
from male, the other half from female animals. 
 
F 
Hz 
AC3-I AC3-C WT AC3-I 
xPLN 
AC3-C 
xPLN 
PLN Σ 
        
0.2 24(4) 12(2) 23(3) 9(2) 13(3) 20(2) 101 
1 9(2) 8(2) 20(3) 8(2) 9(3) 16(2) 70 
2 7(2) 9(2) 20(4) 9(2) 12(3) 13(3) 70 
4 10(4) 12(2) 18(3) 8(2) 14(3) 12(3) 74 
8 22(5) 11(2) 27(4) 8(2) 17(4) 15(3) 100 
10 9(3) 14(2) 22(4) 9(2) 13(4) 13(3) 80 
Σ 81 66 130 51 78 89 495 
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Microscope configuration 
Fluorescence measurements were carried out using an inverted microscope (Axiovert 
200, Carl Zeiss, Germany) equipped with a 63X, 1.4 NA oil immersion lens (Plan 
Apochromat, Carl Zeiss, Germany). The dye was excited by a monochromator 
(Optoscan, Cairn Research Ltd, UK) at a wavelength of 560 ± 15 nm. The fluorescence 
emission was directed through a 595 nm dichroic mirror (XF2029, Omega Optical Inc.), a 
645 ± 37 nm emission filter (XF3081, Omega) and a 1 mm diameter optical fiber to a 
photomultiplier module (H6780, Hamamatsu).  
The signals were amplified by a high-bandwidth, custom built amplifier and digitized at a 
sampling rate of 20 KHz by an A/D converter board (PCI-6071E, National Instruments) 
using a PC. EGFP expression was confirmed by visual control of the green fluorescence 
using a standard EGFP filter set (XF104-2, Omega). 
 
Data analysis and statistics 
Data were processed using Matlab (R14, The MathWorks, Inc.). Background and 
autofluorescence were subtracted from the Ca2+ transients and the time course of the 
normalized x-rhod-1 fluorescence emission was used as a measure of the time course of 
intracellular [Ca2+]i concentration.  
Although single wavelength dye calibration is described in the literature, its reliability 
and reproducibility is highly questionable. The total fluorescence amplitude measured at 
a single wavelength depends on many parameters which are difficult to control over long 
periods of time involving hundreds of experiments (e.g. dye distribution, excitation 
intensity, extinction coefficient, optical path length and detector sensitivity).  
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Therefore, frequency-dependent changes in the time course of the Ca2+ transients were 
analyzed using normalized fluorescence transients. Ca2+ transients were fit to 
mathematical models for the purpose of calculating time derivatives. Calcium release was 
best fit by a modified model of RyR activation which was previously published  [121]: 
[Ca2+]i(t)=[P(t)/(1-P(t))]n , where t is time, and P(t) is the time-dependence of the Ca2+ 
release described by P(t) = 0.5·(1-e-t/τ)m.  
The parameters τ, n and m were used as fit parameters. Calcium uptake was best fit by a 
 
 
Figure 21. Analysis of x-rhod-1 Ca2+ transients. A, average X-Rhod-1 fluorescence 
transients from WT myocytes at frequencies of 0.2, 1 ,2 ,4 ,8 and 10 Hz showing the 
frequency-dependent shortening of the transients. B, representative dual exponential 
fit (dotted line) to the Ca2+ uptake (solid line) for a cell paced at 8 Hz. 
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sum of two exponential functions, [Ca2+]i = Ae-t/τ1 + Be-t/τ2 , where A, B, τ1 and τ2 were 
used as fit parameters. For statistical comparison 2-tailed t-tests or ANOVA with 
correction for multiple comparisons were used. Unless otherwise noted, data is expressed 
as mean ± standard error. Significance level was set at p < 0.05. 
 
5.4 Results 
Chronic CaMKII inhibition and PLN ablation did not prevent the frequency-dependent 
shortening of the time constant of the SR Ca2+ uptake 
 
Cytosolic Ca2+ transients were measured in field stimulated cells paced from 0.2 
to 10 Hz. Shortening of the transients occurred with increasing pacing frequencies as 
shown in Figure 21A for WT cardiac myocytes. Two time constants, τ1 and τ2, were used 
to fit to the tail of each transient as described in the methods section. A representative fit 
for a cell paced at 8 Hz is shown in Figure 21B. One time constant was consistently 
smaller than the other contributing less than 1 % to the total transient 50 ms after the peak 
of the transient. The value of the larger time constant, however, was consistently on the 
order of the duration of the transient and was therefore used to quantify the fluorescence 
decay. 
The frequency dependence of the second time constant is shown in Figure 22A for AC3-
I, AC3-C and WT cells. With the increase in pacing frequency from 0.2 Hz to 10 Hz, 
significant shortening of the Ca2+ time constant occurred in the AC3-I (170 ± 28 ms at 
0.2 Hz vs. 18.96 ± 0.69 ms at 10 Hz), AC3-C (222 ± 23 ms at 0.2 Hz vs. 18.25 ± 0.34 ms 
at 10 Hz) and in the WT myocytes (174 ± 15 ms at 0.2 Hz vs. 18.78 ± 0.37 ms at 10 Hz) 
and is shown in Figure 22A and C. The mean values of the time constant were 
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consistently smaller in the AC3-I compared to the AC3-C or WT myocytes, but the 
differences were not significant for most frequencies.  
PLN deficiency reduced the time constant of the Ca2+ uptake at all frequencies due to the 
higher Ca2+ pump activity, but our data still show a frequency-dependent shortening, as 
 
 
 
 
Figure 22. Frequency-dependent decrease of the time constant of the Ca2+ uptake after 
exponential fit. A, time constant for AC3-I, AC3-C and WT myocytes as a function of 
pacing frequency. ††: p<0.05. B, Ca2+ uptake time constant for AC3-I x PLN-/-, AC3-C 
x PLN-/- and PLN-/- myocytes. ‡‡: p<0.005. C,D, statistical comparison between 0.2 
Hz and 10Hz. *,†,‡,ƒ,§,§§: p<0.001.  
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indicated by Figure 22B and D. In the absence of PLN, significant shortening of the time 
constant occurred with increasing pacing frequencies in AC3-I x PLN-/- (37.3 ± 5.2 ms at 
0.2 Hz vs. 15.05 ± 0.75 ms at 10 Hz), AC3-C x PLN-/- (45.9 ± 7.7 ms at 0.2 Hz vs. 14.99 
± 0.66 ms at 10 Hz), and in PLN-/- (41.8 ± 3.8 ms at 0.2 Hz vs. 15.99 ± 0.67 ms at 10 
Hz) myocytes. Similar as in the presence of PLN, mean values of the Ca2+ uptake time 
constant were slightly shorter in the AC3-I x PLN-/- cells, but the difference was not 
significant for most frequencies. 
 
Chronic CaMKII inhibition and PLN ablation did not prevent the frequency-dependent 
shortening of the Ca2+ transient 
 
As a second criterion for the frequency-dependent shortening of the Ca2+ transients, we 
measured the fluorescence decay time from 90 % to 20 % of the maximum.  
With an increase in pacing frequency, Ca2+ transients shortened (Figure 21A). Similar to 
the time constant, the duration of calcium uptake decreased significantly with increasing 
pacing frequency in the AC3-I cells (269 ± 41 ms at 0.2 Hz vs. 45.3 ± 1.6 ms at 10 Hz), 
AC3-C (351 ± 31 ms at 0.2Hz vs. 43.5 ± 1.2 ms), and in the WT (281 ± 21 ms at 0.2Hz 
vs. 46.5 ± 1.1 ms at 10Hz) myocytes as shown in Figure 23A and C. Mean values of the 
Ca2+ uptake duration were slightly smaller in the AC3-I than in the AC3-C or WT cells, 
but the difference was not significant at most frequencies.  
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PLN ablation generally increased the rate of SR Ca2+ uptake leading to a shorter decay 
phase during the transient at all frequencies and for all mouse models as indicated by 
Figure 23B. However, consistent with the measurement of the Ca2+ uptake time constant, 
phospholamban ablation did not abolish the frequency-dependent shortening of the 
transient as presented in Figure 23B and D because the duration of Ca2+ uptake was 
 
 
 
 
 
Figure 23. Frequency-dependent shortening of the SR Ca2+ uptake duration as measured 
by the fluorescence decay duration from 90 % to 20 % of maximum. A, duration of Ca2+ 
uptake for AC3-I, AC3-C and WT myocytes. ††: p<0.005. B, duration of the Ca2+ 
uptake for AC3-I x PLN-/-, AC3-C x PLN-/- and PLN-/- myocytes. ‡‡: p < 0.001. C,D, 
statistical analysis for 0.2 Hz and 10 Hz. *,†,‡,ƒ,§,§§:p<0.001 
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significantly decreased at higher pacing frequencies in the AC3-I x PLN-/- (62.5 ± 5.4 ms 
at 0.2 Hz vs. 35.2 ± 5.3 ms at 10 Hz), AC3-C x PLN-/- (86 ± 10 ms at 0.2 Hz vs. 34.9 ± 
1.2 ms at 10 Hz) and in the PLN-/- (70.7 ± 4.1 ms at 0.2 Hz vs. 38.8 ± 2.0 ms at 10 Hz) 
myocytes.  
Mean values of Ca2+ uptake duration were consistently smaller in the AC3-I x PLN-/- 
compared to the AC3-C x PLN-/- cells, but the difference was not significant for most 
frequencies. 
 
Chronic CaMKII inhibition and PLN deficiency did not prevent the frequency-dependent 
increase in the Ca2+ uptake rate 
 
The maximum Ca2+ uptake rate (Vmax) was defined as the maximum time-derivative of 
the falling phase of the Ca2+ transient and increased approximately linear with pacing 
frequency in AC3-I, AC3-C and WT myocytes as shown in Figure 24A.  
With an increase in pacing frequency, Vmax (in 100 ms-1) increased significantly in the 
AC3-I (0.648 ± 0.082 at 0.2 Hz vs. 1.964 ± 0.081 at 10 Hz, p<0.001), AC3-C (0.325 ± 
0.024 at 0.2 Hz vs. 2.025 ± 0.039 at 10 Hz, p<0.001) and in the WT (0.436 ± 0.020 at 0.2 
Hz vs. 1.974 ± 0.041 at 10 Hz, p<0.001) cardiac myocytes as presented in Figure 24A 
and C. Maximum Ca2+ uptake rates were higher in cells expressing the CaMKII inhibitor, 
and the differences were significant at 0.2, 2, and 4 Hz. In the absence of PLN, Ca2+ 
uptake rates were higher, and the frequency dependence was reduced, but interestingly, 
the frequency-dependent increase in Vmax was still significant over the full range of 
frequencies. Vmax (in 100 ms-1) increased with increasing pacing frequencies in the 
AC3-I x PLN-/- (1.70 ± 0.11 at 0.2 Hz vs. 2.50 ± 0.13 at 10 Hz), AC3-C x PLN-/- (1.134 
± 0.097 at 0.2 Hz vs. 2.608 ± 0.096 at 10 Hz) and in the PLN-/- (1.435 ± 0.043 at 0.2 Hz- 
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vs. 2.35 ± 0.11 at 10 Hz) cardiac myocytes as presented in Figure 24D. Similar to Figure 
24A, Ca2+ release was significantly faster at several pacing frequencies, i.e. 0.2, 1, and 8 
Hz, in the AC3-I x PLN-/- cells compared to the control cells, AC3-C x PLN-/- and PLN-
/-.  
To show that the frequency dependence of Vmax was reduced by phospholamban 
ablation, we fitted the Vmax-frequency relationship to linear functions, and calculated the 
slopes of the Vmax-frequency relationships as shown in Figure 24E and F. In PLN 
deficient cells the slopes of the Vmax-frequency relationships were all positive and 
smaller than in cells in which PLN was present. The frequency dependence of Vmax was 
reduced in the AC3-I vs. AC3-I x PLN-/- cells (1.500 ± 0.058 vs. 1.00 ± 0.12), in the 
AC3-C vs. AC3-C x PLN-/- cells (1.766 ± 0.042 vs. 1.32 ± 0.12), and in the WT vs. 
PLN-/- cells (1.599 ± 0.040 vs. 0.863 ± 0.078). 
 
Combined chronic CaMKII inhibition and PLN ablation prevented early activation of 
Ca2+ uptake at increasing pacing frequencies.  
 
We determined the time to maximum SR Ca2+ pump activation by measuring the time 
from the peak fluorescence to the time at which Vmax was reached. When the pacing 
frequency was increased, the Ca2+ pump activated earlier resulting in a shorter time-to-
Vmax as shown in Figure 25A.  
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Figure 24. Frequency-dependent increase of the maximum SR Ca2+ uptake rate as 
measured by the maximum time derivative of the tail of the transient. A, maximum 
Ca2+ uptake rate for AC3-I, AC3-C and WT myocytes and linear fit of the AC3-I data 
(line). ††: p<0.05. B, maximum Ca2+ uptake rate for AC3-I x PLN-/-, AC3-C x PLN-/- 
and PLN-/- myocytes and linear fit of the AC3-I x PLN-/- data (line). ‡‡: p<0.01. C,D 
statistical comparison between 0.2Hz and 10Hz. *,†,‡,ƒ,§,§§:p<0.001. E,F slopes of 
the linear functions fitted to the frequency dependence as demonstrated in A,B. 
 
 
 
 
 89
 
 
 
Figure 25. Frequency-dependent shift of Vmax from the time of peak release. A, time to 
Vmax for AC3-I, AC3-C and WT myocytes (open symbols) and for AC3-I x PLN-/-, 
AC3-C x PLN-/- and PLN-/- myocytes (filled symbols). Linear fits to the data of the 
AC3-I data (top line) and the AC3-I x PLN-/- data (bottom line). ‡‡: p<0.05. B,C 
Statistical comparison between 0.2 Hz and 10 Hz. *,†,‡,ƒ,§:p < 0.005. 
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Time-to-Vmax shortened significantly in the AC3-I (53.9 ± 6.8 ms at 0.2 Hz vs. 19.54 ± 
0.51 ms at 10 Hz), AC3-C (70.0 ± 6.1 ms at 0.2 Hz vs. 18.09 ± 0.47 ms) and in the WT 
(55.8 ± 3.6 ms at 0.2 Hz vs. 19.80 ± 0.26 ms at 10 Hz) myocytes.  
There was no significant difference in the frequency dependence of the time-to-Vmax 
between AC3-I, AC3-C and WT myocytes.  
PLN gene deletion dramatically reduced the frequency dependence of the time-to-
maximum Ca2+ pump activation, but did not abolish it in the AC3-C x PLN-/- and in the 
PLN-/- myocytes as these cells showed a significant earlier activation during the transient 
at 10 Hz compared to 0.2 Hz as shown in Figure 25C.  
Time-to-Vmax decreased significantly in the AC3-C x PLN-/- (25.2 ± 1.8ms at 0.2Hz vs. 
14.95 ± 0.70 ms at 10 Hz) and in the PLN-/- (21.35 ± 0.97 ms at 0.2 Hz vs. 16.67 ± 0.57 
ms at 10 Hz) myocytes. The combination of CaMKII inhibition and PLN deficiency in 
the AC3-I x PLN-/- cells completely abolished the frequency dependence of the time-to-
Vmax as evidenced by the  mean values of this parameter at the smallest and highest 
frequencies (15.9 ± 2.1 ms at 0.2 Hz vs. 15.94 ± 0.77 ms at 10 Hz) and by the slope of the 
linear fit to the time to Vmax – frequency relationship drawn in Figure 25A, which was 
0.07 ± 0.11 ms/Hz in the AC3-I x PLN-/- myocytes. At all frequencies, time-to-Vmax 
was slightly shorter in AC3-I x PLN-/- than in the AC3-C x PLN-/- or PLN-/- cells, 
although the difference was significant only at 0.2, 1 and 8 Hz. 
 
Chronic CaMKII inhibition increased the duration of the Ca2+ release in cardiac 
myocytes lacking PLN. 
 
We investigated the influence of pacing frequency on the time course of the intracellular 
calcium release by measuring the time-to-maximum from 10 % to 90 % of the peak 
 91
fluorescence. Although the frequency dependence of the SR Ca2+ release was smaller 
than 0.5ms/Hz, the differences between 0.2 and 10 Hz were still significant in some 
cases. Figure 26A shows that time-to-maximum Ca2+ release was slightly smaller at 
higher pacing frequencies in the AC3-I (11.80 ± 0.78 ms at 0.2 Hz vs. 8.76 ± 0.52 ms at 
10 Hz) and in the AC3-C (12.68 ± 0.95 ms at 0.2 Hz vs. 9.31 ± 0.84 ms at 10 Hz) cells. 
In the WT myocytes the mean value of the time-to-maximum release was also reduced at 
 
 
 
 
 
Figure 26. Frequency-dependent acceleration of RyR2 activation as measure by the 
time from 10 % to 90 % of peak release. A, RyR2 activation time for AC3-I, AC3-C 
and WT myocytes. ††: p<0.05. B, RyR2 activation time for AC3-I x PLN-/-, AC3-C x 
PLN-/- and PLN-/- myocytes. ‡‡: p < 0.001. C,D statistical analysis for 0.2Hz and 
10Hz. *,†,‡,ƒ:p < 0.05. 
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the maximum frequency (9.52 ± 0.67 ms at 0.2 Hz vs. 8.07 ± 0.43 ms at 10 Hz), but the 
difference was not significant, showing that CaMKII may not significantly influence the 
Ca2+ release dynamics in these cells. Consistently, there was no significant difference 
across all frequencies in the time-to-maximum between AC3-I, AC3-C and WT 
myocytes. In the absence of PLN, calcium release was faster at higher frequencies in the 
AC3-C x PLN-/- (14.53 ± 0.95 ms at 0.2 Hz vs. 10.6 ± 1.2 ms at 10 Hz, p < 0.05) and in 
the PLN-/- myocytes (13.20 ± 1.00 ms at 0.2 Hz vs. 9.70 ± 0.76 ms at 10 Hz, p < 0.05). 
However, in the myocytes with combined chronic CaMKII inhibition and PLN 
deficiency, Ca2+ release was slowed, i.e. in the AC3-I x PLN-/- cells, time-to-maximum 
was 12.1 ± 1.1 ms at 0.2 Hz and 13.4 ± 1.5 ms at 10 Hz, but the difference was not 
significant.  
The tendency of AC3-I in the PLN-/- cells to slow Ca2+ release at higher frequencies was 
further emphasized by the positive slope of the linear fit to the time-to-maximum – 
frequency relationship in the AC3-I x PLN-/- myocytes (0.29 ± 0.14 ms/Hz), while the 
slope was negative in the AC3-C x PLN-/- and the PLN-/- myocytes (-0.39 ± 0.09 ms/Hz 
and -0.20 ± 0.09 ms/Hz, respectively).  
 
Chronic CaMKII inhibition slowed Ca2+ release in cardiac myocytes lacking PLN 
We measured the maximum time derivative of the rising phase of the Ca2+ transient as a 
second criterion to characterize the frequency dependence of the time course of the Ca2+ 
release and the results are shown in Figure 27. The maximum Ca2+ release rate (in 100 
ms-1) slightly increased when the pacing rate was raised from 0.2Hz to 10 Hz in the AC3-
I (10.47 ± 0.64 at 0.2Hz vs. 13.27 ± 0.73 at 10Hz) and AC3-C (9.71 ± 0.98 at 0.2Hz vs. 
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13.21 ± 0.87) cells (Figure 27A). It was also increased in the WT cardiac myocytes 
(12.91 ± 0.73 at 0.2Hz vs. 14.60 ± 0.52 at 10Hz), but the difference was not significant (p 
= 0.07). There was no significant difference in the maximum Ca2+ release rate between 
AC3-I, AC3-C and WT myocytes across all frequencies. In the phospholamban deficient 
 
 
 
 
 
Figure 27. Frequency-dependent increase of the maximum Ca2+ release rate. A, 
maximum release rate for AC3-I, AC3-C and WT myocytes. Linear fit to the AC3-I 
data. ††: p < 0.005. B, maximum release rate for AC3-I x PLN-/-, AC3-C x PLN-/- 
and PLN-/- myocytes. Linear fit to the AC3-I x PLN-/- data (line, positive slope) and 
AC3-C x PLN-/- data (line, negative slope). ‡‡: p < 0.005 C, D Statistical comparison 
between 0.2Hz and 10Hz. *,†,‡,ƒ,§:p < 0.005. 
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cardiac myocytes, however, the maximum Ca2+ release rate showed the tendency to 
increase with pacing frequency in the AC3-C x PLN-/- (8.12 ± 0.51 at 0.2 Hz vs. 12.1 ± 
1.1 at 10 Hz) and in the PLN-/- (9.28 ± 0.56 at 0.2 Hz vs. 12.31 ± 0.72 at 10 Hz) 
myocytes, and decrease in the AC3-I x PLN-/- myocytes (9.92 ± 0.94 at 0.2 Hz vs. 9.2 ± 
1.0 at 10 Hz) although the latter difference was not significant (Figure 27B and D). 
Therefore, the combination of chronic CaMKII inhibition and PLN deficiency 
significantly reduced the frequency dependence of the Ca2+ release. Consistently, a linear 
fit to the maximum Ca2+ release rate – frequency relationship revealed a slightly negative 
slope for the AC3-I x PLN-/- of -1.6 ± 1.1 s-1/Hz and a clearly positive slope for the AC3-
C x PLN-/- and PLN-/- myocytes of 4.6 ± 0.9 s-1/Hz and 2.3 ± 0.7 s-1/Hz, respectively.  
This result was consistent with the time-to-maximum measurement, suggesting that Ca2+ 
release was slowed in the AC3-I x PLN-/- myocytes with increasing pacing frequency. 
 
5.5 Discussion 
Ca2+/Calmodulin dependent protein kinase II has been implicated to play a role in 
the frequency-dependent shortening of the Ca2+ transient in mouse, rat and ferret 
ventricular myocytes  [123, 125, 156] leading to the frequency-dependent acceleration of 
relaxation. FDAR was suggested to originate from the frequency-dependent 
phosphorylation of phospholamban and therefore to rely on both CaMKII and 
phospholamban. Most published experiments were performed under non physiological 
conditions, i.e. low temperatures and low pacing rates and often used pharmacological 
inhibitors e.g. KN-93 or KN-63 which are known for their unspecific side effects. The 
distinctive nature of the physiological pacing rate (on the order of 600-700 bpm in the 
mouse heart) is appreciated by our measurements of the Ca2+ uptake presented in Figure 
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22 to Figure 25. Although the mean values of the time constant, duration of the Ca2+ 
uptake, maximum uptake rate and early activation of the Ca2+ uptake varied considerably 
in the low frequency range among the various cell types, they clearly converged at the 
physiological pacing rate of 10 Hz. In fact, considering the results at the maximum 
pacing frequency of 10Hz alone, neither of the quantification methods describing the 
Ca2+ uptake  experiments  showed a significant difference between the expression of the 
inhibitory peptide AC3-I or the control peptide AC3-C despite the prominent and well 
documented differences in baseline PLN phosphorylation  [162, 180].  
 
Chronic CaMKII inhibition and phospholamban ablation do not eliminate the frequency-
dependent shortening of the Ca2+ transient.  
 
The equivalence of characterizing the shortening of the Ca2+ transient by either fitting the 
data to an exponential decay with a characteristic time constant or by calculating the 
duration of the fluorescence decay is supported by the consistency of the results 
presented in Figure 22 and Figure 23. These figures clearly show that chronic CaMKII 
inhibition did not change the frequency-dependent acceleration of the Ca2+ uptake. This 
observation is consistent with earlier reports that showed that calmodulin blockade by 
W7 in isolated rat myocytes or more specific CaMKII inhibition by KN-93 and KN-62 or 
even collective PKA, PKC, PKG and CaMKII inhibition by K252-a did not affect the 
frequency dependence of muscle relaxation and Ca2+ uptake in single cells [181, 182]. 
However, our findings appear to contradict those of Bassani  [156] et al. and Li et al.  
[125] who reported that rate-dependent acceleration of [Ca2+]i transient duration in rat 
cardiac myocytes was mediated by CaMKII by comparing steady-state with post-rest 
twitches. The discrepancies might be related to the different experimental protocols. 
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Comparing the rate of relaxation during steady-state twitches with that of post-rest 
twitches following periods of rest may not be equivalent to examining the steady-state 
properties at a number of different frequencies as in our study. We tested the hypothesis 
that phospholamban is a major determinant of the frequency dependence of the Ca2+ 
uptake by using PLN deficient cells. We found that PLN ablation did not inhibit the 
frequency adaptation of the Ca2+ uptake, although significantly hastening the decay of 
[Ca2+]i as expected based on the inhibitory action of PLN on SERCA2a. Nevertheless, 
PLN deficiency caused a 70 % reduction in the dynamic range of the time constant at all 
frequencies. Therefore, phospholamban is a major contributor to the frequency 
dependence of the Ca2+ uptake but not the only regulatory mechanism. This result is 
consistent with other studies in isolated myocytes and muscle preparations from 
phospholamban knockout mice  [52, 123] showing significant slowing of the Ca2+ and 
force transients with decreasing frequencies and after rest. However, the increased Ca2+ 
uptake rate in the absence of phospholamban seems to contradict the study from Bluhm et 
al.  [36] who reported complete loss of FDAR and a negative force-frequency 
relationship in isolated mouse papillary muscles after phospholamban ablation. However, 
the small frequency interval of 2 to 6 Hz in their PLN null preparations might have 
hampered the observation of a prominent frequency adaptation.  It has been argued that 
the frequency-dependent shortening of the Ca2+ transient in PLN-/- myocytes may result 
from CaMKII phosphorylation of the SR Ca2+ pump because KN-93 prevented the 
shortening of the Ca2+ uptake time constant at higher frequencies  in PLN null myocytes 
[52, 123]. Our results demonstrate that in PLN deficient myocytes the ability to shorten 
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SR Ca2+ transients is clearly preserved during chronic CaMKII inhibition (Figure 22B 
and Figure 23B).  
 
Chronic CaMKII inhibition and phospholamban ablation do not prevent the frequency-
dependent increase in the maximum rate of Ca2+ uptake  
 
The maximum Ca2+ uptake rate increased approximately linear with pacing frequency in 
the AC3-I, AC3-C and WT cells as presented in Figure 24. PLN ablation increased the 
Ca2+ uptake rate at all frequencies although reducing the dynamic range of uptake rates 
by about 40 % as evident by comparing Figure 24A and Figure 24B. However, the 
increase in Ca2+ uptake rate was still 1.47 ± 0.08 fold in the phospholamban deficient 
cardiac myocytes that expressed the CaMKII inhibitor AC3-I (P<0.001) when the pacing 
frequency was raised from 0.2 to 10 Hz. We suggest therefore, that shortening of the Ca2+ 
transient may occur at increasing pacing frequencies through a frequency-dependent 
increase in SERCA2a activity that does not require phospholamban or CaMKII activity. 
 
Chronic CaMKII inhibition and phospholamban ablation prevents early activation of 
Ca2+ uptake at increasing pacing frequencies.  
 
When the pacing is increased the maximum activity of SERCA2a was reached earlier 
during the time course of the Ca2+ transient in the AC3-I, AC3-C and WT cardiac 
myocytes, as evident in the time from peak [Ca2+]i to Vmax (insert in Figure 25A). There 
was no difference in the activation times between AC3-I, AC3-C and WT myocytes in 
the presence of phospholamban. In PLN null myocytes, however, the frequency 
dependence of maximum SERCA2a activation was still present but only significantly 
reduced in the AC3-C x PLN-/- and the PLN-/- myocytes, although the activation time at 
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the largest frequency was still significantly shorter in these cells when compared to the 
AC3-I, AC3-C and WT myocytes. Chronic CaMKII inhibition by cytosolic AC3-I 
expression in combination with PLN ablation abolished the frequency dependence of the 
SERCA2a activation in AC3-I x PLN-/- cells as shown in Figure 25C and indicated by 
the slope of the frequency dependence, which was negligible in the AC3-I x PLN-/- cells 
and negative in all other cell types. This result indicates that the time at which the 
maximum Ca2+ uptake rate occurs seems to be dependent on both phospholamban and 
CaMKII. 
 
Increase in pacing frequency slows SR Ca2+ release in phospholamban deficient cardiac 
myocytes with chronic CaMKII inhibition.  
 
Because CaMKII activity is known to influence the open probability the SR Ca2+ release 
channel  [183], we investigated the effect of chronic CaMKII inhibition on the time 
course of the rising phase of the intracellular Ca2+ transient. Although phospholamban 
does not directly interact with RyR2, interruption of the SERCA2a - phospholamban 
interaction increases SR Ca2+ uptake and SR Ca2+ load  [21, 22, 52, 55]. Therefore, 
phospholamban null mice may serve as a model of increased SR Ca2+ load. Importantly, 
expression of RyR2 was not affected by phospholamban gene deletion  [56, 57] or 
chronic CaMKII inhibition  [180]. When the pacing frequency was increased, SR Ca2+ 
release was accelerated in AC3-I, AC3-C and WT myocytes as shown in Figure 26A and 
Figure 27A, although the difference was not significant for the WT cells (Figure 26C and 
Figure 27C). Furthermore, the tendency to hasten Ca2+ release at higher frequencies was 
indicated by the slopes of the linear fit to the frequency dependence, showing a shorter 
time-to-maximum (Figure 26A) and a higher maximum rate of the Ca2+ release with 
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increasing pacing frequencies. In the presence of PLN there was no apparent difference in 
the frequency dependence of the time course of the Ca2+ release between AC3-I, AC3-C 
and WT cells. However, combined phospholamban deletion and chronic CaMKII 
inhibition (AC3-I x PLN-/-) resulted in a slowing of the Ca2+ release at higher 
frequencies as shown in  B and Figure 27B, while phospholamban deletion alone (AC3-C 
x PLN-/- and PLN-/-) still displayed an accelerated Ca2+ release at higher pacing 
frequencies, as presented in Figure 26D and Figure 27D. The slopes of the linear fits to 
the SR Ca2+ release time (rate) – frequency relationships shown in Figure 26B (Figure 
27B) were consistently positive (negative) in the AC3-I x PLN-/- myocytes and negative 
(positive) in the AC3-C x PLN-/- and PLN-/- control myocytes. Therefore, we suggest 
that when SR Ca2+ load is high, chronic CaMKII inhibition slows Ca2+ release at higher 
pacing rates. This finding is consistent with a significant reduction in RyR2 
phosphorylation at the known CaMKII site (Ser 2815) reported in the AC3-I myocytes  
[180] which in turn had been associated with a decreased open probability of the isolated 
channel  [159, 167, 168] and a decreased amplitude and rate of SR Ca2+ release in intact 
cardiac myocytes  [125, 169, 170].  
 
A potential role for CaMKII in regulating calcium release at high SR Ca2+ load 
Genetic CaMKII inhibition did not seem to affect the frequency dependence of the SR 
Ca2+ uptake as measured by the time constant, the duration and the rate of fluorescence 
decay at physiological frequencies and temperatures. CaMKII inhibition also did not 
affect the slight increase in the rate of Ca2+ release with pacing frequency in the presence 
of PLN. When SR Ca2+ load was increased artificially by PLN ablation, CaMKII 
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inhibition reduced the rate of Ca2+ release. Therefore, we hypothesize that CaMKII 
activity may have a regulatory function on the RyR2 by increasing Ca2+ release when the 
SR Ca2+ load is high, hereby reducing the risk of Ca2+ overload.  
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CHAPTER VI 
 
A MICROFLUIDIC DEVICE TO CONFINE A SINGLE CARDIAC MYOCYTE IN A 
SUB-NANOLITER VOLUME ON PLANAR MICROELECTRODES FOR 
EXTRACELLULAR POTENTIAL RECORDINGS 
 
6.1 Abstract 
A hybrid chip is described which combines a microfluidic network fabricated in a 
silicone elastomer (PDMS) with planar microelectrodes. It was used to measure 
extracellular potentials from single adult murine cardiac myocytes in a restricted 
extracellular space. The recorded variations in the extracellular potentials were caused by 
transmembrane currents associated with spontaneously initiated intracellular calcium 
waves. Single cells were trapped inside the 100 pl microchamber by pressure gradients 
and maintained for several hours by continuous perfusion. In addition, the localized 
delivery of drugs to a portion of the cell was demonstrated. The impedance of the 
electrodes was reduced by a factor of 10 to 20 after the electrodeposition of platinum 
black. Biopotentials recorded from single cells with platinum black electrodes showed a 
three-fold decrease in the noise, resulting in a maximum signal-to-noise ratio of 15:1. 
Characteristic variations in the frequency and shape of the extracellular potential peaks 
were observed among different cells which are most likely due to differences in the 
sarcoplasmic reticulum Ca2+ load. Our device architecture permits the integration of 
electrochemical and optical sensors for multi-parameter recordings. 
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6.2 Introduction 
 
Extracellular potentials from small cells are generally measured using saline-filled 
glass micropipettes [184] which are loosely held to the cell membrane mechanically or by 
suction. The movement of the cell during the measurement and the risk of destroying it 
by rupturing the thin membrane make this technique laborious and time consuming. In 
addition, simultaneous recordings from multiple separate sites with defined interelectrode 
spacing on the same cell are not practical. Voltage sensitive dyes [185, 186] have been 
employed to overcome these problems, but phototoxicity and photobleaching make them 
unsuitable for long-term recordings. In contrast, extracellular microelectrodes offer a 
non-invasive alternative for the long-term study of excitable cells from cardiac and 
neuronal tissue. Biosensors based on monolayers of embryonic cardiac myocytes cultured 
on microelectrode arrays [187, 188] and transistor arrays [189-191] have become a useful 
tool in physiology [192] and pharmacology, [193] and have already been deployed as 
portable, non-specific toxin detectors [83, 194]. 
A single-cell fluorescence assay based on a microfluidic channel structure fabricated in 
poly(dimethylsiloxane) (PDMS) was recently reported by A.R. Wheeler et al. [95], who 
demonstrated the delivery of nanoliter volumes of analytes to a single Jurkat T cell 
confined in a 500-picoliter microchamber. 
As pointed out by G.T. Kovacs, [82] measurements of extracellular potentials using 
planar microelectrodes require the size of each recording electrode to be comparable to 
the size of the cell. If an electrode is not entirely covered by a cell, a recordable signal 
cannot be obtained from that electrode because of a voltage division across the areas 
exposed to the conducting solution. It is therefore common practice to grow cells on the 
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electrodes in a confluent monolayer. In particular for cardiac experiments, the 
requirement to culture cells on the electrodes generally limits the cell types suitable for 
extracellular recordings to those which can proliferate in culture, e.g. embryonic cells or 
cells derived from tumor cell lines, such as the cardiac HL-1 cell line [195]. Klauke et al  
[93] recently described an array of microelectrodes designed to stimulate single adult 
rabbit ventricular myocytes in 100- picoliter large microscopic chambers on a chip, but 
their design did not incorporate microfluidics. Single cells had to be selected individually 
from an external cell suspension and manually pipetted into the small, oil-covered 
compartments on the chip. Moreover, with the lack of continuous perfusion, normal 
homeostasis could not be sustained for a long period of time, leading eventually to 
unpredictable and irreversible pathologic changes. In general, the difficulty of positioning 
and keeping single cells at a well defined location close to the recording electrode may be 
one important reason why planar microelectrodes have not yet been used to measure 
extracellular potentials from isolated, non-attached excitable cells.  
To overcome all these limitations, we have developed a hybrid microfluidic device, the 
Nanophysiometer, which confines a single cardiac myocyte to a 100 picoliter volume on 
a set of planar microelectrodes.  
As one possible application, we measured extracellular potentials from isolated murine 
cardiac myocytes associated with the propagation of intracellular calcium waves.  
In cardiac cells, excitation-contraction coupling is mediated by a small influx of Ca2+ 
through the voltage-gated Ca2+ channels in the external cell membrane. The small 
increase in intracellular Ca2+ subsequently leads to the activation of intracellular Ca2+- 
receptors (ryanodine and IP3), which trigger a massive release of Ca2+ from the 
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sarcoplasmic reticulum (SR). The calcium-induced calcium release (CICR) mechanism 
greatly amplifies the amount of calcium ions which enters the cell via the sarcolemma 
during the activation of contraction and can also feed back on sarcolemmal ion currents. 
[196, 197] Localized spontaneous elevations in intracellular calcium concentration, 
known as calcium sparks, are usually observed in quiescent cells, occur at low rates (1-3 
s-1), [198] and lead to both the initiation and the propagation of slow (50-100 µm/s) [198] 
intracellular calcium waves. Their frequencies and amplitudes depend on the SR Ca2+ 
load [199] which itself varies with the extracellular Ca2+ concentration [198, 200]. 
Previous studies have convincingly shown that spontaneous release of Ca2+ ions in 
cardiac myocytes activates a transient depolarizing inward current which constitutes a 
potential arrhythmogenic process in the heart [200-203]. 
For the investigation of the fundamental cellular mechanisms of spontaneous activity it is 
essential that experiments are carried out on isolated cells rather than tissues or cell 
cultures to eliminate spurious interactions with other cells. We believe that our 
Nanophysiometer could be a valuable tool in investigating the electrical activity of non-
attached isolated primary cardiac cells in a controlled extracellular space. 
 
6.3 Device concept and fabrication 
A schematic drawing and a microscope image of the Nanophysiometer are shown 
in Figure 28 and Figure 29, respectively. The device is composed of a PDMS 
microchannel network auto adhered to a set of microelectrodes on a glass slide, which 
were fabricated by thin film deposition of platinum.  
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Microchannel fabrication 
 
 
Figure 28. Schematic overview of the microfluidic channels and microelectrodes. The 
cell trap is located in the center of the device at the confluence of the vertical fluidics 
channels and the horizontal electrode traces. The cell suspension is pipetted into the 40 
µl reservoir on the upper left side of the chip, from where single cells are drawn into 
the microchamber by pressure gradients. Arrows indicate the directions of the pressure 
gradients applied by using external syringes during the experiment. 
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The microchannels were realized in PDMS (RTV 615, GE Silicones) by replica molding 
[101] using a rigid mold (master) on a silicon wafer. The master was fabricated by 
spinning a 30-µm thick layer of photoresist (SU-8 2050, Microchem) on a 3” diameter 
silicon wafer and by exposing it to UV light through a metal mask using a contact mask 
aligner. The photoresist was processed according to the manufacturer’s datasheet. An 
optional 30 minutes hard bake at 200 °C on a hot plate was performed to increase the 
durability of the resist. Each master containing four relief structures was placed in a 
plastic culture dish and covered by a 5 mm layer of the PDMS/curing agent mixture at a 
mixing ratio of 10/1. After curing of the elastomer for five hours at 60 °C in a convection 
oven, the devices were cut out and mechanically separated from the master. Access holes 
 
 
 
 
Figure 29. Bright-field microscope image of the cell trap for the electrode 
configuration shown in Figure 28. An isolated cardiac myocyte is captured in a 125 
µm long and 25 µm wide microchamber in the chip. With a channel height of 30 µm, 
the cell trap has a volume of about 100 pl. Arrows indicate the directions of the 
applied pressure gradients. 
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to the channels were then punched by using a sharp stainless steel pipe. On average, it 
took eight hours to fabricate a set of four microfluidics chips, which were in general all 
functional. More technical details about the microfabrication process can be obtained 
from the work of G. Whitesides [98] and S.R.Quake [104].  
The PDMS structure was manually aligned relative to the electrodes by using an inverted 
microscope and sealed on the glass substrate by autoadhesion. As shown in Figure 2, only 
the tips of the electrodes were exposed to the conducting Tyrode’s solution inside the 
microchamber.  
We used stainless steel capillaries inserted into the access holes to connect the 
microfluidics channels via standard microtubing (0.5 mm inner diameter, Cole Parmer) to 
1 ml syringes. For efficient cell manipulation we controlled the syringes coupled to the 
suction and waste channels by hand. The syringes linked to the two 8 μm wide drug-
delivery channels were mounted in computer-controlled syringe pumps (PHD 22/2000, 
Harvard Apparatus), which allowed a minimum flow rate of 40 pl/s. 
 
Microelectrode fabrication 
The microelectrodes were fabricated by means of an ion etch process. Titanium and 
platinum were first deposited on a 17 mm square and 1-mm thick glass substrate by 
electron beam evaporation. First, a 10-nm thick titanium layer acting as adhesion layer 
was deposited, followed by a 90-nm thick platinum layer. Then, a mask was patterned on 
the platinum films by standard photolithography in 1-μm thick photoresist (AZ5214-E, 
Clariant Corp.). In the following ion etch [204] process, the metal was removed in all 
areas which were not protected by the resist. Then, the photoresist was stripped off the 
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electrodes in an ultrasonic remover bath (AZ400-T, Clariant Corp.) at a temperature of 70 
°C. Finally, the surface was thoroughly cleaned with acetone. The yield of fabricating 
thin film electrodes was about 80% after process optimization.  
The microelectrodes were electroplated with platinum black to reduce their impedance. 
Prior to the electrodeposition, the substrates were thoroughly cleaned in an ultrasonic 
acetone bath, soaked for 5 minutes in hexane and then rinsed several times with acetone. 
Platinum black was deposited with the microfluidic channels aligned on the electrodes to 
limit the area of deposition and to deliver the electrolyte. Therefore, only the tips of the 
electrodes were exposed to the platinizing solution. The deposition process was 
monitored via an inverted microscope. 
We used a voltage-controlled current source (circuit diagram not shown) interfaced with 
a PC to control the deposition current. The channel was filled with a 2.5% 
chloroplatinic/0.05% lead acetate solution (3140, diluted, YSI Inc.). Generally, we 
applied a 0.7 µA DC current to the small recording electrodes (125 µm2 area, Figure 29) 
and a 2.0 µA DC current to the large reference electrode (500 µm2 area) in order to obtain 
approximately the same current density for each electrode. The current was switched off 
as soon as a widening of the edges of the electrode was observed under the microscope. 
The deposition times were usually between 10 and 20s. We used a stylus surface profiler 
(Alphastep 200, Tencor Instruments) to measure the thickness of the deposit. We also 
measured the impedance of the microelectrodes before and after the deposition of 
platinum black with a dynamic signal analyzer (3562A, Hewlett-Packard).  
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Amplifier design 
Extracellular potentials were amplified by a custom-designed low-noise differential 
amplifier built from off-the-shelf components. A simplified schematic is shown in Figure 
30. More detailed diagrams of all circuits described herein can be obtained from the 
authors. The device consisted of an instrumentation amplifier, an integrator, a gain stage, 
and a low-pass filter. Instead of using a high-pass RC filter network, which would cause a 
significant decrease of the input impedance and the common mode rejection ratio, we 
used an integrator to implement AC coupling. Its inverted output was connected to the 
reference pin of the instrumentation amplifier to attenuate constant and very low 
frequency components of the input signal. With this technique, the microelectrodes were 
directly coupled to the inputs of the instrumentation amplifier, which had an input 
impedance of 1.014 kΩ. The time constant of the integrator was chosen to give a high-
 
 
 
 
Figure 30. Setup of the measurement electrodes and the readout electronics for the 
extracellular recordings. The amplifier was connected to the three recording electrodes 
connected in parallel and to the large reference electrode 1. The push-button switch 
was linked to a second recording channel and used to mark visually observed 
contractions of the cell. 
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pass cut-off frequency of 0.08 Hz to reduce low frequency background noise. The signal 
was then further amplified by a second stage resulting in a total gain of 20,000, and 
subsequently low-pass filtered with a selectable cut-off frequency ranging from 15 to 
100Hz. The noise of the amplifier (inputs shorted) referred to the input was 14.9 nV Hz-
1/2. After connecting the microelectrodes to the inputs of the amplifier, the noise increased 
about 5 fold, which is comparable with previously described amplifiers for extracellular 
recordings [189, 193, 205]. 
 
Device assembly 
When the PDMS microfluidic device was sealed on the glass substrate, sufficient 
insulation was provided by the elastomer to prevent shorting of the interconnecting 
traces, and therefore no further passivation was required. To improve the seal between 
the elastomer and the electrodes, a mechanical clamp (Figure 31) was used to press the 
PDMS block against the substrate and fix the assembly to a heated microscope stage. The 
temperature of the device was controlled by flowing water from a heat exchanger through 
a tube integrated within the aluminum base plate as shown in the schematic in Figure 
31B. 
 
6.4 Experimental Procedures  
Single cardiac myocytes inside the cell trap were monitored with an inverted 
fluorescence microscope (Axiovert 200, Zeiss, Germany) equipped with a CCD camera. 
Images were captured by a digital videodisc (DVD) recorder and digitized by an image 
capture board (Bandit II CV, Edmund Optics) linked to a standard PC.  
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Figure 31. (A) Sectional drawing of the clamp on the stage of an inverted microscope. 
Temperature control of the device was provided by the heated microscope stage and an 
integrated water tube that could be connected to an external circulating heat exchanger. 
(B) Photograph of the clamp mechanism that ensures a reliable seal between the PDMS micro 
channels and the electrodes. The transparent lid permitted the observation of the cell in 
transmitted light. 
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Myocyte isolation 
Single ventricular myocytes were isolated from 2 to 5 months old mice according to the 
method described in detail by Anderson et al [206]. Briefly, animals were paralyzed by a 
pentobarbital (50 mg/kg) overdose and hearts were rapidly excised and placed in ice-cold 
nominally Ca2+-free HEPES-buffered saline solution. The aorta was cannulated and the 
heart was perfused in a retrograde fashion with a Ca2+-free solution for 5 minutes at 37 
°C. To release single cells from the tissue, a 15-minute perfusion with a collagenase-
containing solution was carried out, followed by a 5-minute perfusion with a 0.2 mM 
Ca2+ solution. The ventricle and septum were cut away, coarsely minced, and placed in a 
beaker containing a low-Ca2+ solution with 1% bovine serum albumin at 37 °C. Myocytes 
were dispersed by gentle agitation and maintained in Tyrode’s solution, which contained 
(in mM) NaCl 137, glucose 10, HEPES 10, KCl 5.4, CaCl2 2.5, MgCl2 1.0, NaH2PO4 0.3. 
Experiments were usually done within the first three hours after the isolation.  
 
Single-cell manipulation and trapping 
The cell suspension was pipetted into a 4 mm diameter hole on the chip, which formed a 
60 µl volume cell reservoir (Figure 28). The bottom of the reservoir was linked to the 100 
µm wide main channel, which was connected to the microchamber (cell trap) in the 
center of the device. A pressure gradient was manually applied to pull single cells from 
the reservoir into the main channel. A single cell was trapped in the microchamber 
perpendicular to the main channel by a second pressure differential, as indicated by 
arrows in Figure 29. The directions of all pressure gradients are specified in Figure 28. 
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The cell trap consisted of a 125 µm long and 25 µm wide side channel with a 5 µm wide 
restriction at the end.  
Assuming that 80 % or more of the cells were alive after the isolation, a single cell could 
reliably be trapped in the microchamber within seconds. However, approximately 30% of 
the trapped cells changed cell morphology and rounded up within a few seconds after the 
trapping, indicating a severe mechanical damage.  The other fraction of cells showed no 
changes in morphology and could be maintained in the cell trap for one hour or longer.  
The success rate for trapping large single cells decreased with the condition of the cells in 
bulk cell suspension. Experiments were stopped if less than 30% of the cells were viable, 
which was usually the case 5 hours or more after the isolation from the tissue.  
Single cardiac myocytes captured in the cell trap are shown in Figure 29 and Figure 30. 
Cell debris was sometimes caught in the trap but could be removed by reversing the 
pressure gradient in the suction channel. We expect that the capture rate of viable cells 
would be higher if round-shaped cell types were used.  
 
Impedance measurements 
The impedance of the microelectrodes was measured with the PDMS device aligned on 
them, as shown in Figure 30. The cell trap was filled with Tyrode’s solution and the 
electrodes were connected to an auxiliary circuit. It consisted of a high input impedance 
unity-gain amplifier to measure the voltage across a pair of microelectrodes and a 
current-to-voltage converter to detect the current. The circuit was designed with carefully 
chosen components to minimize loading effects and its outputs were connected to the 
signal analyzer. The frequency of a sine wave was swept logarithmically over the range 
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of 0.05 to 50 Hz, which resembled the bandwidth used in the biological experiments. The 
magnitude and the phase of the impedance were computed by the signal analyzer based 
on the current and voltage measurements. 
 
Recording of extracellular potentials 
Large single adult cardiac myocytes were individually trapped inside the microchamber. 
The 30 µm height and the rectangular shape of the micro channel left a gap between the 
cell and the suction channel, which allowed a continuous perfusion with Tyrode’s 
solution during the experiment. This can be inferred from Figure 32, which shows a 
single cell partly exposed to a fluorescein solution (F6377, Sigma-Aldrich Corp.).  
Prior to the extracellular potential recordings, each cell was perfused with Tyrode’s 
solution for several minutes to ensure its integrity and to allow it to recover from the 
possible mechanical stress experienced during the trapping procedure.  
The electrode configuration and the setup for the recording of extracellular potentials are 
shown in Figure 30. Potentials were measured differentially between the large reference 
electrode 1 and the three small recording electrodes 1-3 connected in parallel. The 
reference electrode 1 was situated in the main channel, while the recording electrodes 
were located inside the cell trap. The other reference electrode 2, shown in Figure 29, was 
not used for the extracellular recordings described herein. The amplified signals were 
visualized by a digital oscilloscope and digitized by an analog-to-digital converter board 
(PCI 6071E, National Instruments).  
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We used a push-button switch to identify the visually observed contractions in the 
potential recordings where the signal-to-noise ratio was low.  
The switch generated rectangular pulses (shown in Figure 35 a and b) which were 
recorded simultaneously with the potentials.  
We have used two different electrode designs, shown in Figure 29 and Figure 30 and in 
Figure 32. The configuration depicted in Figure 30 was used for all extracellular 
recordings. The other electrode arrangement, shown in Figure 32, was designed for 
 
 
 
 
 
Figure 32. Fluorescence-microscope image of a single cardiac myocyte partially 
exposed to a fluorescein solution. The cell did not block the suction channel, so that 
perfusion could be sustained during the experiments. 
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combined electrochemical and optical experiments, but its performance has not yet been 
evaluated. 
 
6.5 Results 
An important feature of our microfluidics design is the ability to deliver drugs 
locally to a single cell. To demonstrate this, we trapped a large single cardiac myocyte 
inside the microchamber and perfused it locally with a fluorescein solution. The 
microscope image in Figure 32 shows a portion of the cell exposed to the solution. The 
dye was absorbed by the cell resulting in bright fluorescence of the entire intracellular 
space.  
To characterize the performance of our microelectrodes, we took scanning–electron 
microscope (SEM) images of the metal surfaces, determined the thickness of the 
 
 
 
 
Figure 33. SEM images of a platinum electrode surface before (A) and after (B) the 
electrodeposition of platinum black. 
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platinum black deposition, and measured their associated impedance. The 
electrodeposition of platinum black resulted in a rough surface, thereby increasing its 
effective area. SEM images of a platinum microelectrode before and after the deposition 
process are shown in Figure 33 (A) and (B), respectively. The average thickness of the 
platinum black layer was 0.6 µm and increased with longer plating time. We restricted 
the deposition time to 10-20 seconds to avoid tall crystalline spikes that reduced the 
height of the trap and resulted in cell damage. 
We measured the impedances of gold and platinum microelectrodes in a frequency range 
of 0.05 Hz to 50 Hz, before and after the electrodeposition of platinum black. The graph 
in Figure 34 clearly shows that the impedances of both platinized electrodes were about 
10 to 20 times lower than those of the bare metal electrodes. Furthermore, all electrodes 
exhibited a decrease in impedance with increasing frequency, which is a characteristic 
behavior for an electrode-electrolyte interface. We have modeled the frequency 
dependence of the electrode impedance by a series combination of a resistance R and a 
polarization capacitance C, the value of each is frequency-dependent, according to the 
Warburg concept. [207-210] It states that the resistance and reactance of a metal-
electrolyte interface are approximately equal and that the capacitance varies with the 
frequency f as f-α, where α is a constant ranging for most metal electrode/electrolyte 
interfaces from 0.2 to 0.7 [184].The fits of the curves in Figure 8 yielded a capacitance 
per unit area of 7540 f -0.47µF cm-2 (f is the frequency in Hz) and an impedance times unit 
area of 29.86 f -0.53Ωθcm2 for the platinum black-coated platinum electrode. For the 
platinum black-coated gold electrode, the linear fit yielded a capacitance per unit area of 
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6240 f-0.26 µF cm-2 and an impedance times unit area of 36.10 f-0.74 Ωθcm2. The standard 
error of the fit was in both cases smaller than 0.5%.  
The estimated values of the capacitance and the impedance of our electrodes were 
consistent with those reported in the literature [184]. Even though the platinum black-on-
gold electrodes showed smaller impedance in the higher frequency range, we used 
platinum black-on-platinum electrodes in our experiments. The reason was that the gold 
electrodes showed a considerable degradation of the platinum black layer after a single 
use, while the platinum electrodes could be reused for at least five experiments. This may 
be due to poor adhesion properties of platinum on gold surfaces. 
Figure 34 shows a series of 20-s long extracts from recordings of four different 
experiments, corresponding to distinct cells. The peaks were correlated with the 
 
 
 
 
Figure 34. Impedance measurements of platinum and gold electrodes before and after 
electrodeposition of platinum black in the frequency range used for the recording of 
extracellular potentials. 
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spontaneous contraction waves and were expected to occur in quiescent cardiac myocytes 
under our experimental conditions. The occurrence of contraction waves was indicated in 
the first two measurements by the rectangular pulses below the potential traces. 
The calcium-activated inward current which accompanies the propagating calcium wave 
is carried by Na+ ions entering the cell via the Ca2+-activated Na+/Ca2+ exchanger. [211-
213] There is also a calcium-activated outward current, carried by chloride ions, which 
contributes significantly to the early repolarization during the regular action potential 
[214-217].  
 
 
 
 
 
Figure 35. Four 20-s long extracts from typical extracellular potential recordings. All 
measurements were carried out with the same electrode configuration shown in Figure 
29 andFigure 30. Traces (A) and (B) were recorded using bright metal platinum 
electrodes and a bandwidth of 15 Hz, while traces (C) and (D) were recorded by using 
platinum black-coated platinum electrodes with a bandwidth of 30 Hz. Visually 
observed contractions were marked in the traces (A) and (B) to correlate the 
contraction waves with the extracellular potential recordings when the signal-to-noise 
ratios were low. The Arrow in (C) points to the peak shown in Figure 36. 
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These transmembrane currents produced variations in the extracellular potentials that 
were detected by the microelectrodes. However, extracellular potential recordings with 
comparable signal-to-noise ratios to those shown in Figure 35 (C) and (D) could be 
obtained only from cells that met two criteria. First, they had to be at least 20 µm in 
diameter to cover 80 % or more of the recording electrode surface. Second, they had to be 
in focus with the bottom of the cell trap and thus close to the recording electrodes. 
Usually, less than 50 % of the trapped cells met those requirements. An even smaller cell 
trap would probably improve the success rate, although it could obstruct large cells.  
Measurements (A) and (B) were recorded using bare platinum electrodes and a 
bandwidth of 15 Hz, while measurements (C) and (D) were recorded using platinum 
black electrodes and a bandwidth of 30 Hz. Traces (C) and (D) showed a three times 
 
 
 
 
Figure 36. Time course of an extracellular potential peak caused by a spontaneous 
intracellular calcium wave. The data was taken from the third peak of the recording 
shown in Figure 35 (C). 
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higher signal-to-noise ratio (for a two times larger bandwidth) than traces (A) and (B), 
which could be attributed to the platinum black deposition. 
Repeatedly, we observed considerable variations in frequency and peak width for 
different cells taken from the same preparation. These differences are particularly 
noticeable by comparing traces (C) and (D), and are most likely due to either variations in 
SR Ca2+ load or properties of the SR release mechanism, as reported by other 
investigators based on fluorescence experiments [114, 198, 200] or numerical models 
[218, 219]. Contraction waves occurred approximately 17 times per minute in the cell 
represented by trace (C), with an average peak width (FWHM) of 230 ± 50ms. 
Spontaneous activity was significantly increased in the cell represented by trace (D), with 
almost one contraction wave per second. This cell displayed a peak width (FWHM) of 
142 ± 8ms, indicating a higher propagation velocity or altered channel kinetics. The 
observed  differences among the four experiments are in agreement with results reported 
by Cheng et al. [198], who described variations of more than 50 % in spark frequency 
and wave propagation velocity. The time course of a single extracellular potential peak is 
shown in Figure 36. The qualitative comparison of its shape with data from fluorescence 
experiments using the calcium dye fluo-3 [198, 220] suggests a correlation of the 
intracellular Ca2+ wave and the Ca2+-mediated extracellular currents.  
To understand the differences in wave occurrence and propagation, and to elucidate the 
coupling of intracellular calcium release and extracellular currents, combined 
fluorescence and electrical measurement are required. 
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6.6 Outlook 
Our device architecture permits trapping and maintaining of single cells in a 
restricted extracellular space. Although we have used the integrated microelectrodes to 
measure extracellular potentials from cardiac myocytes, the use of the Nanophysiometer 
is not limited to this application. Other cell types, such as skeletal muscle or nerve cells, 
could be expected to perform similarly in the microfluidic environment. Depending on 
their size and shape, the dimensions of the microchamber would have to be adapted. The 
microfluidic design provides a small extracellular volume and in general assures small 
distances from the cell to the measurement electrodes. This not only permits electrical 
recordings with an adequate signal-to-noise ratio, but also significantly reduces diffusion-
limited response times of electrochemical sensors. Furthermore, the restricted 
extracellular space allows rapid control of the chemical environment while the cell is kept 
alive by perfusion and fixed at a stable position close to the recording electrodes by the 
microfluidic cell trap. With the integration of electrical, electrochemical and optical 
sensors, the Nanophysiometer provides a basis for the future development of single cell 
biosensors and automated single cell assays. 
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CHAPTER VII 
 
SUMMARY AND FUTURE WORK 
 
7.1 Summary 
 The dissertation describes the development and application of the 
Nanophysiometer, a microfluidic network combined with a thin film microelectrode 
array, to study force – excitation coupling in single cardiac myocytes. The microfluidic 
device was used for simultaneous recordings of multiple physiological variables from 
single non-attached adult cardiac myocytes in a chemically controlled microenvironment. 
The Nanophysiometer was fabricated in a silicone elastomer and imaged using an 
inverted microscope, a high speed CCD camera and an optical fiber array coupled to 
photomultipliers for high bandwidth fluorescence recordings. Using microfluidics, the 
localized delivery of a fluorescent dye to a membrane patch of a cardiac myocyte was 
demonstrated. The Nanophysiometer automatically aligned and stabilized single cardiac 
myocytes on the microscope during long term sarcomere contraction measurements, 
thereby reducing motion artifacts. Intracellular calcium transients and sarcomere 
contraction measurements were combined to test the hypothesis that phospholamban 
(PLN) ablation in mice increases the cardiac myofilament response to cytosolic calcium 
concentration. It was demonstrated that sarcomere acceleration may be used as an index 
of contractility when length dependent passive resistance and velocity dependent viscous 
damping are considered. The results show that sarcomere acceleration during contraction 
was increased 9.1 ± 2.1 fold and indicate that the slightly, 1.65 ± 0.30 fold elevated 
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amplitude of the SR Ca2+ release may not be the only cause of the increased contractility 
in the PLN deficient cells. A previously published proteomic analysis of PLN deficient 
mouse hearts and our results indicate that significant changes in myofilament protein 
expression and phosphorylation may have contributed significantly to the increased force 
development in these hearts. 
Further more, genetic phospholamban ablation significantly reduced the dependence of 
the SR Ca2+ uptake on the stimulation frequency, but did not abolish it. Even the 
combination of genetic deletion of PLN and chronic inhibition of the Ca2+/Calmodulin 
dependent protein kinase II (CaMKII) did not prevent the frequency dependence of the 
SR Ca2+ uptake. Our results suggest that a mechanism of frequency adaptation must exist 
in the mammalian ventricle that does not require phospholamban or CaMKII. However, 
chronic CaMKII inhibition significantly slowed Ca2+ release at physiological frequencies 
in the absence of PLN indicating a role of CaMKII in the regulation of Ca2+ release at 
high SR Ca2+ load. 
When the techniques described here are combined, the Nanophysiometer will be capable 
of simultaneous measurements of extracellular potentials, intracellular and extracellular 
ion and metabolite concentrations (Ca2+, pH, O2, glucose, lactate) and sarcomere length 
in a chemically controlled microfluidic environment. 
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7.2 Future work 
Precise chemical control of the extracellular environment using on-chip valves and 
peristaltic pumps 
 
Single cardiac myocytes were confined and stabilized in the microfluidic cell trap 
of the Nanophysiometer for optical recordings. The success rate for trapping cells was 
50-70 % even when the cell isolation yielded 80 % or more viable cells. Pressure 
gradients in the microfluidic device were established manually via attached syringes. The 
lack of precise pressure control due to large dead off-chip volumes lead to sudden 
 
 
 
 
 
Figure 37. Principle of operation of on-chip valves fabricated in crossed-channel 
architecture. (A) Cross section of a flow channel with two valves when viewed after a 
cut along the dotted line (lower microscope image). The membrane between the upper 
pressurized control channel and the lower flow channel is very thin (~30 µm) and is 
deflected downward after the application of pressure. (B) Bottom-view microscope 
image of the device with two open valves. (C) Bottom-view of the microfluidic device 
with two closed valves. 
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changes in pressure during the measurement or myocyte trapping causing mechanical 
damage of the sarcolemma and leading to hyper contracture and cell death.  
In the future, the success rate could be significantly increased by optimizing the on-chip 
active valves and peristaltic pumps in the Nanophysiometer. Valves are fabricated by 
multilayer soft lithography as described by Unger et al. [79].  
The principle of operation of two on-chip valves is shown in Figure 37. A two layer 
PDMS device is fabricated by bonding the pneumatic/hydraulic control layer and a 
perpendicular flow channel together so that the two channels are separated by a thin 
PDMS membrane. The control channel can be pressurized with Nitrogen (or preferably 
oil) causing deflection of the membrane and pinching of the flow channel below. Because 
the active element is the roof of the channel itself, simple on-off valves as the ones shown 
in Figure 37 have truly zero dead volume. A peristaltic pump may be realized by 
 
 
Figure 38. (A) Schematic of a prototype Nanophysiometer with peristaltic pumps 
along the two vertical perfusion channels, drug inlet 1 and drug inlet 2, and 
microelectrodes. (B) Microscope image of the multilayer Nanophysiometer without 
microelectrodes for better presentation (courtesy Yuxin Liu). 
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arranging three valves in series along a single channel with a dead volume about equal to 
volume of one valve, (i.e. on the order of ~ 25 pl) [79]. A Nanophysiometer design with 
two peristaltic pumps for rapid chemical control of the extracellular environment is 
shown in Figure 38. It is important to note that the ability for a valve to close at a given 
pressures strongly depends on the aspect ratio of the lower flow channel, i.e. the ratio of 
channel width to its height. This flow channel aspect ratio must be equal or larger than 10 
for a valve to close at reasonable pressures, < 30 psi (207 kPa). Therefore, the higher the 
roof of a flow channel, the wider it must be in order to be closed by a membrane valve. 
Because the flow channels in the Nanophysiometer are 40 - 50 µm high to allow cardiac 
myocytes to pass through, they would have to be designed extremely wide in order close. 
To avoid mm-size microfluidic structures, the flow channels can be fabricated using a 
two layer photolithographic process leading to shallower areas where the fluidic lines 
cross the control channels. 
 
Direct force – [Ca2+]i relationship measurement in isolated heart muscle preparations 
and single cardiac myocytes 
 
For a more detailed understanding of myocyte excitation contraction coupling and 
dynamics it would be beneficial to measure forces directly under a varying loading 
conditions [71]. Direct force measurements in intact cardiac myocytes are extremely 
difficult and require the attachment of the fragile sarcolemma membrane to a force 
transducing device. Optical recordings of intracellular calcium concentration and 
sarcomere shortening in phospholamban deficient cardiac myocytes revealed an 
increased sensitivity of the myofilaments to cytosolic [Ca2+]. We presented a novel 
method that allows evaluating relative changes in the active force of shortening in 
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unattached myocytes by analyzing relative changes in maximum acceleration under 
consideration of passive elastic and viscous forces that resist shortening. Our 
measurement of unloaded myocyte shortening needs further validation in a well 
characterizes system that allows a direct assessment of contraction force indicative of the 
underlying inotropic and lusitropic state of the myocardium. Being able to measure forces 
dynamically and apply variable loading conditions would allow us to explore the length-
tension relation ship in great detail and would provide insight into the mechanical 
feedback through stretch activated [Ca2+]i ion channels [69, 221].  
 
Sarcomere acceleration and force frequency relationships in isolated cardiac myocytes 
with chronic CaMKII inhibition. 
 
Chronic CaMKII inhibition did not influence the time course of calcium uptake at 
physiological frequencies and temperatures, even in the absence of phospholamban. At 
first glance the data presented in Chapter V seem to suggest that CaMKII is not involved 
in the frequency-dependent acceleration of relaxation (FDAR). However, sarcomere 
shortening (or better, sarcomere contraction force) as a function of pacing frequency in 
CaMKII deficient cardiac myocytes might reveal a potential role of CaMKII in the 
frequency-dependent regulation of contraction and relaxation through direct interaction 
with other contraction modulating proteins. The calcium sensitivity of the myofilaments 
is known to depend on temperature, pH, [PO4]i and [Mg2+]i  [41, 42], as well as on the 
phosphorylation of the myofilament proteins troponin-I (TnI) and myosin binding 
protein-C (MyBP-C) [222]. Phosphorylation of TnI decreases the calcium sensitivity of 
the myofilaments suggesting that phosphorylated TnI promotes relaxation [59, 222-225], 
while calcium-mediated phosphorylation of MyBP-C increases maximum force at a given 
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[Ca2+]i [64]. In fact, analysis of force – [Ca2+]i relationships in isolated mouse papillary 
muscle bundles shows that increasing stimulation frequency increased force production 
per unit change of calcium concentration (positive force-frequency relationship) and 
decreased the frequency-dependent calcium sensitivity of the myofilaments during 
relaxation [226]. Therefore, the measurement of myofilament protein phosphorylation, 
sarcomere shortening (or better, sarcomere contraction force) as a function of pacing 
frequency in CaMKII deficient cardiac myocytes might reveal a possible role of CaMKII 
in the frequency-dependent regulation of contraction and relaxation interacting with other 
contraction regulating proteins. 
 
Implications of high diastolic Ca2+ concentration and origin of arrhythmias in VLCAD 
deficient mice 
 
The results presented in Appendix B show that VLCAD deficiency in mice increased SR 
Ca2+ calcium load and fractional Ca2+ release, diastolic calcium concentration and the rate 
of sarcomere shortening. On the other hand, the most striking observation in the intact 
VLCAD deficient mouse heart was inducible ventricular tachycardia by physiological 
stress such as fasting, cold or exercise [227]. The data shown in this chapter are an 
attempt to characterize the physiological and pathological changes associated with a 
metabolic defect in fatty acid beta oxidation on the single cell level, but the role of these 
changes in the genesis of arrhythmias was not investigated.  
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The increased diastolic Ca2+ concentration could trigger delayed afterdepolarizations 
resulting from the depolarizing inward current of the sarcolemmal Na+/Ca2+ exchanger 
[228-230]. Future experiments on VLCAD deficiency need to address the molecular 
mechanism of arrhythmia on the organ, tissue and single cell level. Figure 39 shows a set 
of sarcomere contractions recorded from four VLCAD-/- (A-D) and four WT control (E-
H) myocytes. For each cell, 25 consecutive sarcomere contractions were recorded and 
superposed with the stimulus occurring at time zero. The data show that a noticeable 
delay between the sarcomere length minima occurred in the VLCAD deficient cells (in 
about 30 % of the analyzed cells), which was never observed in the WT control cells. 
However, more contraction data must be collected and if possible complemented by 
whole heart LV pressure and simultaneous calcium or action potential recordings to 
decide if these delays in single cell sarcomere contractions are statistically significant and 
whether they may lead to arrhythmias in the VLCAD deficient heart.  
 
 
Figure 39 Beat-to-beat variations of normalized sarcomere transients in four VLCAD-
/- (A-D) and four WT CONTROL (E-H) cardiac myocytes. Time is measured in ms 
from the onset of the stimulus. 
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APPENDIX A 
 
THIN-FILM IROX PH MICROELECTRODE FOR MICROFLUIDIC-BASED 
MICROSYSTEMS 
 
A.1 Abstract 
Microsensors are valuable tools to monitor cell metabolism in cell culture 
volumes. The present research describes the fabrication and characterization of on-chip 
thin-film iridium oxide pH microsensors with dimensions of 20×20 μm2 and 20×40 μm2 
suitable to be incorporated into nl volumes. IrOx thin films were formed on platinum 
microelectrodes by electrochemical deposition in galvanostatic mode. Anodically grown 
iridium oxide films showed a near super-Nernstian response with a slope of -77.6 ± 2 
mV/pH at 22 oC, and linear responses within the pH range of 4-11. Freshly deposited 
electrodes showed response times as low as 6 s. Long-term studies showed a baseline 
drift of 2-3 mV/month, which could easily be compensated by calibration. This work 
demonstrated for the first time the use of planar IrOx pH microelectrodes to measure the 
acidification rate of CHO and fibroblast cells in an on chip cell culture volume of 25 nl 
with microfluidic control.  
 
A.2 Introduction 
We are witnessing the introduction of bioinstrumentation that combines 
microfabrication, microfluidics, and micromechanics to create self-contained Bio-Micro-
Electro-Mechanical Systems (BioMEMS), which serve as a complete biological 
laboratory-on-a-chip [231-240]. Devices to monitor physiological parameters and cellular 
activity of living cells in vitro generally employ fluorescent dyes, calorimetric probes, 
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radioactive labels, or electrochemical/electrical sensors. Sensors located in the extracellular 
space do not require invasive manipulation or cause toxic effects, and therefore allow for 
long term recordings. The sensing of extracellular pH has been used to detect perturbations in 
metabolic activity as a result of receptor activation, drug and toxin effects, or enzyme 
inhibition  [241, 242]. Biosensors based on extracellular pH measurement have been 
demonstrated, and a Microphysiometer system (Cytosensor Microphysiometer - Molecular 
Devices, Inc.) is commercially available to assess metabolism in microliter cell culture 
volumes with temporal resolutions on the order of minutes [243-245].   
The Cytosensor uses a Light Addressable Potentiometric Sensor to determine 
acidification rates, and has been used for a number of cellular studies ranging from 
measuring metabolic activity during pharmacological and toxicological interventions to 
cell signal transduction [242, 246]. Typically, 3×105 cells are cultured between two 
membranes in a 4-μl volume equipped with the sensor and a perfusion system. The 
resolutions of the instrument for pH and acidification rate measurements are 0.001 pH 
and 0.001 pH min-1, respectively. 
Ion-sensitive field effect transistors (ISFET) have also been used to measure acidification 
rates of living cells cultured on gate electrode surface areas ranging from 400 μm2 up to 
6000 μm2   [247, 248]. Furthermore, ISFET’s have been incorporated in 10 μl chambers 
filled with approximately 2×105 cells. The measured acidification rate for RT112 and 
LS174T tumor cells are in the range of 0.065-0.08 pH min-1  [249]. 
The scaling down of this approach requires the development of a miniature pH sensor for 
nl cell culture volumes in a microfluidic-controlled environment. Additionally, if the 
device is compatible with optical techniques, it will enable better understanding of 
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complex cellular processes. In contrast to use of a multitude of agent-specific analytical 
methods, sensors that respond to effects on cell homeostasis would provide a broader and 
more effective method to detect and identify environmental toxins. This concept will 
have numerous applications in medical research, as it would improve the efficiency of 
drug discovery, drug development, pharmaceutical screening, and environmental 
monitoring  [250]. 
Micro pH electrodes with sensing areas typically below 500 μm2 are needed to measure 
pH inside microfluidic devices. As described in the literature  [232-239, 251], one of the 
most promising materials for thin-layer pH electrodes is IrOx film. The main advantages 
of IrOx in comparison with other pH-sensitive oxides include a wide pH response range, 
fast response time, high pH sensitivity, low potential drift, and low sensitivity to redox 
pair interference [252]. An additional technological advantage is the ability to form IrOx 
layers by means of different chemical and physical methods, which can match 
application-specific requirements in chemistry, biology and medicine. These attributes 
make IrOx one of the best choices as sensitive material for pH electrodes.  
Different techniques have been used to produce iridium oxide pH electrodes, such as 
reactive sputtering using iridium targets in an oxygen plasma [253-255], thermal 
oxidation of Ir wire [256, 257], high-temperature carbonate-melt oxidation of Ir wire 
[237, 258], thermal decomposition of an iridium salt [259], electrochemical oxidation of 
Ir electrodes during potential cycling [233, 234, 239, 251, 260], and anodic iridium oxide 
film (AIROF) electrodeposition in galvanostatic mode [232, 238, 252, 261-263]. While 
other methods require complex procedures such as high-temperature treatment, 
electrochemical activation, or expensive iridium targets, the electrochemical methods 
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have found a wide range of practical applications because of their relative simplicity and 
their manufacturability in large-scale applications. Furthermore, these methods allows for 
selective deposition on planar microelectrodes. 
Conventional IrOx pH electrodes are formed by thermal or electrochemical oxidation of Ir 
wire with diameters as small as 20 μm. Because the integration of wire electrodes into 
microfluidic devices is very difficult or practically impossible, the only feasible 
alternative is planar thin-film electrodes. Few applications of thin-film IrOx pH 
electrodes—with active surface areas of 1 × 1 mm2, 0.1 × 1 mm2 and 0.2 × 0.05 mm2—
have been found in the literature [239, 252, 264]. The scope of our research was to 
develop technologies for the fabrication of thin-film planar IrOx electrodes with active 
sensing areas below 500 μm2, to incorporate the sensors into an on-chip miniature cell 
culture volume, and to evaluate their performance in acidification rate measurements to 
monitor cell physiology.  
 
A.3 Methods 
Materials and reagents 
Hydrogen peroxide (30% solution in water), iridium tetrachloride, oxalic acid 
dihydrate, 5% Nafion solution, and anhydrous potassium carbonate supplied by Aldrich, 
Inc. were used. Universal pH buffers (for pH 2, 4, 6, 7, 8, and 10) were obtained from 
VWR Scientific. Titanium (99.95%, rod diam. 2mm), and platinum (99.95%, rod diam. 
2mm) were purchased from Goodfellow Corp., and fused quartz (rod diam. 24mm), from 
Technical Glass Product. RPMI 1640 buffer was supplied by Molecular Devices Corp. 
Mouse fibroblast cells (A9 L HD2 S.C. 18) and Chinese hamster ovary (CHO) cells (M 3 
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WT4) were supplied by ATCC (CRL-10255 and CRL-1981, respectively). The cell 
media and additives were all supplied by BioWhittaker. All chemicals were used as 
received. Double-distilled (DI) water was used for the preparation of all solutions. 
 
Electrode fabrication 
The electrode structures were formed on glass microscope slides (76 mm x 25 mm x 
1mm, Fisher Scientific), which were initially cleaned in accordance to a standard 
cleaning procedure [237]. The electrodes consisted of two layers: a Ti adhesive layer (10 
nm) and a Pt working layer (100 nm). Thin-film electrodes were formed by e-beam 
vacuum evaporation of Ti and Pt from carbon crucible liners (Kurt J. Lesker, Inc.). The 
total gas pressure and substrate temperature were maintained at 5x10-6 torr and 273 K, 
respectively, during the film deposition. The deposition rate was 0.5 nm/sec for Ti films 
and 1.0 nm/sec for Pt films. The deposition rate and the thickness of the films were 
controlled by a quartz crystal microbalance (Maxtek, Ink.). The Ti and Pt films were 
deposited in a single process without breaking vacuum. After deposition, each substrate 
was cut into individual 1 × 1 in2 chips for thin-film microelectrode fabrication. For 
electrode insulation we used thin films of silicon oxide. The 150 nm SiOx films were 
deposited by e-beam evaporation using fused quartz targets at a residual pressure of 2 x 
10-5 torr (the rate of deposition was 0.1-0.2 nm/s). The microelectrode configuration was 
created by patterning platinum films using standard photolithography with 1 μm-thick 
photoresist (AZ5214-E, Clariant Corp.). The metal was removed using an ion etch 
process in all areas that were not protected by the resist. The photoresist was stripped 
from the electrodes in an ultrasonic remover bath (AZ400-T, Clariant Corp.) at 70 °C. 
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Finally, the surface was thoroughly cleaned with acetone and distilled water. The 
windows in the silicon oxide films were formed by a standard lift-off photolithographic 
process. Microelectrodes with working areas of 20 × 40 μm2, 20 × 20 μm2 and 5 × 10 
μm2 were fabricated using the processes described above. A microscope image and a 
schematic cross section of the micro electrodes are shown in Figure 40A and B, 
respectively. 
 
 
A 
 
 
B 
 
 
 Ti Pt 
SiO IrOx 
glass 
 
 
 
Figure 40 (A) Bright-field microscope image of Pt microelectrodes covered with a 150-
nm thick SiO2 layer. One of the two rectangular openings is exposing the bare Pt surface, 
while the other is coated with a electrochemically deposited IrOx  thin film for pH sensing. 
(B) Schematic cross section of the Ti/Pt microelectrodes with SiO2 layer for electrical 
insulation, and IrOx coating of the pH microelectrode.  
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IrOx electrochemical deposition 
IrOx films were selectively electrodeposited onto the microfabricated Pt electrodes 
through small windows in the SiOx insulation layer. The deposition solution was prepared 
based on the method described by Yamanaka  [238, 263] and Marzouk  [232, 252]. In our 
protocol, a 75-mg portion of iridium tetrachloride was dissolved in 50 ml of DI water, 
and the solution was magnetically stirred for 15 min. A 0.5 ml aliquot of aqueous 30% 
hydrogen peroxide was added, and the resulting solution was stirred for another 10 
minutes. A 250-mg portion of oxalic acid dihydrate was added, and the solution was 
stirred again for 10 min. Small amounts of anhydrous potassium carbonate were 
gradually added to the stirred solution to adjust its pH to 10.5. The solution was 
contained and stored at room temperature for 2 days to allow for stabilization. The color 
of the solution changed from yellow to light-violet, indicating it could be used for a 
successful deposition. After stabilization, the solution was stored in a dark bottle at 4oC in 
a refrigerator until use  [232]. We used deposition solution for up to two months after its 
preparation. 
All electrochemical experiments were performed with a CHI model 660A 
potentiostat/galvanostat (CH Instruments) in a three-electrode cell. In beaker 
experiments, potentials were measured relative to an Ag/AgCl (CHI 111, CH 
Instruments) reference electrode. The counter electrode was a Pt wire, 1mm diam., (CHI 
115, CH Instruments). The IrOx electrode potential was monitored in open circuit 
potential (OCP) mode. A DRIREF-450 (WPI) Ag/AgCl reference electrode, 450 μm 
diam., was used for pH measurement inside microchannels. 
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Both modes – galvanostatic and cyclic potential cycling – were used for the deposition of 
iridium oxide films. A constant current density of 1-1.5 mA/cm2 applied for 500 s proved 
to be the optimal condition for the formation of a dark blue IrOx film in galvanostatic 
mode. Light-blue iridium oxide films were created by cycling 100 times between 0.0 V 
and 0.55 V at 75 mV/s in the potential cycling mode. The thickness of the anodic IrOx 
films ranged from 0.05 to 0.1 μm, depending on the deposition method and process 
parameters. We used a stylus surface profiler (Alphastep 200, Tencor Instruments) to 
measure the thickness of the films after electrodeposition. Immediately after deposition, 
the pH sensitive IrOx films were rinsed with distilled water and dried under a stream of 
nitrogen. Then, for comparison purposes, some of the iridium oxide microelectrodes were 
coated with proton-exchanging Nafion resin by momentarily dipping them into a 5% 
Nafion solution and subsequently air-drying them at 80oC [232, 252]. The pH 
microelectrodes were ready for use after they were soaked in a universal buffer of pH 7.0 
for two days, a practice which proved to be necessary in order to reduce potential drifts  
[232, 252]. When not in use, the microelectrodes were stored in universal buffer solution 
(pH 7.0) at room temperature in a dark place. 
 
Microfluidic device fabrication 
The microchannels in our microfluidic devices were fabricated by replica molding using 
a patterned photoresist on a silicon wafer as the master, and poly(dimethylsiloxane) 
(PDMS) as the biocompatible polymer (Sylgard 184, Dow Corning, Midland, MI). The 
master was fabricated by spinning a 20 µm layer of photoresist (SU-8 2050, Microchem) 
on a 3 in.-diameter silicon wafer, followed by a UV light exposure through a metal mask 
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using a contact mask aligner. The photoresist was processed according to the 
manufacturer’s recommendation on the datasheet. An optional 30- minute hard bake at 
200 °C was performed on a hot plate to increase the durability of the resist. The master 
was placed in a plastic culture dish and covered by a 5 mm layer of the PDMS/curing 
agent mixture at a ratio of 10:1 by weight. After curing the elastomer in the moulding 
dish for five hours at 60 °C in an oven, the devices were cut out and mechanically 
separated from the master. The feature sizes of the microfluidic networks ranged from 
20-1000 μm. Access holes to the channels were punched with a sharpened stainless steel 
pipe. Each microfluidic device was manually aligned relative to the pH electrode by 
using an inverted microscope, and sealed onto the electrode/glass substrate by 
autoadhesion. We used glass capillaries inserted into the access holes to connect the 
microfluidic channels via standard microtubing (0.5 mm inner diam., Cole Parmer) to 1 
ml syringes. The microsyringe pump controller “Micro 4” (WPI, Sarasota, FL) was used 
to control the flow of solution in the microfluidic device with flow rates ranging from 10 
nl/min to 10,000 nl/sec. 
 
A.4 Results and discussion 
Properties of electrochemical IrOx films 
The key characteristics of thin-film IrOx electrochemical pH electrodes are 
sensitivity, response time, stability, and reproducibility. We studied these properties of 
our films and demonstrated the possibility of using them in microfluidic devices. We 
deposited IrOx films by galvanostatic and potential cycling methods. However, our 
 141
results show that films deposited by the galvanostatic method had superior properties and 
therefore we will not further discuss IrOx films formed by the potential cycling method.  
We incorporated miniature pH sensors in microfluidic devices with the following active 
electrode areas: 5 × 10 µm2, 20 × 20 µm2 and 20 × 40 µm2. We observed a decrease in 
stability and reproducibility for iridium oxide films with areas of 5 x 10 µm2. We 
attribute this behavior to non-uniform film deposition, an issue which can be addressed 
by optimizing the electrode design and the deposition conditions. However, experiments 
on a small number of cells in a microfluidic device do not require electrode dimensions 
comparable to the cell size. We therefore chose to optimize and characterize the 
properties of the larger (20 × 20 µm2 and 20 × 40 µm2) electrodes. 
The analytical characteristics of IrOx pH microelectrodes were tested before their 
application in microfluidics devices. The response of our IrOx electrodes to exposure to a 
series of universal buffer solutions in the pH range between 4 and 10 is presented in 
Figure 41A. Figure 41B demonstrates a linear super-Nernstian response resulting in a 
sensitivity of -77.6 ± 2 mV/pH. This value agrees with results obtained in the literature 
for the electrochemical deposition of IrOx on macroelectrodes  [232, 252, 260]. We 
further developed the fabrication process, allowing for the selective deposition of IrOx 
films on microelectrodes. In addition, our pH electrode sensitivity was superior compared 
to that of electrodes formed by other methods, like reactive sputtering  [253-255] and 
thermal decomposition of IrCl3 · H2O  [259], which typically have lower sensitivities in 
the range of 55 - 70 mV/pH. 
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As stated in [236, 265], the response of anhydrous IrO2 films to pH changes with a slope 
of approximately 59 mV/pH (Nernstian response) can be explained using the following 
redox reaction 
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Figure 41. Calibration of microelectrodes for pH measurements. (A) Open circuit 
potential of a IrOx pH electrode during periodic cycling of 5 different standard pH 
calibration solutions with 30 s measurement intervals.  
(B) Average potentiometric response of a IrOx pH electrode in the pH range of 4 to 
10 at a temperature of 22oC, The error bars represent the standard deviation for all 
measurement points corresponding to a particular pH. 
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IrO2 + H+ + e- ↔ IrO · OH 
or 
2IrO2 + 2H+ + 2e- ↔ Ir2O3 + 2H2O. 
 
Hydrated iridium oxide exhibits super-Nernstian responses explained by the mechanism 
of one transferred electrons per 1.5 H+ ion, resulting in a slope of approximately 90 
mV/pH [236, 266]: 
2[IrO2(OH)2 · 2H2O]2- + 3H+ + 2e-  ↔ [Ir2O3(OH)3 · 3H2O]3- + 3H2O 
 
Our films had near-super-Nernstian response, which suggests the prevalence of a 
hydrated form of iridium oxides  [236, 264]. 
 
 
Figure 42. Response time of the IrOx microelectrode as a function of storage time. 
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The sensitivity of the pH electrodes remained practically constant during 5-6 weeks 
storage time in pH 7 buffer solution, as previously described. Dry storage of IrOx 
electrodes led to noticeable sensitivity decrease of typically 20-30%. Soaking these 
electrodes for 1 h in buffer solution restored their sensitivity to the original value. 
We observed a substantial influence of the age of the deposition solution on the 
sensitivity of the IrOx pH electrodes. Iridium oxide films deposited from fresh solution 
showed the maximum sensitivity of -77 mV/pH. We observed practically no change from 
process to process (± 1-2 mV/pH) up to a shelf life of 1 month for the deposition solution. 
The films deposited from solutions older than 1 month showed a 10-15 % decrease in 
sensitivity, and a spread in sensitivity reproducibility of ±5 mV/pH.  
The potential drift during pH measurements is another important characteristic of IrOx 
electrodes. We used standard buffer solutions in the pH range of 4-10 to calibrate the 
deposited IrOx films. We recorded the OCP of the IrOx electrode relative to the Ag/AgCl 
reference at room temperature.  
In order to quantify potential drifting we placed the IrOx electrodes and the reference 
electrode in 50-ml beakers with different buffer solutions according to the following 
procedure. The potential measurement corresponding to each pH buffer was conducted 
for 30 s, which proved to be long enough to reach steady state in the potential response 
for fresh electrodes. Then, the potential measurement was paused while the pH buffer 
solution was replaced by a different one.  
These kinds of measurements were usually conducted within 2 hours, with a total of 200 
alternations among buffer solutions. Figure 41a shows typical kinetics of electrical 
potential for iridium oxide pH electrodes (20 × 20 µm2) exposed to different buffer 
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solutions. Usually, the potential drift was ± 2-3 mV for each buffer solution. This 
phenomenon is identified in the literature as “hysteresis of the sensor response.”  
The drift is typically ± 2 mV for IrOx-coated Ti wires [252]. Fast response times are 
crucial for biological experiments in microfluidic devices. Therefore, we quantified 
response times of the IrOx pH microelectrodes and their long-term behavior. As usually 
described in the literature, the response time of pH electrodes is defined as the time 
required to reach 90 % of the equilibrium value [267, 268]. The typical response time of 
our pH microelectrodes was 6 s within one week of deposition. A 50% increase in the 
response time was observed for the first 3 weeks of aging, as well as a two-fold increase 
of the standard deviation, as shown in Figure 42. After four weeks of aging, we observed 
a 100% increase in the response time relative to the freshly deposited IrOx pH electrodes. 
These data are in close agreement with the response times reported in the literature, 
which range from 5 to 15 s for 1 mm IrOx-coated wire pH electrodes  [232, 252]. This 
response-time range is suitable for many biological applications including pH 
measurement. Aging of more than four weeks caused substantial increase in the response 
time of the pH electrodes — over 40 s on average — which is obviously unacceptable in 
many cases. This study demonstrated that our electrochemically deposited IrOx electrodes 
can be used within a month of their formation, provided that the characteristic times of 
processes intended to be measured are longer than the pH electrode response time.  
Several publications describe the use of Nafion layers to minimize the interfering effects 
associated with anion redox species and for protection of the sensor surface from 
aggressive solutions [252, 254]. We conducted analogous studies to investigate the 
protection of IrOx films by dip coating with Nafion. However, we found that Nafion 
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deposition caused substantial increases in response time, which reached 150–200 s for 
dip-coated Nafion layers post baked between 60-100 ºC.  
We also investigated the compatibility of bare IrOx sensing electrodes and cell culture 
media using different buffer solutions (Dulbecco Modified Phosphate Buffered Saline 
(DPBS), with and without Hepes) used for cell growth, and found no degradation in the 
sensing properties. Therefore, we used IrOx without Nafion coating in all subsequent 
experiments.  
In summary, our results showed that IrOx films formed by using the galvanostatic method 
have near-super-Nernstian response: -77.6 ± 2 mV/pH in the 4-10 pH range. We 
measured potential drifts of 2-3 mV and response times ranging from 6 to 12 seconds for 
up to one month of storage. IrOx thin-film pH-sensing microelectrodes with such 
characteristics were integrated into our microfluidic devices, as described in the 
following paragraphs.  
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Properties of IrOx pH electrodes in microfluidic devices 
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Figure 43. (a) Schematics of a microfluidic device for investigating the properties of our 
pH microelectrodes (A) in microfluidic channels (B). 1 – waste channel; 2, 3, 4, and 5 – 
input channels for DI water, pH 6, 7, 8 buffer solution, respectively; 6 – Ag/AgCl 
reference electrode; The inset shows a detailed view of the pH microelectrode in the 
sensing channel. (b) Optical image of the sensing channel with pH microelectrode and 
Ag/AgCl reference electrode. (c) Picture of the clamp mechanism (A), which ensures a 
reliable seal between the PDMS block containing the microchannels (B), Ag/AgCl 
reference electrode (C) and the glass substrate with thin film microelectrodes. 
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A schematic drawing and a microscope image of our microfluidic device with multiple 
input ports are shown in Figure 43a and b, respectively. The device was comprised of a 
PDMS microchannel network auto adhered to a glass slide patterned with an array of 
platinum microelectrodes, one of which was coated with IrOx for pH sensing. 
Additionally, we used a clamp to provide mechanical stability and to achieve a good seal 
between the elastomer and the substrate (Figure 43c). This assembly was mounted on a 
microscope stage for observation. The microchannels were designed to direct buffer 
 
 
 
 A      B 
  
Figure 44 (A) Open circuit potential of IrOx pH microelectrode inside the microfluidic 
sensing channel during exposure to different standard pH calibration solutions in 30 s 
measurement intervals. (B) Potential transient after a step-like change of the calibration 
solution by one pH unit. 
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solution across the IrOx pH electrode (20 × 20 µm2) and the reference electrode (450 µm 
diam.) located in the sensing channel. The calibration of pH electrodes in the microfluidic 
channel was done in the biologically relevant pH range of 6-8, as these electrodes were 
intended to be used for the acidification-rate measurements of various living cells. Input 
channels 3, 4, and 5 were designated for the delivery of buffer solutions with pH 8, 7, and 
6, respectively. Input channel 2 was used for DI water delivery to flush the working area.  
Calibration of the IrOx pH electrodes was conducted by repeating the following steps: (i) 
filling the sensing channel with buffer solution of known pH; (ii) measuring the resulting 
OCP between the reference and the IrOx electrodes. The calibration process for pH 
electrodes consisted of more than 100 changes of buffer solutions. Data from an 
 
 
 
 
Figure 45. Open circuit potential of the IrOx pH microelectrode for different flow rates 
of solution in the microfluidic channel. a corresponds to a flow rate of 250 nl/s, b 500 
nl/s, c 1000 nl/s, d 2500 nl/s, e 5000 nl/s, and f  10 000 nl/s.  
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exemplary calibration of IrOx pH microelectrodes in our microfluidic device are shown in 
Figure 44. Each individual measurement was performed for 30 s. We determined the 
maximum deviation from the average potential for each individual pH level to be 2 mV 
over the course of the 1-hour calibration. The sensitivity of these electrodes was in the 
range of 70-78 mV/pH. A fast response is an important requirement for IrOx pH 
electrodes in microfluidic applications. Figure 45 shows the typical response of an IrOx 
pH microelectrode to a change of 1 pH unit in the sensing channel. The response time 
extracted from the data was 5 s. In summary, measurements taken with our IrOx pH 
microelectrodes in microfluidic channels were virtually the same as those from 
macroscopic experiments in beakers, with respect to sensitivity, potential drift, and 
response time.   
Next, we investigated the performance of the IrOx sensing electrodes in our microfluidic 
devices under flow conditions ranging from 10-10,000 nl/s. We observed that flow rates 
< 200 nl/s did not result in a considerable potential increase. The behavior of the OCP at 
six different flow rates above 200 nl/s is depicted in Figure 45. We used the same volume 
of buffer solution for each segment, therefore the measurement interval decreased with 
increasing flow rate. The spikes depicted in the graph were caused by the adjustments 
between flow rates. We noticed a constant potential increase of 0.6 mV/min for the first 
three flow rates, which ranged from 250 to 1000 nl/s (marked a, b and c in the graph). 
The potential increase reached 6 mV/min for 2500 nl/s, 30 mV/min for 5000 nl/s and 
became irreproducible for flow rates above 10,000 nl/s. However, for flow rates between 
200 and 1000 nl/s, the potential increase was quite reproducible, a behavior which 
allowed pH measurements to be conducted at these flow rates. The reason for this 
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potential increase is not well understood, however Marzouk et al. reported similar 
changes in the electrode characteristics at increased flow rates for IrOx-coated Ti wire in 
a flow-injection-analysis device  [232]. We did not investigate this effect further because 
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Figure 46. Test of the thin film pH microelectrode in a microfluidic device (a) Optical 
image of the pH sensing, reference electrode and a 25 nl cell culture volume filled with 
fibroblast cells for acidification measurements. The inset shows a close view of the 
sensing volume, the pH microelectrode and the filter structure used to trap cells. (b) 
Time course of the Open circuit potential of the IrOx pH microelectrode during an 
acidification rate measurement for A9 L HD2 fibroblast cells. 
(c) Acidification rate measurement of M3 WT4 CHO cells. 
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flow rates > 200 nl/s are unrealistic for cell culture experiments in lab-on-a-chip devices 
with nl culture volumes.  
 
Incorporation of IrOx microsensors into nl cell culture volumes 
The metabolic activity and the physiological state of a living cell can be characterized by 
the rate at which the cell produces acidic byproducts. In order to record metabolic 
changes of a small number (1-1000) of cells in multiple wells in a parallel approach for 
high throughput drug screening applications, it is necessary to scale down the sensor size 
and provide fluidic access to the cell culture volume for perfusion and drug delivery. We 
used an optically-transparent PDMS polymer in combination with our miniature pH 
sensing electrodes to fabricate microfluidic-based microsystems to achieve this goal. The 
optical transparency would allow for parallel fluorescence measurements for a multi 
parameter assessment of cell physiology.  
Such a device, as shown in Figure 46A, can be mass-produced, each unit consisting of a 
glass substrate with thin-film IrOx pH microsensors and a PDMS microfluidic network 
containing a 25 nl cell culture volume connected to perfusion and cell-seeding channels. 
A magnified image, showing live fibroblasts and the thin-layer IrOx pH electrode, is 
presented in the inset of Figure 46A. All cells were grown in T-flasks to 85% confluency. 
Medium was removed; cells were washed with DPBS (Dulbecco Modified Phosphate 
Buffered Saline) and detached by a trypsin treatment. Detached cells were suspended in 
growing medium. Immediately before starting pH measurements, the cell medium was 
replaced with modified RPMI 1640 with low buffering power (1 mM PBS). The cells 
were then seeded into our PDMS Nanobioreactor, which had the following dimensions: 
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1000 μm wide, 1000 μm long, 25 μm high, and a total volume of 25 nl. Cells were 
loaded by applying a vacuum to either perfusion channel, thereby pulling the cells from 
the seeding channel into the Nanobioreactor chamber.  
The cells were confined by two 3-μm filters located at the entrance of the left and right 
channels. We successfully trapped most of the administered fibroblast and CHO cells, 
which have diameters of about 11-18 μm and 10-12 μm, respectively.  
After seeding 10-25% of the surface area with cells, we stopped the media flow by 
releasing the vacuum, and we started to record the OCP between the IrOx and the 
Ag/AgCl reference electrode. The results are presented in Figure 46B and C for fibroblast 
and CHO cells, respectively. The potential changes are directly proportional to pH 
variations inside the Nanobioreactor chamber and can be expressed in pH units if divided 
by the electrode sensitivity of -70 mV/pH. We observed a near-linear signal increase, 
which corresponded to an acidification rate of 0.03 pH min-1 for fibroblast cells, 
presented on Figure 46B. After a deviation from linearity was observed we stopped 
measurements because the pH was beyond the physiologically relevant range. After the 
experiment the sensitivity of our pH electrodes was re-measured and we found no 
degradation. However, there could be a sensitivity change in long term experiments when 
the electrodes are exposed to small organic molecules and proteins produced by the cells  
[269]. Similar measurements were conducted using CHO cells as shown in Figure 46C. 
Based on these data we calculated an acidification rate of 0.06 pH min-1 for the linear 
region of the graph. The larger acidification rate for the CHO cells was expected since 
they are metabolically more active than fibroblast cells. Comparable acidification rates 
are reported in the literature  [241, 245]. 
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A.5 Conclusions 
We developed planar pH microelectrodes with dimensions smaller than 500 µm2 
on transparent glass slides using selective electrochemical deposition of IrOx onto 
lithographically-defined Pt thin-film electrodes. The IrOx pH microelectrode was 
incorporated as a transducer into a microfluidic-based PDMS device with a 25 nl cell 
culture volume. The characteristics of our IrOx pH electrodes were highly reproducible: 
sensitivities of -77.6 ± 2 mV/pH, potential drifts of 2-3 mV/month (static solution), and 
response times of 5-15 s within one month of deposition. The properties of our pH 
electrodes did not change when incorporated into microfluidic devices. We demonstrated 
for the first time the use of IrOx microelectrodes for acidification rate measurements in nl 
on-chip cell culture volumes for CHO cells and fibroblast cells. The average acidification 
rates were 0.03 pH min-1 and 0.06 pH min-1 for fibroblast and CHO cells, respectively, 
and are in agreement with previously published data. Our results demonstrate the 
feasibility to scale down pH electrodes and cell culture volumes to measure acidification 
rates in volumes less than 1 nl. 
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APPENDIX B 
 
FATTY ACID β-OXIDATION DEFECTS, BIDIRECTIONAL VENTRICULAR 
TACHYCARDIA, AND RYANODINE RECEPTOR DYSFUNCTION 
IN VLCAD NULL MICE 
 
 
B.1 Abstract 
Familial catecholaminergic polymorphic ventricular tachycardia is characterized 
by polymorphic ventricular tachycardia, bidirectional ventricular tachycardia (BVT), and 
a high risk of sudden cardiac death. Recently, mutations involving the cardiac ryanodine 
receptor (RyR) and calsequestrin have been identified in patients with these arrhythmias.  
Patients with mutations in the mitochondrial very-long-chain Acyl-CoA dehydrogenase 
(VLCAD) enzyme are also at risk for sudden cardiac death. Here we identify a novel 
mechanism of fatty acid and catecholamine-dependent BVT due to cardiac RyR 
dysregulation in mice lacking VLCAD (VLCAD-/-). These mice exhibit: VT with the 
typical bidirectional morphology with isoproterenol infusion, increased levels of cardiac 
ryanodine receptor 2, increased [3H] ryanodine binding in heart microsomes, and 
enhanced intracellular calcium release at the cardiomyocyte level. Both the amplitude and 
rate of intracellular SR Ca2+ release was increased in single cardiac myocytes isolated 
from VLCAD-/- mice, while the L-type Ca2+ current (ICa) was not changed. Diastolic 
cytosolic calcium as measured by indo-1 fluorescence was higher in VLCAD-/- cells 
suggesting an increase in the time-independent cytosolic and mitochondrial Ca2+ 
concentration. This defect in calcium homeostasis was not seen in VLCAD wild type 
controls. We conclude that mitochondrial VLCAD deficiency represents a novel 
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mechanism of ryanodine receptor channelopathy leading to abnormal intracellular 
calcium handling and arrhythmias in mice and perhaps also in VLCAD deficient humans. 
Key Words: | genetics - inborn errors| VLCAD| Ryanodine Receptor| Mitochondria| 
Calcium| Catecholaminergic and bidirectional ventricular tachycardia. 
 
B.2 Introduction 
Children with mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency 
(VLCAD) are usually diagnosed at presentation in the clinic by episodes of metabolic 
crisis and death. Deficiencies in these mitochondrial fatty acid oxidation (FAO) enzymes 
have been implicated in cardiomyopathy, arrhythmias, and sudden unexpected death, as 
well as in a variety of other illnesses [270]. Phenotypes of FAO deficiency in humans 
include non-ketotic hypoglycemia, heart and liver lipidosis, encephalopathy, skeletal 
myopathy and sudden death. VLCAD deficiency (the focus of this report) causes 
ventricular tachycardia (VT) in almost 50% of the presenting cases [271-275]. Most of 
the cases of sudden death occur in the first year of life. The molecular mechanisms of 
arrhythmias associated with these defects have yet to be delineated. Survival into 
adulthood is possible, but long-term follow-up of patients who survive both the infancy 
and childhood periods has not been carried out. Thus, it remains unknown whether older 
patients with these defects contribute to a subset of cases with familial or 
catecholaminergic ventricular tachycardia.  
While VLCAD is a mitochondrial protein encoded by a nuclear gene [276], ryanodine 
receptors are intracellular  Ca2+ release channels, mainly clustered in the root structures 
of the sarcoplasmic reticulum of striated muscles. The RyRs are characterized by their 
large size and four-fold symmetry [277]. Three distinct isoforms encoded on different 
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chromosomes share about 2/3 sequence homology [278]. The RyRs are hetero-oligomers 
consisting of four RyR protomers and four FK 506 (tacrolimus) binding proteins (FKBP) 
[279]. The RyRs have a mass of 2.3megaD, (the protomers are about 0.56megaD) while 
FKBP is approximately 12kD [279, 280]. RyRs are now known to be widely distributed 
in tissues. In skeletal muscle, RyR1 is morphologically identical to the foot-structures 
spanning the gap between the terminal cisternae of SR and the sarcolemma/ transverse 
tubules (T-tubule) [281]. Similar morphological structures have been identified and 
characterized in cardiac muscle fractions for RyR2 [282]. The third isoform, RyR3 is 
widely expressed in a variety of tissues but in minuscule amounts. The functional 
characteristics of RyR1, RyR2 and RyR3 have been studied in isolated SR membrane 
fractions as well as in purified receptors. Mutations in the cardiac ryanodine receptor 
(RyR2) gene are known to cause both catecholaminergic polymorphic ventricular 
tachycardia (CPVT) - also termed familial polymorphic ventricular tachycardia (FPVT), 
or bidirectional VT [283-286] and  arrhythmogenic right ventricular dysplasia (ARVD2) 
[287, 288].  These mutations cause abnormalities in the regulation of channel activity.  A 
“gain-of-function” or increased Ca2+ leak from the sarcoplasmic reticulum (SR) has been 
proposed [289].  In this paper, we use our mouse model of VLCAD deficiency [227],  to 
show a novel role for mitochondrial fatty acid β-oxidation defects in disturbances of 
calcium homeostasis in heart.  The working hypothesis of our study was to test whether 
mitochondrial VLCAD deficiency leads to functional changes in the cardiac ryanodine 
receptor at the subcellular level, with enhanced intracellular Ca2+ release from the 
sarcoplasmic reticulum (SR) that is reminiscent of human cases with defective RyR2 
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channels. Here, we also discuss the possible role for FAO defects in the clinical 
manifestations of affected patients with these inherited arrhythmogenic diseases. 
 
B.3 Materials and Methods 
VLCAD deficient mice   
All animals in this study were cared for according to the Institutional Animal Care 
and Use Committee (IACUC) at Vanderbilt University. Mice were generated and 
genotyped as previously described  [227, 290]. Upon sacrifice or at autopsy, whole heart 
ventricles and skeletal muscle (slow- and fast-twitch) were harvested for total protein.  
Immunoelectron microscopy was performed in heart tissue from two month old VLCAD 
+/+ and VLCAD -/- mice.  
 
Preparation and characterization of subcellular fractions from different organs  
Hearts and other organs are harvested from euthanized animals in conformity with the 
IACUC animal care codes.  Subcellular fractionation was performed by the method of 
Chamberlain and Fleischer  [291]. The resulting subcellular fractions or pellets were 
resuspended in a small volume of resuspension buffer, flash-frozen in liquid nitrogen and 
stored at -80ºC. 
 
[3H] Ryanodine Binding Assay.  
[3H] ryanodine binding was determined at 60 nM ryanodine as described previously  
[278].  Summarizing the process briefly, cardiac microsomes (50 µg) were incubated in 
50µl of buffer containing 10mM K-HEPES, pH 7.4, 1M KCl, 25µM CaCl2, and 60nM 
[3H]ryanodine (~15,000 cpm/pmole, obtained from Amersham) for 1 h at room 
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temperature. Nonspecific binding was measured in the presence of 20µM cold ryanodine 
(Sigma). Free ligand was separated from the bound by sedimenting the microsomes in a 
Beckman TL-100.1 rotor at 95,000 revolutions / min for 15 min at 4ºC. The supernatant 
was removed by aspiration, the pellets rinsed twice and resuspended in 200 µl water, and 
the radioactivity was measured in 5 ml of Cytoscint (ICN, Cleveland, OH) in a Beckman 
LS 5000TD scintillation counter. 
 
Calcium loading assays using antipyrylazo III 
Calcium loading assays were performed in a diode array spectrophotometer. Ca2+ loading 
assay medium consisted of 100 mM potassium phosphate buffer, pH 7, 1 mM of MgCl2 , 
0.2mM antipyrylazo III, and 50 µg of protein. Na2ATP (1 mM) was added, and the 
reaction was initiated by addition of 50 µM CaCl2 (antipyrylazo III is used as the 
metallochromic indicator).  Measurement of the difference in absorbance between 710 
and 790 nm was done at 37 ºC.  Ruthenium red (10 µM) was added to selected samples 
70 seconds after the reaction has been initiated to block Ca2+ leak from the SR.  A general 
formula was used to calculate the rate of Ca2+ loading as previously published  [292]. 
 
Preparation of ventricular myocytes 
VLCAD knockout and wild-type control mice were anesthetized by intraperitoneal 
injection of Avertin solution (5mg Avertin per 10 g body weight, T48402, Sigma-
Aldrich) containing Heparin (3 mg/10ml, H9399, Sigma-Aldrich). The heart was rapidly 
excised and placed into ice-cold Ca2+-free Hepes-buffered normal Tyrode (NT) solution. 
The aorta was cannulated and the heart was perfused with Ca2+-free NT solution at room 
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temperature for 10 min to stop contractions. The NT solution contained (in mM): Na+ 
140, K+ 4.5, Mg2+ 0.5., Cl- 150, H2PO4- 0.4, HCO3- 10, Hepes 10, glucose 10. The 
perfusion was switched to NT solution containing 10µM Ca2+, collagenase (178 U/ml, 
CLS2, Worthington Biochemical) and protease (0.64 U/ml, P5147, Sigma-Aldrich) for 12 
min at 37 ºC. Tissue from the atria and aorta was discarded. The remaining ventricular 
tissue was coarsely minced and placed into NT solution containing bovine serum albumin 
(10 mg/ml, A9647, Sigma-Aldrich). Myocytes were dissociated by gentle agitation.  Ca2+ 
concentration in the working solution was increased from 0.1 mM to 0.5 mM. For the 
glucose-free experiments, glucose was replaced by palmitic acid (10 µM, P0500, Sigma-
Aldrich) in all solutions. Cells were stored in 0.5 mM Ca2+ Tyrode solution until used, 
usually within 3 hours after isolation.  
 
Measurement of indo-1 calcium transients 
Dissociated cardiomyocytes were loaded with 20 µM of an acetoxymethyl ester form of 
the Ca2+-sensitive fluorescence dye indo-1 (I1203, Molecular Probes-Invitrogen). Cells 
were kept in this solution for 15 min at room temperature and then centrifuged at 27 g for 
10min. The supernatant was removed and the cells were re-suspended in glucose free 
Tyrode solution containing 1.0 mM Ca2+. Experiments were started approximately 30 
min after washing to allow complete de-esterification of the fluorescent dye. To minimize 
phototoxic effects on Ca2+ transients, only 100 ul of stained cells were pipetted into the 
bath solution which was completely replaced after each exposure to the excitation light. 
The bath contained glucose free Tyrode solution with 1.0 mM Ca2+ at 37ºC, 
supplemented with an insulin/transferrin/selenium mixture (100X medium supplement, 
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41400, consisting of 10 µg/ml insulin, 5.5 µg /ml transferrin, 6.7 ng/ml sodium selenite, 
Gibco-Invitrogen) to improve the performance of the isolated cells at the high stimulation 
frequencies [293]. Myocytes were field stimulated at the physiological rate of 600 beats 
per minute via two parallel platinum wires. Fluorescence measurements were carried out 
using an inverted microscope (Axiovert 200, Carl Zeiss, Germany) equipped with a 63X, 
1.4 NA oil immersion lens (Plan Apochromat, Carl Zeiss, Germany). The excitation light 
was emitted by a monochromator (Optoscan, Cairn Research Ltd, UK) at a wavelength of 
365 ± 15 nm and reflected by a 390 nm dichroic mirror (390DRLP, Omega Optical). The 
fluorescence emission was split into two components by a second dichroic mirror 
(450DCLP, Omega Optical). The transmitted light was passed through a 495 ± 10 nm 
(495DF20, Omega Optical), and the reflected component was passed through a 405 ± 21 
nm bandpass filter (405DF43, Omega Optical). The light from each wavelength was 
collected by 1 mm diameter optical fibers mounted directly behind the emission filters 
imaging a ~16 µm diameter spot on the cell. The light from each fiber was collected by 
photomultiplier modules (H6780, Hamamatsu) and amplified by a custom-built low-noise 
DC coupled amplifier. The signals were digitized at a sampling rate of 20 KHz by an A/D 
converter board (PCI-6071E, National Instruments) in a conventional PC.  
 
Fluorescence calibration 
Intracellular Ca2+ measurements were converted to free [Ca2+]i according to the equation 
[110]: [Ca2+]i =Kd β [R-Rmin]/(Rmax-R)], using an in vivo dissociation constant of the 
dye of 844nM [146]. The β value, the ratio of the free to the bound indo-1 fluorescence 
was measured at 485nm. Rmin and Rmax were determined in vivo as previously 
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described  [146]. Indo-1 loaded cells were exposed to 10 mM caffeine twice to empty the 
SR stores and subsequently superfused with Ca2+-free Tyrode solution. The bath solution 
was then replaced with a Ca2+ buffer solution containing 5 mM EGTA and 10 µM of the 
nonfluorescent ionophore Br-A23187 (B7272, Sigma-Aldrich). Measurements were 
taken after the fluorescence reached stable values at both wavelengths. For Rmax 
determination, the metabolic inhibitor cyanide p-(trifluoromethoxy)-phenylhydrazone 
(3µM, C2920, Sigma-Aldrich) was added to the solution to avoid spontaneous 
contractions during the increase of the extracellular Ca2+ concentration. Cells were 
perfused for 15 min with EGTA-free solution containing 15 mM Ca2+ before Rmax was 
measured. The Ca2+ ionophore was present throughout the entire experiment. 
 
Sarcomere contraction measurement  
Sarcomere contraction was measured in single cells using a commercial contractility 
measurement system (Ionoptix) consisting of a 240 frames-per-second CCD camera 
(MYO100, Ionoptix) connected to a side port of the microscope, a frame grabber PC card 
(FRGRAB, Ionoptix) and an analog/digital converter (DSI200, Ionoptix) to record the 
stimulus. Data were acquired using the Ion Wizard software. Cells were field-stimulated 
at 240 beats per minute to obtain 60 data points for each contraction at the maximum 
acquisition rate of 240 frames per second. Although faster stimulation rates are more 
physiological and desirable, the limiting camera frame rate reduced the number of data 
points per contraction at higher frequencies. 
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Electrophysiology 
L-type Ca2+ current (ICa) was recorded in whole-cell mode voltage clamp configuration 
according to previously published methods  [294]. Briefly, pipettes (2-3 MΩ) contained 
(in mM): Cs+ 120, Ca2+ 3, Cl- 126, MgATP 1, NaGTP 1, phosphocreatine 5, HEPES 10, 
EGTA 10  [295]. The pH was adjusted to 7.2 with CsOH. The bath solution contained 
NT solution as described above with 10 µM palmitic acid and 1.8 mM Ca2+. Holding 
potential was -90 mV. ICa was measured during 500 ms test pulses at potentials from -
40mV to +40mV following a 50 ms pulse at -50 mV to inactivate the Na+ current  [158, 
169]. 
 
Data analysis and statistics 
Data were expressed as means ± SEM. Statistical analysis was performed by Student’s t-
test between VLCAD-/- and VLCAD+/+ myocytes. Data were analyzed with Matlab 
(R14, The MathWorks, Inc.). Ca2+ release and uptake, as well as sarcomere contraction 
and relaxation were fit to empirical mathematical functions for the purpose of calculating 
release and contraction rates by numerical differentiation. Ca2+ release was best fit by a 
modified model of RyR activation previously published [121]: 
  [Ca2+]i(t)=[Ca2+]max·(P(t)/1-P(t))n , where t is time, [Ca2+]max is the peak Ca2+ release, 
and P(t) the time-dependence of the Ca2+ release described by P(t)=(1-e-t/τ)m. The 
parameters τ, n and m were used as fit parameters. Ca2+ uptake was best fit by a sum of 
two exponential function [Ca2+]i=Ae-t/τ1+Be-t/τ2 where A, B, τ1 and τ2 were used as fit 
parameters. Sarcomere contraction and relaxation were fitted by the same functions after 
replacing the Ca2+ concentration by the sarcomere length in each equation. 
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Data were expressed as means ± SEM. Statistical analysis was performed by Student’s t-
test between VLCAD-/- and VLCAD+/+ myocytes. 
 
B.4 Results 
Polymorphic ventricular tachycardia and bidirectional VT in VLCAD deficient mice 
VLCAD +/+ and VLCAD-/- mice were used for this report. These mice, although 
viable, demonstrated easily inducible VT in the absence of physiological stress [290]. 
Ventricular tachycardia in the VLCAD deficient mice was consistently polymorphic.  VT 
with the typical bidirectional morphology with isoproterenol infusion is shown in Figure 
47 and is characteristic of patients with catecholaminergic ventricular tachycardia.  
Using programmed ventricular stimulation, ventricular tachycardia could be induced in 
6/12 (50 %) of VLCAD deficient mice compared with 2/16 (12 %) wild-type mice.  
Inducibility of ventricular tachycardia was increased in the VLCAD-/- mice to 10/12 (83 
%) when isoproterenol was used, while isoproterenol did not increase arrhythmia 
inducibility in wild type mice.  
 
 
Figure 47. Surface electrocardiogram (lead I) during VT in a VLCAD-/- mouse. ECG 
recording of bidirectional VT in a VLCAD-/- mouse. Arrows indicate positive QRS 
complexes and arrowheads indicate negative QRS complexes. The alternating QRS 
axis in lead I is typical of bidirectional VT. 
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Figure 48. Western blots for cardiac and skeletal muscle RyR isoforms.  (A) Western 
blot from whole heart for VLCAD, in wild type (+/+, VLCAD+/+) and homozygous 
deleted (-/-, VLCAD-/-), control lane, α-MMDH, Mitochondrial Malate 
Dehydrogenase.  (B) SDS-PAGE for subcellular fractions as observed with Coomassie 
Blue. Lane 1 M = Marker, lane +/+ = heart microsomes from the VLCAD+/+ mice, 
lane -/- = microsomes from the VLCAD-/- mice.  Asterisks denote typical 
characteristics of microsomal fractions from top to bottom (RyRs, myosin, Ca2+ pump, 
and calsequestrin) as previously described  [1]. Protein expression by Western blot 
analyses for the RyRs at two months of age in wild-type (+/+, VLCAD+/+) and 
homozygote deleted (-/-, VLCAD-/-). 45 µg of total protein was loaded per lane. (C)  
RyR2 expression in heart microsomes. (D) RyR1 expression in skeletal muscle 
microsomes. The faster mobility bands below the RyRs in C and D have been 
previously referred to as proteolytic cleavage products of the RyRs.  (E and F) 
corresponding densitometry for protein levels of RyR2 and RyR1 respectively.  All 
data are in mean ± SE from three experiments (* p<0.01, † p<.0002, VLCAD+/+ vs. 
VLCAD-/-). 
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Increased expression of ryanodine receptor 2 isoform in mouse hearts with fatty acid β-
oxidation deficiency 
 
Bidirectional VT is linked to excessive RyR activity [289]. We tested whether the RyRs 
were differently expressed in the VLCAD deficient mouse.  
Western blot analyses using isoform specific antibodies showed a 3.0 ± 0.8 fold increase 
in RyR2 expression in VLCAD-/- mice compared with VLCAD +/+ hearts (p<0.01, 
Figure 48B). We subsequently performed western blot analyses in skeletal muscle and 
brain tissue homogenates to assess the expressions of RyR1 and RyR3. We found that in 
VLCAD-/- mice RyR1 levels were increased 3.3  ± 0.1 fold in skeletal muscle, 
(p<0.0002, Figure 48C),  and RyR 3 levels were increased 2.4 ± 0.8 fold in brain 
homogenates (data not shown).  Densitometry to quantify RyR1 and RyR2 expression is 
shown in Figure 48E and F, respectively. Overexpression of RyR2 was confirmed in 
cardiomyocytes from VLCAD-/- hearts by immunoelectron microscopy (Figure 49A 
VLCAD+/+, B VLCAD-/-, C Negative control). We also quantified immunogold 
particles in the vicinity of the Z-line. The number of gold particles in the vicinity of the z-
line was 10 ± 4 particles for the VLCAD+/+ and 19 ± 4 particles for the VLCAD -/- mice 
(p<0.03, Figure 49D). Given a previous report of RyR localization in the mitochondria  
[296],  we also quantified gold particles present in the mitochondrial cristae of 
VLCAD+/+ and VLCAD-/- mice. The number of gold particles in the mitochondrial 
cristae was 4 ± 2 particles for the VLCAD+/+ mitochondria and 9 ± 3 for the VLCAD-/- 
mitochondria (p<0.003, Figure 49D).  
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Augmented ryanodine binding in microsomes from VLCAD deficient mice 
 
 
 
Figure 49. Representative immunogold staining of RyR2 in mouse heart and 
3[H]ryanodine binding assays.  A to D are related to RyR 2 specific antibody labeling of 
the myocardial sarcomeric units around the Z-line (arrow-heads) and the mitochondria 
(M ~ arrows).  (A). VLCAD +/+, (B). VLCAD-/-, and (C). Negative control lacking 
antibody in the VLCAD -/- mice. One should note the distribution of the gold particles, 
which appear to be less organized in the VLCAD-/- mice. The Particles are spread over 
the longitudinal tubules. These gold particles in the VLCAD -/- mice are also less 
organized over the mitochondria. (D). Quantitative assessment of gold particles in the 
vicinity of the z-line and over the mitochondria, *p< 0.03, comparing SR = 
Sarcoplasmic reticulum, † p<0.008 comparing mitochondria, VLCAD+/+ vs. VLCAD-/-
. (E) [3H] ryanodine binding assays. Ryanodine binding assays with RyR enriched 
microsomes and mitochondrial fractions from the VLCAD+/+ and VLCAD-/- mice. 
Binding assay results from four independent experiments in the microsomes and three 
independent experiments in the mitochondria are plotted as Mean ± SE, ‡ p<0.001 
comparing SR = Sarcoplasmic reticulum, § p<0.004 comparing mitochondria, VLCAD 
+/+ vs. VLCAD-/-. 
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We subsequently performed [3H] ryanodine binding assays with purified microsomal and 
mitochondrial fractions from the VLCAD+/+ and VLCAD-/- mice.  
Ryanodine binding was 1.7 ± 0.3 pmol / mg protein in the VLCAD+/+ microsomes and 
3.5 ± 0.2 in the VLCAD-/- microsomes (p<0.001, Figure 49E). Ryanodine binding assays 
in mitochondrial fractions were 1.16 ± 0.05 pmol / mg protein for the VLCAD+/+ 
mitochondria and 1.43 ± 0.05 for the VLCAD-/- mitochondria (p<0.04). We performed 
Ca2+ loading assays with heart microsomes to assess the sarcoplasmic reticulum Ca2+ 
content, using antipyrylazo III (APIII). We found no difference in Ca2+ loading in heart 
microsomes between the VLCAD+/+ and VLCAD-/- mice.  Loading rates were 29 ± 2 in 
the VLCAD-/- microsomes, compared with 34 ± 6 nmol/ min/ mg protein for the 
VLCAD+/+ control microsomes (p<0.2, VLCAD+/+ vs. VLCAD-/-), suggesting that the 
sarcoplasmic reticulum Ca2+ uptake capacity was not impaired in VLCAD-/- hearts.  
 
Enhanced SR Ca2+ release in VLCAD deficient Cardiomyocytes 
Given the hypothesis that arrhythmias due to RyR2 mutations are caused by enhanced 
Ca2+ release from the SR [284, 297], we subsequently measured Ca2+ transients in 
dissociated cardiomyocytes from the VLCAD +/+ and VLCAD-/- mouse, to test whether 
the observed RyR2 overexpression in VLCAD deficiency was associated with changes in 
intracellular Ca2+. 
We initially measured SR Ca2+ release by fluorescent imaging in the presence of either 
glucose or fatty acid substrates, using the Ca2+-sensitive dye x-rhod-1 (4µM, X14210, 
Molecular Probes-Invitrogen).  
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Our initial analyses using glucose in the recording solution showed no difference in the 
normalized fluorescent Ca2+ signals between the VLCAD +/+ and VLCAD-/- 
cardiomyocytes (Figure 50A and B, VLCAD+/+ and -/-, GL = Glucose).  
Because VLCAD deficiency is mainly a defect in fat metabolism and not of glucose 
metabolism, we investigated the effect of palmitate (C16-fatty acids) on the intracellular 
Ca2+ transient of the VLCAD+/+ and VLCAD-/- cardiomyocytes. We found that 
substitution of glucose by 10µM palmitic acid did not alter the SR Ca2+ release in the 
 
 
 
Figure 50. Palmitate enhances SR Ca2+ release in VLCAD-/- cardiomyocytes.  
Normalized fluorescence intensities using the cytosolic Ca2+ indicator x-rhod-1 in 
VLCAD+/+  and VLCAD-/- cardiomyocytes. There are changes in the time course of 
intracellular Ca2+ release when glucose is replaced with palmitic acid. (A). Mean x-
rhod-1 fluorescence upstrokes  measured in the presence of 10mM glucose (GL) or 
10µM palmitic acid (PA). (B) The averaged and normalized Ca2+ transient in 
VLCAD+/+ and VLCAD-/- cardiomyocytes with glucose and palmitic acid using x-
rhod-1 fluorescence. We used 10mM glucose (GL) in the bath solution from 
VLCAD+/+ (n=19) and VLCAD-/- (n=9) cells. We used 10µM palmitic acid (PA) for 
VLCAD+/+ cells (n=17) and VLCAD-/- (n=16).  Cells were field-stimulated at 10Hz 
and data were digitally low-pass filtered at 600Hz.  
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VLCAD+/+ cardiomyocytes (Figure 50A and B, VLCAD+/+, PA = Palmitate), but 
significantly altered the  Ca2+ transient of VLCAD-/- cardiomyocytes (Figure 50A and B) 
 
Increased Ca2+ release and systolic [Ca2+]i in VLCAD deficient cardiomyocytes with 
palmitate 
 
 
 
Figure 51. VLCAD deficiency is associated with increased release of Ca2+ 
from intracellular stores.  (A) Averaged intracellular indo-1 Ca2+ transients 
from VLCAD-/- (n=20) cells and VLCAD+/+ (n=18) cells field stimulated 
at 600 beats per minute. (B) Systolic intracellular Ca2+ was significantly 
increased in VLCAD-/- cardiomyocytes (n=20) compared with control 
(n=18), *p=0.003, VLCAD+/+ vs. VLCAD-/-.  (C) Maximum intracellular 
Ca2+ release rates were significantly increased in VLCAD-/- cells (n=20) 
compared to control (n=18), † p<0.001, VLCAD+/+ vs. VLCAD-/-. We 
also found an increase in SR uptake rate ‡ p<0.05, VLCAD+/+ vs. VLCAD-
/-.   (D) Both the duration of the Ca2+ release and the Ca2+ uptake were 
unaffected by VLCAD knockout in the same cells. 
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We proceeded to measure intracellular Ca2+ release and uptake with the ratiometric dye 
indo-1 (see Method section) in order to more precisely quantify the intracellular Ca2+ 
concentration ([Ca2+]i).  We found a 1.9 ± 0.3 fold increase of pacing stimulated SR Ca2+ 
release in the VLCAD-/- cells compared to the control. The absolute Ca2+ release was 
110 ± 18nM in VLCAD-/- and 59.6 ± 7.6nM in VLCAD+/+ myocytes (Fig. 5A). 
Similarly, systolic intracellular Ca2+ levels were also elevated in the VLCAD-/- mice. It 
was 806 ± 65 nM in the VLCAD-/- mice and 526 ± 58 nM in VLCAD+/+ controls (Fig. 
5B). As a result, diastolic [Ca2+]i , as calculated from the difference of the peak [Ca2+]i 
and  the Ca2+ release for each cell, was also increased 1.5 ± 0.20 fold in the VLCAD-/- 
cardiomyocytes. We also determined the maximum Ca2+ release rate as defined by the 
maximum time-derivative of Ca2+ release, expressed in units of nM per 100ms.  We 
found a 1.9 ± 0.2 fold increase in the maximum Ca2+ release rate from VLCAD-/- 
cardiomyocytes compared to the VLCAD+/+ control, with a maximum  Ca2+ release rate 
of 1170 ± 80 nM in the VLCAD-/- cells and 605 ± 56 nM in VLCAD+/+ cells per 100 
ms (Fig. 5C). In both groups, SR Ca2+ uptake rates were about five times slower than the 
release rates, with absolute amounts of 235 ± 10 nM and 138 ± 5nM per 100 ms in the 
VLCAD-/- and VLCAD+/+ control, respectively (Fig. 5C). Thus, the maximum Ca2+ 
uptake rates were increased 1.7 ± 0.1 fold in the VLCAD deficient cardiomyocytes, 
which was to be expected due to the increased Peak Ca2+ release in these cells. In 
contrast, the durations of the SR Ca2+ uptake and release as measured by the times from 
10 % to 90 % of the rise and the fall of the transients, respectively, were unchanged 
(Figure 51D).  
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Enhanced contraction velocity in VLCAD-/- cardiomyocytes 
 
We subsequently tested whether the defect in Ca2+ homeostasis at the cellular level led to 
changes in cardiomyocyte contractility in the VLCAD deficient mouse. We found that 
the time course of sarcomere contraction was hastened in the VLCAD deficient 
cardiomyocytes (Figure 52A), although there was no significant difference in the 
sarcomere contraction amplitude, which was 85 ± 15 nm in the VLCAD-/- cells, and 96 ± 
 
 
Figure 52. VLCAD deficiency leads to changes in the time course of the 
sarcomere contraction. (A) Representative normalized sarcomere contractions in 
VLCAD-/- cells (n=15) and VLCAD+/+ cells (n=16).  (B) Maximum amplitude of 
sarcomere contraction was found unchanged in VLCAD-/- cells (n=15) compared 
with VLCAD+/+ cells (n=16). (C) Width of contracion (D) Maximum rate of 
sarcomere contraction was significantly higher in VLCAD-/- cardiomyocytes, * 
p=0.016, VLCAD+/+ vs. VLCAD-/-. Sarcomere relaxation was found not affected 
in the VLCAD-/- cells. 
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11 nm in the VLCAD+/+ cells (Figure 52B), despite the increase in peak [Ca 2+]i (Figure 
51A and B). Diastolic sarcomere length was 1.75 ± 0.01 µm in the VLCAD-/- cells and 
1.74 ± 0.07 in the VLCAD+/+ cells. The width of the sarcomere length transient was 
defined as the time from 50 % of sarcomere contraction to 50 % of sarcomere relaxation. 
It was 70 ± 5 in the VLCAD+/+ and 51 ± 3 in the VLCAD-/- cells (Figure 52C).  
Maximum contraction velocity was defined by the maximum time-derivative of the 
contraction amplitude and was expressed in units of µm per 100 ms. The maximum 
contraction velocities were 0.42 ± 0.03 µm in the VLCAD-/-, and 0.33 ± 0.02 µm per 100 
ms in VLCAD+/+ cells (Figure 52D). Time from 10 % to 90 % of the maximum 
sarcomere contraction was shorter in the VLCAD-/- cells.  Contraction times were 25 ± 1 
ms in the VLCAD-/- cells and 32 ± 2 ms in the VLCAD+/+ cells (Figure 52E).  
Sarcomere relaxation was not changed in the VLCAD +/+ and VLCAD-/- cells (Figure 
52D and E). We found no differences in the maximum sarcomere relaxation velocities 
(Figure 52D) and the times from 90 % to 10 % of sarcomere relaxation (Figure 52E) 
between the VLCAD+/+ and VLCAD-/- cardiomyocytes. 
 
Altered Ca2+ release in VLCAD deficient cardiac myocytes is not due to changes in ICa 
We subsequently tested whether the increase in SR Ca2+ release was due to changes in ICa 
in the presence of palmitate. The slow and the fast time constants of the inactivation at 
0mV were unchanged, with 92 ± 6 ms and 12 ± 4 ms in the VLCAD-/- and 92 ± 5 ms and 
12 ± 3ms in the VLCAD+/+ cells, respectively  
Figure 53A). We measured the current-voltage relationship of mean peak ICa and found 
no difference in the in the VLCAD-/- and the VLCAD+/+ cells (Figure 53B).  
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These data suggest that the observed changes in intracellular Ca2+ release in VLCAD-/- 
cells in the presence of palmitate are not due to the amount of Ca2+ entering the cell 
through sarcolemmal L-type Ca2+ channels.  
 
 
 
Figure 53 VLCAD deficiency does not lead to changes ICa. (A) Current-voltage 
relationships of mean peak ICa recorded in VLCAD-/- (n=7) and VLCAD+/+ 
(n=5) cardiomyocytes. (B) Representative ICa traces in VLCAD-/- (n=7) and 
VLCAD+/+ (n=5) cells. 
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Inactivation of the VLCAD gene in mice leads to alterations in other calcium related 
proteins in heart 
 
Although changes in calcium homeostasis in the mouse heart appear to be mainly a defect 
in SR Ca2+ release, we also tested whether VLCAD inactivation led to alterations in other 
calcium related proteins. We found that in addition to increased RyR expression (Figure 
48), western blot analyses showed a modest increase in calsequestrin levels (Figure 54A), 
 
 
Figure 54. Western blot analysis of SR proteins involved in CICR. Western blots are 
for A) calsequestrin,  B) SERCA, C) Monomeric and pentameric phospholamban, 
D) Monomeric phospholamban at different protein concentrations.   Densitometry 
for protein levels is given with each representative blot, and it is calculated from  
three independent experiments, (*p< 0.01, † p<0.001, VLCAD+/+ vs. VLCAD-/-)  
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which suggests an increase in absolute SR Ca2+ content.  Protein levels of sarcoplasmic 
reticulum Ca2+ adenosine triphosphatase (SERCA) were not changed (Figure 54B).  
Similarly, there were no significant changes in the protein levels of the monomeric form 
of phospholamban (boiled products, Figure 54C and D), although the pentameric form of 
phospholamban (PLN) was increased 6.0 ± 0.9 fold in the VLCAD-/- cells (non-boiled 
Figure 54C, VLCAD-/-) compared with control (non-boiled Figure 54C,  VLCAD+/+). 
 
B.5 Discussion 
VLCAD deficiency and Cardiac EC coupling 
The present data show for the first time that there might be a link between genetic 
defects in mitochondrial fatty acid oxidation and calcium disorders in the heart. Our 
results show that VLCAD deficiency leads to significant changes in the intracellular 
calcium release (Figure 51) and sarcomere contraction (Figure 52). In VLCAD-/- cells, 
Ca2+ release was significantly higher and faster. This may have lead to the increased 
contraction velocity observed in these cells (Figure 52), although the amplitude of 
contraction was the same in both groups. VLCAD ablation did not alter the amplitude of 
the trigger calcium current, ICa, nor did it change the time course of ICa inactivation. 
Taken together, our data suggest that VLCAD deficiency increases the gain of the cardiac 
EC coupling. 
 
VLCAD and SR protein expression 
We found significant RyR2 overexpression in whole heart tissues as evidenced by 
isoform specific Western blot analysis (Figure 48) and immunoelectron microscopy 
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(Figure 49), the latter revealing increased ryanodine receptor localization in the 
mitochondria of the VLCAD deficient cardiomyocytes. These changes in ion channel 
expression may be part of compensatory molecular events that occur in the absence of the 
VLCAD gene. Similarly, calsequestrin was overexpressed in VLCAD-/- myocytes 
indicating an increased amount of Ca2+ stored in the SR of the VLCAD-/- cells.  
Taken together, VLCAD deficiency likely increases intracellular Ca2+ release by 
increasing Ca2+ stores and the number of Ca2+ release channels. Consequently, the ratio 
of the pentameric to the monomeric form of PLN was increased in the VLCAD-/- cells 
indicating a higher level of PLN phosphorylation. This may be a compensatory response 
to VLCAD ablation aimed to increase SR Ca2+ pump activity in the setting of an 
increased [Ca2+]i release and possibly higher diastolic intracellular calcium concentration, 
but without an increase in SERCA2a expression (Figure 51 and Figure 54). 
 
VLCAD and energy metabolism 
We have previously shown that VLCAD deficient mice have a number of biochemical 
changes, suggestive of complex alterations in lipid metabolism and lipid transport that are 
present in the heart at birth, while ultra structural abnormalities develop postnatal [227]. 
It is therefore conceivable that several of these biochemical changes directly relate to the 
disease phenotype. Mitochondria in the VLCAD-/- heart muscle are larger, more variable 
in size and morphology, and fill a substantially larger portion of the sarcoplasmic 
volume. Although the slow mitochondrial Ca2+ fluxes might not contribute to EC 
coupling on a beat-to-beat basis, small graduate changes in mitochondrial calcium 
concentration ([Ca2+]m) may influence mitochondrial energy production and cytosolic 
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calcium concentration. Mitochondria can accumulate massive amounts of Ca2+, as much 
as 100nmol Ca2+ per mg mitochondrial protein (corresponding to 10 mmol per liter 
cytosol, assuming 40 mg mitochondrial protein per g wet weight), although under 
physiological conditions, [Ca2+]m is likely to be much smaller [298]. [Ca2+]m increase can 
occur when energy demands are relatively high, i.e. when contractile activation and Ca2+ 
pumping are consuming ATP at high rates, or when cellular energy production is low. 
The rise in [Ca2+]m provides a negative feedback on mitochondrial ATP production and 
eventually compromises the mitochondria  [299]. Our results show that despite the larger 
size and the larger amount of mitochondria, total ATP production was not increased in 
the VLCAD-/- hearts. Therefore, mitochondrial metabolism was in fact depressed. The 
increased diastolic indo-1 fluorescence (Figure 51) would support the hypothesis that 
more Ca2+ is stored in the mitochondria of the VLCAD-/- cells than in the mitochondria 
of the VLCAD+/+ control cells, thereby increasing the time-independent fluorescence 
signal. A larger mitochondrial Ca2+ load would also suggest that an increased Ca2+ 
release into the cytosol via Na/Ca exchange when [Na+]i is high [300]. The increased 
number of RyR2 that we found in the mitochondria may support this hypothesis (Figure 
49). However, further experiments are needed to decide whether the increase in diastolic 
indo-1 fluorescence (Figure 51) was in fact due to an increase in free [Ca2+]i or possibly 
caused by significant Ca2+ accumulation in the mitochondria. This, in turn, would point to 
a more important role of [Ca2+]m in the hearts of the VLCAD deficient mice. 
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VLCAD and substrate dependence of [Ca2+]i 
At a molecular level, palmitate cannot be readily metabolized in the absence of VLCAD, 
and fatty acids likely accumulate in the VLCAD-/- cells. While RyR2 and calsequestrin 
overexpression may have caused the larger Ca2+ transient amplitude in the VLCAD-/- 
cells, the observed changes in the time course of the normalized Ca2+ transient in these 
cells seemed to be substrate dependent as they did not occur when the recording solution 
contained glucose instead of palmitate (Figure 50). Our study was focused on the effects 
of VLCAD deficiency on proteins which are involved in EC coupling and we addressed 
possible mechanisms in single cardiac myocytes that could lead to the arrhythmia 
observed in the VLCAD-/- mice. Most of our experiments were performed under the 
same energy substrate conditions. However, Figure 50 warrants further investigation 
whether the accumulation of toxic metabolites lead to the observed changes in 
intracellular calcium signaling and sarcomere contraction. 
 
Clinical relevance of this study 
Pediatric patients with VLCAD deficiency often present with acute episodes of 
arrhythmias and death without prior evidence of myocardial dysfunction. We have 
created a knock out mouse model of VLCAD deficiency in which polymorphic VT and 
bidirectional VT were much more likely to be induced by programmed stimulation (50 
%) or by isoproterenol infusion (83 %) than in the wild-type control. The features of 
these arrhythmias observed in the VLCAD-/- mice mimic the electrophysiological 
consequences of mutations in the cardiac ryanodine receptor in humans. Using 
dissociated ventricular cardiac myocytes from VLCAD-/- mice, we have demonstrated 
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that the genetic defect in the fatty acid metabolism resulted in a compensatory increase in 
the intracellular calcium transients leading to changes in sarcomere contractility.  Our 
results indicate that intracellular calcium dynamics was altered in VLCAD-/- cells with 
fatty acid substrates and may therefore also point to the molecular basis for lipidosis 
induced arrhythmias in other cases of fatty acid oxidation deficiency. Long-term follow-
up of patients with VLCAD deficiency has been limited by the fact that most of the cases 
present in childhood with sudden death and cardiac dysfunction. However, patients may 
survive into adulthood with rare reported complaints of skeletal myopathy, 
encephalopathy, and normal structural heart. In this present work we provide first 
evidence in mice that abnormal fat metabolism caused by genetic deletion of the VLCAD 
gene is associated with increased intracellular calcium release, increased diastolic 
calcium concentration and increased sarcomere contractility in single cells which could 
lead to delayed afterdepolarizations in the heart, a known cause of ventricular 
tachycardia. Further studies are necessary to determine whether the changes identified in 
isolated cardiomyocytes and ventricular tissue in fact contribute to the disease phenotype 
that causes sudden death mice and in humans. 
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